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Abstract
The E. coli biotin ligase enzyme, BirA, has been previously used by the Ting research group for
site-specific labeling of peptide-tagged cell surface proteins. We sought to expand the utility of
biotin ligase-mediated labeling to functional group handles, including azides and alkynes, for
bio-orthogonal chemistry. Since the BirA and its point mutants were unable to ligate these
probes to an acceptor peptide, we screened biotin ligases from multiple species to identify
more permissive enzymes. We determined that the Pyrococcus horikoshii biotin ligase utilizes
an azide-bearing biotin analog and that the Saccharomyces cerevisiae biotin ligase can utilize an
alkyne-functionalized biotin analog. We subsequently demonstrated that the azide-
functionalized biotin analog can be derivatized with a phosphine probe via the Staudinger
ligation.
We next turned to the goal of delivering quantum dots to the cytosol of living cells, which in the
future may permit intracellular single-molecule imaging. We investigated viral methods of
delivery, but found that our protocol caused quantum dots to be trapped in endocytic vesicles.
We then validated previous reports that the pore-forming toxin streptolysin 0 be used to
deliver quantum dots to the cytosol of living cells.
Lipoic acid ligase, or LpIA, has been previously applied to site-specific protein labeling of
peptide-tagged proteins using small molecule probes including lipoic acid and coumarin
fluorophores. We utilized LpIA and its substrate, the LAP peptide, to create sensors for protein-
protein interactions. If LpIA is fused to one protein and LAP is fused to another, only when the
two proteins interact do LpIA and LAP come into proximity, allowing probe ligation onto the
peptide to occur as a readout of the interaction. We demonstrate that proximity-dependent
coumarin ligation detects protein-protein interactions in living mammalian cells with extremely
low background, a signal-to-background ratio of at least 5:1, and sufficiently fast kinetics to
label interactions with a half-life of at least 1 minute. The reporter quantitatively responds to
subpopulations of interacting proteins, allowing dissociation constants to be measured.
Coumarin fluorescence accurately reports the subcellular localization of the interaction under
study. Finally, we applied proximity-dependent coumarin ligation to imaging of the interaction
of PSD-95 and neuroligin-1, two proteins involved in synaptic maturation, in neurons.
Thesis Supervisor: Alice Y. Ting
Title: Associate Professor of Chemistry
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Chapter 1: Introduction: Current methodologies for protein labeling, intracellular
nanoparticle delivery, and protein-protein interaction detection
Part I: Introduction to site-specific protein labeling in the cellular context
The discovery of the green fluorescent protein (GFP) revolutionized the field of protein imaging.
By fusing proteins of interest to GFP, or engineered fluorescent protein variants with emission
spectra spanning the visual spectrum,[1] the localization, trafficking, and interactions of
proteins can be visualized in living cells by fluorescence microscopy.[2] However, protein
labeling by genetic fusion to fluorescent proteins suffers several fundamental limitations. First,
fluorescent proteins are generally restricted to ensemble fluorescence imaging, because it is
difficult to detect fluorescent proteins at the single-molecule level unless technically
challenging experimental techniques, such as immobilization and stroboscopic excitation, are
employed.[3] Although photo-activatable fluorescent protein variants have recently been used
for single-molecule imaging,[4] organic fluorophores are generally brighter than fluorescent
proteins and so are better suited to this purpose. In addition, labeling proteins with expanded
biophysical functionalities would extend our ability to interrogate protein function beyond a
simple fluorescent readout. Second, fluorescent proteins are large, and therefore can interfere
with the function, interactions, and localization of the proteins to which they are fused.[5-7]
The field of protein labeling, therefore, has focused on introduction of chemical probes to
proteins, including small organic fluorophores, small biophysical probes such as photo-
activatable cross-linkers, and inorganic nanoparticles applicable to new imaging modalities. The
difficulty with this approach is that, while genetic fusion to GFP is both technically easy and
perfectly specific, chemical probes are difficult to target to specific proteins in the cellular
context.
Traditional methods for in vitro labeling with small molecules take advantage of nucleophiles
present in proteins. For example, maleimides and haloalkanes react with the thiol group of
cysteine residues, and N-hydroxysuccinimidyl esters react with amines present in lysine
sidechains and the protein N-terminus. Of course, these reactions are not amenable to labeling
a specific protein in the cellular context because they are not selective; instead they label all
similarly reactive functional groups, which are present in most proteins.[8] While proteins can
be labeled ex vivo and subsequently introduced into cells, for example by microinjection, this is
a cumbersome and technically challenging technique. In order to bring chemical labeling of
proteins into cells, new, selective targeting methods have therefore been devised.
In the most general sense, labeling specificity is achieved in the cellular context through genetic
targeting. The protein of interest can be genetically fused to either a protein or peptide
sequence that possesses reporter activity, or that has unique reactivity toward a chemical
probe. Alternatively, unique functionality can be co-translationally incorporated into the
protein of interest through unique mRNA recruiting sequences. By encoding unique reactivity
or functionality at the genetic level, perfect specificity of chemical targeting can be ensured.
We will provide a brief review of the mechanisms by which site-specific small-molecule protein
labeling on or in living cells has been accomplished through genetic fusions to proteins,
peptides, or through co-translational reporter incorporation in order to motivate the need for
the new labeling methods presented in this work.
Unnatural amino acid mutagenesis
Unnatural amino acid mutagenesis labels proteins by amber codon suppression, allowing co-
translational insertion of an unnatural amino acid at a specific site in a protein. This method has
been utilized for insertion of amino acids bearing reactive groups for chemoselective
derivatization with secondary probes, photo-activatable cross-linkers, and fluorophores, among
other functionalities, in bacterial, yeast, and mammalian cells.[9-12] Among all the methods we
will discuss, unnatural amino acid incorporation has the greatest potential for non-perturbative
protein labeling, as there is no additional sequence appended to the protein; it also provides
perfect labeling specificity. However, the method suffers from competing termination at amber
codons, which can produce truncated protein that can, in some instances, produce dominant
negative effects. Furthermore, for each unnatural amino acid structure one desires to
incorporate, a new aminoacyl-tRNA synthetase must be designed.
Protein-tagging methods
Protein tagging can be accomplished with genetic fusions to proteins that bind small molecules
through non-covalent, though high-affinity, interactions. One example is dihydrofolate
reductase, or DHFR. Two DHFR inhibitors, methotrexate and trimethoprim, bind to the enzyme
with picomolar affinity.[13] Fluorophore conjugates of both of these molecules have been
utilized for cellular labeling of DHFR fusion proteins; however, in the case of methotrexate
labeling, DHFR-deficient cell lines must be utilized due to background from probe binding to
endogenous DHFR.[14, 15] Another example of a protein used for non-covalent labeling is the
F36V point mutant of the FK506 binding protein (FKBP), which binds with picomolar affinity to a
synthetic ligand, SLF'.[16] Because SLF' binds very poorly to endogenous mammalian FKBP, this
method has been used for highly selective labeling in mammalian cells by conjugating dyes to
SLF'.[17] Importantly, all of these small-molecule probes are membrane-permeable, permitting
labeling of intracellular proteins., the non-covalent nature of these binding interactions mean
that the probe dissociates over time, leading to signal decay; in the case of DHFR labeling with
methotrexate derivatives, signal is lost in only one hour.[8]
Enzymes that can covalently self-label with "suicide substrates" solve the problem of probe
dissociation. Two widely utilized, commercially available such methods have begun to be
applied to solving biological problems. The first, developed by the Johnsson lab, utilizes the
DNA repair enzyme 06-alkylguanine-DNA alkyltransferase (AGT). The natural reaction of AGT is
to repair0 6-alkylated guanine residues by covalent transfer of the alkyl group to an active-site
cysteine.[18] AGT can react irreversibly with fluorescent derivatives of 06-benzylguanine,
thereby labeling any protein to which AGT is genetically fused.[18] This technology is referred
to as the the SNAP-tag. An orthogonal mutant AGT enzyme that specifically reacts with 06-
propargylguanine derivatives, referred to as the CLIP-tag, has been developed, facilitating two-
color labeling of intracellular proteins.[19]
Another enzyme-based labeling method utilizes a mutant bacterial haloalkane dehalogenase
called HaloTag. In the natural dehalogenase reaction, an active site aspartate forms an ester
bond with the alkane substrate, which is subsequently cleaved through hydrolysis mediated by
an active-site histidine that serves as a general base.[20] In HaloTag, the histidine has been
mutated to prevent hydrolysis, affording an enzyme that reacts irreversibly with
haloalkanes.[20] Covalent labeling of HaloTag fusions with fluorophore-derivatized haloalkanes
has been demonstrated for intracellular proteins.[20]
Cutinase, a fungal esterase, reacts irreversibly with para-nitrophenylphosphonate (p-NPP).[21]
By synthesizing a p-NPP analog with a terminal thiol, derivatization of the cutinase-pNPP adduct
with maleimide-containing secondary probes is possible.[21] Of course, highly negatively
charged p-NPP is membrane-impermeant, and thiol nucleophiles are found throughout cellular
proteins, so this method is restricted to labeling cell-surface proteins.
Intracellular proteins have also been labeled using native chemical ligation. By expressing
proteins of interest as fusions to inteins, subsequent intein self-splicing generates a protein
with an N-terminal cysteine; this cysteine then reacts selectively with membrane-permeable
thioester-functionalized probes.[22] While recently reported selections to improve the rate of
intracellular intein splicing may solve previous problems of slow kinetics,[23] competition with
endogenous cysteine continues to limit the utility of the method.
Unfortunately, all protein-based tagging methods suffer from the same size problem as GFP,
potentially affecting the localization or function of the protein of interest. Therefore alternative
labeling methods targeted to short peptides have been developed.
Peptide-tagging methods
We begin with peptides that selectively bind small-molecule probes with high affinity. Perhaps
the most important and widely used peptide-tagging method is FlAsH, developed by the Tsien
laboratory. In this method, a tetracysteine-containing hairpin peptide is fused to the protein of
interest, which binds with low-picomolar affinity to biarsenical dyes, which fluoresce upon
binding to the peptide.[24, 25] While the original method was developed for labeling with
fluorescein, additional colors have been developed as biarsenical dyes,[26] and the resorufin-
containing ReAsH probe can be utilized for photoconversion of diaminobenzidine for electron
microscopy,[27]Iallowing multicolor and multimodal imaging. Because these probes are
membrane-permeant,[28] FlAsH can label intracellular proteins, and has already been utilized
for multiple cell biological studies (unlike many of the other methods described in this
section).[29-32] However, the method suffers some problems. First, the biarsenical dyes have
weak affinity for mono- and dithiols present in cells, leading to low-level background; therefore,
only highly over-expressed or multimeric proteins can be imaged.[33] Arsenic toxicity remains a
concern. Background and toxicity are reduced by treating the cells with dithiols, which leads to
long labeling times. Finally, because the tetracysteine tag must be in its reduced form to react
with arsenic, FlAsH labeling is restricted from oxidizing cellular compartments such as the cell
surface and secretory pathway.
Metal ion-binding peptides have also been pressed into use for protein labeling. Hexahistidine
or decahistidine peptides can bind nickel-nitriloacetic acid complexes conjugated to
fluorophores,[34] but low-micromolar affinity of the peptides for nickel complexes leads to
reporter dissociation and rapid signal degradation. An improvement on the method utilizes a
fluorescein dizinc compound to improve affinity,[35] but can only be used for labeling cell-
surface proteins. A similar method utilizes polyaspartate peptides to bind dinuclear zinc
complexes for cell-surface protein labeling.[36] This method is also subject to probe
dissociation unless the target protein contains or is engineered to contain a surface cysteine
that can react with a chloroacetamide moiety in the probe. [37]
Peptides that specifically bind small molecules and proteins have also been developed. A
peptide that specifically binds the organic fluorophore Texas Red with picomolar affinity has
been reported and utilized for cell-surface protein labeling, but accumulation of Texas Red in
mitochondria creates high background that limits the utility of the method. [38] Peptides that
bind the proteins streptavidin and bungarotoxin have been used for cell-surface protein
labeling,[39] but the large size of these proteins prevents their intracellular delivery and could
potentially interfere with the function of the labeled protein.
Tremendous improvements in peptide-directed labeling have been made by introducing the
additional selectivity of enzyme-mediated peptide labeling. In these approaches, enzymes that
normally catalyze covalent post-translational modifications are hijacked to specifically attach
functionalized small-molecule probes to a peptide tag, retaining the specificity of enzme-
substrate interactions while maintaining the small tag size of peptide labeling approaches. The
first example of this utilizes the phosphopantetheinyltransferase Sfp, which normally catalyzes
attachment of coenzyme A (CoA) to a specific serine residue of acyl carrier proteins and
peptidyl carrier proteins involved in the biosynthesis of polyketides and nonribosomal
polypeptides.[40] The principle advantage of Sfp is that it accepts CoA derivatives bearing many
substituents, including biotin and thiols, on the terminal thiol as substrates. [411 Sfp can site-
specifically ligate these CoA derivatives to a specific lysine residue of short engineered peptides
in the cellular context.[42] Because CoA is highly charged, the probes used with this method
cannot cross the cell membrane, meaning it is restricted to the cell surface. Even so, the
phosphopantetheinyltransferase labeling methodology has already contributed significantly to
biological study of the mobility of cell surface receptors.[43, 44]
Formyglycine generating enzyme has recently been put to use in site-specific labeling of cell
surface proteins. This enzyme normally catalyzes co-translational formation of formylglycine in
the active site of sulfatases, a modification which is necessary for their catalytic activity.[45]The
"aldehyde tag" peptide recognized by the enzyme is exceptionally short at only 6 amino acid
residues.[45] Because mammalian formylglycine generating enzyme is localized to the
endoplasmic reticulum, this method has been recently used to install aldehydes into peptide-
tagged cell-surface proteins as they transit the secretory pathway.[46] Aldehydes are otherwise
absent from the cell surface, so the aldehyde-labeled protein can then be chemoselectively
labeled with with hydrazine- and hydroxylamine-functionalized fluorophores in living cells.[46]
Unfortunately, because aldehydes are prevalent in intracellular metabolites, the method will be
generally restricted to the cell surface or purified proteins.
Protein farnesyltransferase has been appropriated for attaching azide- and alkyne-modified
isoprenoid probe onto proteins bearing a 4-amino acid farnesylation motif.[47] These probes
can be selectively derivatized in a secondary chemical step to install fluorophores. However, the
farnesylation motif employed is not orthogonal to endogenous farnesylated proteins, so this
will not be a general tool for site-specific labeling in the intracellular context, as all farnesylated
proteins will be labeled.
Guinea pig transglutaminase normally catalyzes protein cross-linking events by catalyzing
formation of an amide bond between lysine and glutamine sidechains.[48] Most interestingly
for protein labeling applications, transglutaminase is permissive for the structures of amines it
can utilize in this amidation reaction, including biotin- and fluorescein-cadaverine.[48]
Furthermore, a short glutamine-containing peptide called the Q-tag has been reported as a
substrate of transglutaminase.[48] These properties have been co-opted for labeling of Q-
tagged cell surface proteins with fluorophores.[48] However, glutamine residues are not an
orthogonal reactive group on the cell surface, so the enzyme modifies endogenous cell-surface
glutamines as well as the Q-tag. This lack of specificity limits the utility of the method.
We provide a summary and comparison of all of these methods for site-specific protein labeling
in Table 1-1. The Ting research group has reported improved peptide-directed site-specific
protein labeling methodologies based on the enzymes biotin ligase and lipoic acid ligase.
Generally, the theme of this thesis is expanding the utility of the biotin ligase and lipoic acid
ligase labeling methods by extending them to new reactions and'biological problems. Part il of
this introduction will discuss the enzymology of biotin ligase, how the enzyme has been utilized
by the Ting Lab for protein labeling, and our efforts to use biotin ligase to incorporate new
small molecule probes as well as to extend its utility to the intracellular context. Part Ill will
introduce lipoic acid ligase, discuss how this enzyme has been used for labeling, and explain the
new biological problem to which we apply the enzyme: detection of protein-protein
interactions.
Labeling method Tag size Specificity for target protein Intracellular
labeling in living
cells
Unnatural amino acid One amino Perfect Yes
mutAgenesis acid
Protein-directed methods
Fluorescent proteins Large Perfect Yes
Dihydrofolate Large High in DHFR-deficient cell lines Yes
reductase
FK506 binding protein Large High Yes
0-alkylguanine-DNA Large High Yes
alkyltransferase
(SNAP/CLIP tags)
HaloTag Large High Yes
Cutinase Large High for enzymatic step; No
moderate for chemical step
because of competition with
end ogenous cysteine
Native chemical Large Low; competes with endogenous Limited
ligation cysteine
Peptide-directed methods
FlAsH Small Moderate; competes with Yes
endogenous cysteine
Poly(histidine) Small High on cell surface No
Poly(aspartate) Small High on cell surface No
Texas Red binding Small High Limited
peptide
Streptavidin binding Small High No
peptide
Bungarotoxin binding Small High No
peptide
Phosphopantetheinyl- Small High No
transferase
Formylglycine Small High for enzymatic step; high for No
generating enzyme chemical step only on cell
surface
Protein Small Low for enzymatic step; high for No
farnesyltransferase chemical step
Transglutaminase Small Low; competes with endogenous No
glutamines
Biotin ligase Small High for enzymatic step; high for No
ketone biotin derivatization only
on cell surface
Lipoic acid ligase Small High Yes
Table 1-1. Comparison of previously reported site-specific protein labeling methods. Note that
the biotin ligase method is described with respect to ketone biotin labeling.
Part II: Biotin ligase-mediated protein labeling and desired extensions to new small-molecule
probes and intracellular quantum dot labeling
Biotin ligase
Physiological role and biochemical properties of biotin ligase
Biotin is an essential cofactor responsible for carboxyl group transfer reactions involved in
several catabolic pathways, fatty acid biosynthesis, and gluconeogenesis.[49] It must be
covalently attached to a specific lysine residue of the carboxylase proteins that require it; this
attachment is catalyzed by the enzyme biotin ligase.[50] Because biotin is essential for
metabolism, all organisms express one or two biotin ligase enzymes.[51]
The best-characterized biotin ligase by far is the E. coli enzyme, BirA. BirA catalyzes amide bond
formation between a lysine residue and biotin in a two-step reaction as shown in the following
equations:[52]
biotin + ATP & biotinyl-5'-AMP + PPi
biotinyl-5'-AMP + apo-carboxylase - holo-carboxylase + AMP
In the first step, biotin is activated as the adenylate intermediate and pyrophosphate (PPi) is
released; in the second step, the lysine residue serves as a nucleophile to attack the adenylate,
forming the amide product and releasing adenosine monophosphate (AMP).[53] (Apo-
carboxylase refers to the substrate protein prior to post-translational modification; holo-
carboxylase refers to the substrate protein with biotin attached.)
Biotinylation is an extremely rare and specific post-translational modification. E. coli BirA
catalyzes biotinylation of exactly one protein, the biotin carboxyl carrier protein (BCCP) of
acetyl CoA carboxylase ligase; yeast contains up to five biotinylated proteins, and mammals and
plants have four.[51] (While the biotinylation of histones has been sporadically investigated
over the years,[54] this modification has been demonstrated not to occur in vivo. Detection of
histone biotinylation is an artefact of non-specific modification due to high protein
concentrations and long reaction times in vitro,[55] as well as non-specific binding of avidin and
certain antibodies to native, non-biotinylated histones.[56]) Furthermore, exactly one lysine
residue on the biotinylated protein is modified by biotin ligase; it is found at the center of a
consensus sequence that is typically close to the C terminus of the carboxylase.[51] That these
enzymes are able to specifically modify one to five proteins in a cell, while never transferring
biotin to any other lysine residue of any other protein, testifies to their exquisite specificity for
their protein substrates. The kinetics of biotin transfer to BCCP by E. coli BirA have been
previously characterized; the kcat is 0.16 s-1, and the Km values for biotin, ATP, and BCCP are 0.49
pM, 0.3 mM, and 4.39 IM, respectively. [57]
A 15-amino acid peptide substrate for BirA, the acceptor peptide, or AP, has previously been
reported.[58] The kinetics of AP biotinylation by BirA are identical to biotinylation of BCCP in
the steady state, with kcat/Km of 10,000 M' s1 for the AP, and 11,900 M' s' for BCCP.[58]
Interestingly, while biotin ligase enzymes can generally biotinylate BCCPs from other species,
the AP is specifically recognized by BirA and not by other enzymes.[59, 60]
Application of biotin ligase to protein labeling
The biochemical properties of BirA are ideally suited for application to a peptide-based labeling
methodology. BirA has exquisitely high specificity for labeling the AP in the context of
mammalian cells, and mammalian biotin ligase enzymes do not recognize the AP.[59, 61, 62]
Therefore, BirA-mediated protein labeling achieves its site-specific small-molecule conjugation
by harnessing the specificity of an enzyme for its substrate, while retaining the advantages of
small tag size obtained with peptide-directed labeling technologies.
Biotinylation of the AP tag can be detected with fluorescently labeled streptavidin or with
streptavidin-coated quantum dots (QDs).[62-64] QDs are semiconductor nanoparticles with
ideal photophysical properties for single-molecule imaging; they are exceptionally bright,
photostable, and have very narrow emission spectra.[62] BirA-mediated targeting of
streptavidin and QDs has been applied to ensemble and single-molecule imaging of AP-tagged
cell surface proteins.[62-64] However, streptavidin and QDs are both currently restricted to
cell-surface applications, because both are too large to diffuse across the cell membrane.
A ketone isostere of biotin has also been developed and utilized for labeling of cell-surface
proteins.[61, 65] Ketone biotin can be ligated to the AP by BirA and, because ketones are
absent from the cell surface, subsequently selectively reacted with hydrazine- and
hydroxylamine-functionalized secondary probes under physiological conditions. [61] This
methodology has been used to install fluorophores and a benzophenone photo-activatable
cross-linker on cell-surface proteins.[61] However, due to the abundance of ketones and
aldehydes in intracellular metabolites, the secondary conjugation step cannot be applied to
intracellular proteins, restricting ketone biotin labeling to the cell surface.
While these labeling technologies are undeniably powerful, we have identified two
improvements that can be made in BirA-mediated protein labeling: the toolbox of small-
molecule probes that can be attached to proteins must be expanded, and quantum dot labeling
must be extended to intracellular proteins, through the development of methods to deliver
QDs into the cytosol of living cells. The next two sections will provide background information
on each of these problems.
Protein labeling with small-molecule probes in the biological context: Introduction to bio-
orthogonal chemistry
In order to expand the utility of BirA for small-molecule labeling, we focused on designing
probes with reactive "functional handles" compatible with intracellular bio-orthogonal
derivatization. Bio-orthogonal reactions are, in general, chemoselective reactions that can
occur in the biological milieu. For a reaction to be bio-orthogonal, the functional groups
involved in the bio-orthogonal reaction must not be present in biological molecules, the
reaction must not perturb native biomolecules, and it must proceed rapidly under physiological
conditions.[66] Ketone biotin and formylglycine, in their reactivity toward hydrazines and
hydroxylamines, are excellent examples of such a system, but as discussed, this chemistry is
only bio-orthogonal on the cell surface.
In particular, we wished to introduce probes bearing azide and alkyne functional groups. Azides
and alkynes are absent both from the cytoplasm and the cell surface. Alkynes can undergo
copper-catalyzed [3+2] cycloaddition with azides (termed "Click chemistry") to form stable
triazole adducts under physiological conditions.[67, 68] Azides are particularly useful for bio-
orthogonal conjugation in cells because they can be derivatized with additional, non-toxic
secondary reactions aside from Click chemistry. The Staudinger ligation of azides and
triarylphosphines introduces an electrophilic methyl ester in the phosphine reagent to trap the
reactive aza-ylide intermediate, generating a stable amide bond in the product (Figure 1-1).[69,
70] Additionally, a copper-free version of the [3+2] azide-alkyne cycloaddition has been
developed, in which the azide reacts rapidly with a strained cyclo-octyne.[71] We hoped that by
extending BirA-mediated labeling to include azide- and alkyne-functionalized probes, we would
be able to access these more selective secondary conjugation reactions.
Chapter 2 of this thesis describes our efforts to expand the small-molecule substrate scope of
BirA to new probe classes, including probes functionalized for bio-orthogonal chemistry, by
investigating the substrate specificity of biotin ligase enzymes from many species. A further
discussion of previously characterized biotin ligase enzymology that is directly relevant to the
study design will also be presented in Chapter 2.
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Figure 1-1. Proposed mechanism of the
Staudinger ligation. A protein,
represented by the gray circle,
displaying an azide functional group can
react with a triarylphosphine-bearing
probe, proceeding through an aza-ylide
intermediate that reacts with an
intramolecular electrophile, shown in
blue, to produce an amide linkage in
the product. Any compatible probe
structure can be introduced.
Adapted from reference 18 with
permission, copyright 2005, American
Chemical Society.
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Intracellular labeling with quantum dots: Introduction to the delivery problem
As mentioned above, the'use of QDs for single-molecule imaging is currently restricted to the
cell surface because the size (approximately 20 nm)[72] of QDs prevents them from crossing
the cell membrane by diffusion. We sought to extend BirA-mediated QD targeting to
intracellular proteins by devising a method to deliver QDs into the cytosol of living cells (and,
once delivered, we anticipate that delivered streptavidin-coated QDs should be targetable to
intracellular proteins biotinylated by BirA, because biotinylation of the AP in the cellular context
has previously been shown to be specific[59, 61, 62]). More specifically, we sought to develop
methods that are high-throughput (that is, deliver QDs into many cells at once), non-toxic,
simple to use, and accessible to the non-expert.
QDs can be readily internalized by endocytosis; however, these endocytosed QDs remain
trapped in vesicles, which they cannot readily escape,[73, 74] precluding their targeting to
proteins of interest inside the cell. An effective method would transport QDs across the plasma
membrane, or out of endosomes, into the cytosol, leaving them freely diffusible.
Many other methods have been investigated for the delivery of QDs into the cytoplasm of living
cells. We provide a brief review of the field here, along with a discussion of the problems each
method faces, to motivate the need for new methods. We discuss only methods that have been
applied for QD delivery in living cells, as cell fixation can introduce localization artifacts
(especially for charged molecules) and precludes rigorous conclusions from being drawn about
delivery efficacy; we also focus on methods that are applicable in commonly used mammalian
cell lines, rather than methods that are unique to specialized cell types and therefore have no
hope of generality.
Microinjection has been established to afford targetable intracellular QDs.[75]For example, QDs
have been targeted to an AP tag on the cytoplasmic tail of the receptor EphA3 after
intracellular biotinylation by BirA; conformational changes in individual QD-labeled EphA3
molecules were then observed in the cellular context.[76] While microinjection is inarguably
effective, it is technically difficult, low-throughput, and requires specialized instrumentation.
Atomic force microscopy-based nanoinjectors are similarly efficacious, but are even more
inaccessible and low-throughput.[77] Encapsulating QDs in nanospheres consisting of Poly(D,L-
lactide-co-glycolide) has also been reported to afford cytosolic, diffusible QDs that are
targetable via antibody conjugation to intracellular proteins.[78] However, this preparation is
technically challenging, so until these encapsulated QDs become widely available, the method is
not accessible to the non-chemist. A simple, non-toxic, inexpensive method that can deliver
QDs into the cytosol of many cells would make intracellular QD targeting a general method and
extend its accessibility to the non-expert.
One of the earliest methods investigated for QD delivery was targeting to recycling endosomes
via QD conjugation to receptor ligands. Transferrin-conjugated QDs have been demonstrated to
exhibit punctuate, endosomal localization inside living HeLa cells.[79] Direct conjugation of
folate to QDs as well as QD encapsulation in folate-displaying lipid micelles has also been
reported to result in punctuate and likely endosomal localization.[80, 81] Therefore, while
conjugation to receptor ligands does promote QD uptake relative to the rate of free QD
internalization, it does not generally permit internalized QDs to freely enter the cell cytosol.
Cell penetrating peptides, or CPPs, are small, positively charged peptides or proteins that can
cross cell membranes and have received extensive attention in the fields of gene and drug
delivery. [82-84] TAT peptide has been extensively used for delivery of nucleic acids, but TAT-
conjugated QDs remain encapsulated in endosomes to the extent that escape into the cytosol is
undetectable.[74, 85] In fact, Tat peptide only efficiently delivers QDs into cells after their
plasma membrane has been permeabilized with the glycoside detergent digitonin.[86] A similar
endosomal trapping problem has been reported for Pep-1-conjugated quantum dots in some
studies,[87, 88] though another reported demonstrates nuclear targeting of Pep-1-delivered
QDs.[89] Insect neuropeptide has been reported to deliver QDs into the cytosol and nucleus of
living cells, but no assay to demonstrate free diffusibility was performed, so the utility of this
method for intracellular protein targeting remains to be confirmed.[90] The palmitoylated
peptide Palm-1 has been conjugated to QDs, and 48 hours after delivery, some percentage of
QDs were demonstrated to escape from endosomes into the cytosol based on co-localization
analysis with an endosomal marker.[91] Despite this long delivery time, these cytosolic QDs
may prove useful for protein labeling. It is clear, though, that with peptide-based delivery
methods, at best some percentage of QDs escape from endocytic vesicles, with the rest
remaining trapped.
Cationic polymers such as polyethyleneimine (PEI) and poly-L-lysine have similarly been
extensively used for transfection. The mechanism of PEI delivery has been the subject of some
study. The association of the PEI with negatively charged cargo such as DNA promotes its
association with and uptake by cells. Protonatable groups on the polymer then act as a "proton
sponge," "soaking up" protons as the endosome acidifies, promoting additional proton and
chloride counter-ion uptake and eventual osmotic rupture.[92, 93]While PEI has been reported
to afford endosomal escape of delivered QDs, the concentrations of PEI required for this effect
were highly toxic; non-toxic concentrations and PEI formulations resulted in endosomal
trapping.[94] Derivatized poly-L-lysine has been demonstrated to promote QD uptake, but the
resultant intracellular QD pattern is punctuate,a likely indicator of endosomal trapping.[95]
Cationic liposomes are effective commercially available nucleic acid transfection reagents.
Commercial lipofectamine has been put to the purpose of delivering QDs, and found to be
efficacious in affording endosomal escape based on co-delivery of siRNA[96] and also
comparison to endosomal dye localization.[75] However, the delivered QDs were observed to
form huge aggregates inside the cell of several hundred nanometers in size, rather than to
freely diffuse.[75] The commercial transfection reagent FuGene has been reported to deliver
targetable QDs into cells, but no experimental data to confirm the reported localization was
presented, and aberrant kinesin motility was observed, so this result must be confirmed.[97]
Carbon nanotubes have been extensively studied for drug delivery applications because they
associate with the cell membrane and internalize into clathrin-coated vesicles with high
efficiency.[98, 99]However, QD-nanotube conjugates remain trapped in endosomes and are
eventually trafficked to lysosomes,[100].
Electroporation is a classical method of transfection. While electroporation delivers QDs into
cells, it results in formation of very large QD aggregates rather than freely diffusible QD
delivery.[75]
Osmotic lysis is a delivery method in which cells are allowed to take up cargo via pinocytosis in
buffer made hypertonic with high concentrations of sucrose and polyethyleneglycol. After the
cargo has been loaded into vesicles, the cells are exchanged into hypotonic buffer, causing
osmotic shock and vesicle rupture.[101] This method has been utilized for loading of QD-
conjugated kinesin and myosin V into cells; subsequently, the motor protein-QD conjugates
were observed to freely diffuse as well as to "walk" on microtubules or actin, respectively, with
the expected velocity and step size.[102, 103] This suggests that osmotic lysis can afford free
cytosolic QDs. However, the method is not without toxicity; subjecting cells to osmotic lysis of
pinocytic vesicles once does not cause gross changes in cell morphology, after multiple rounds
of lysis, up to 40% of cells die.[101]
Biological toxins including shiga toxin, diphtheria toxin, anthrax toxin, and cholera toxin, which
either afford delivery from endocytic vesicles or escape from the endoplasmic reticulum after
undergoing retrograde transport, have been used to deliver many types of cargo. [104] Cholera
toxin has been applied to QD delivery, but resulted in QDs being trapped in endosomes that
eventually acculumated in the perinuclear region, the typical late endosome localization.[105]
Shiga toxin and ricin have similarly been shown to result in endosomal trapping of QDs.[106]
Streptolysin 0 is a particularly interesting biological toxin that forms pores in biological
membranes through which membrane-impermeant cargo can passively diffuse.[107]
Streptolysin 0 treatment has previously been shown to afford cytosolic delivery of
monodisperse, diffusible QDs into the cytosol of living cells, but limited imaging data was
presented in the literature and no targeting to proteins was attempted. [108] While this method
has potential for cytosolic QD delivery, it has issues of toxicity. We will discuss the mechanism,
benefits, and drawbacks of streptolysin 0 in much greater detail in Chapter 3 of this thesis.
In conclusion, most methods applied to the delivery of QDs suffer from technical inaccessibility,
endosomal trapping, QD aggregation, or toxicity. We provide a summary comparison of these
methods in Table 1-2. Therefore, the application of BirA-mediated QD targeting to intracellular
proteins awaits the development of a general, easy-to-use method for delivering
monodisperse, diffusible QDs into the cytosol of living cells. Chapter 3 of this thesis describes
our efforts to apply viral mechanisms of cell entry and streptolysin 0-mediated cell
permeabilization to the QD delivery problem.
Delivery method Subcellular Evidence of Targeting to Toxicity
localization aggregation intracellular
of QDs after proteins
delivery
Direct Injection methods
Microinjection Cytosolic No Yes Mild
Nanoinjector Cytosolic No No Low
Receptor ligands
Transferrin Endosomal No No Low
Folate Endosomal No No Low
Cel-penetrating peptides
Tat Endosomal No No Low
Pep-1 Endosomal No No Low
Insect Cytoplasmic No No Low
neuropeptide and nuclear
Palm-1 Cytosolic No No Low
and
endosomal
Cationic polymers
Polyethyleneimine Cytosolic No No High
Poly-L-lysine Endosomal No No Low
Cationicliposomes
Lipofectamine Cytosolic Yes No Low
FuGene Cytosolic No Yes Low
Biological toxins
Cholera toxin Endosomal No No Low
Shiga toxin Endosomal No No Low
Ricin Endosomal No No Low
Streptolysin 0 Cytosolic No No Moderate
Other delivery methods
Carbon nanotubes Endosomal/ No No Low
lysosomal
Electroporation Cytosolic Yes No Low
Osmotic lysis of Cytosolic No No; QD- Mild
pinocytic vesicles protein
conjugate
prepared ex
vivo and
delivered
intact
Poly(D,L-lactide- Cytosolic No Yes Low
co-glycolide)
nanosphere
encapsulation
Table 1-2. Comparison of previously reported quantum dot (QD) delivery
methods.
Part IlIl: Lipoic acid ligase-mediated protein labeling and introduction to protein-protein
interaction detection
Since the work introduced in Part II of this chapter, a superior ligase enzyme for small-molecule
protein labeling has been introduced: E. coli lipoic acid ligase, or LplA. We therefore abandoned
our BirA engineering efforts and designed future applications to utilize LpiA-mediated labeling.
In this section we will first describe the biochemical properties of LpIA and how it has been
applied to site-specific protein labeling, then detail the problem to which we will apply LpIA:
detection of protein-protein interactions.
Lipoic acid ligase
Physiological role and biochemical properties of lipoic acid ligase
Lipoic acid, like biotin, is a cofactor that must be covalently attached to the enzymes that
require it, such as the glycine cleavage system, alpha-ketoglutarate dehydrogenase, and
pyruvate dehydrogenase.[109] Free lipoic acid can be conjugated to specific lysine residues of
its cognate proteins through the ATP-dependent action of lipoic acid ligase, or LpIA, in E.
coli,[110] in exact analogy to BCCP biotinylation by BirA. (A parallel lipoylation pathway exists,
catalyzed by the enzymes LipB and LipA, in which octanoic acid produced by the fatty acid
biosynthetic pathway is transferred from acyl carrier proteins to lipoyl acceptor domains, then
enzymatically converted to lipoic acid via sulfur insertion.[109]) The kinetic properties of the
enzyme have been investigated; its Km for lipoic acid and ATP are 1.7 ptM and 3 pIM,
respectively.[110] Its kcat for lipoic acid ligation is 0.22 s .[111] Interestingly, LpIA also has
previously been reported to catalyze attachment of octanoic acid and selenolipoic acid to lipoyl
acceptor proteins.[110]
Two peptide substrates for LpIA have previously been reported by the Ting lab. The original
peptide substrate, called LAP1, was rationally designed by comparing consensus sequences of
naturally occurring lipoylated proteins.[112] While the kcat for ligation of a small-molecule
substrate to this peptide by LpIA, at 0.05 s', was found to be only about 2-fold slower than the
kcat of ligation of this substrate to a lipoylated domain of E. coli pyruvatede hydrogenase, at
0.11 s-1. However, the affinity of LpIA for LAPl is so poor that initial attempts to measure the Km
were unsuccessful, except to estimate that it must be greater than 200 pM.[112] A high-affinity
peptide substrate, the LAP2, was therefore obtained by yeast-display evolution.[111] LpIA
catalyzes lipoic acid attachment to the LAP2 with a kcat of 0.22 s1 and a tremendously
decreased Km of 13 ptM.[111]
Application of lipoic acid ligase to protein labeling
Similarly to BirA, the ability of LpIA to selectively ligate small molecules to peptide substrates
had great promise for developing a peptide-directed labeling strategy for recombinant proteins
in the cellular context. LplA, however, has an important advantage: many small molecule
probes can be accommodated by this enzyme.
The capacity of wild-type LpIA to attach octanoic acid and selenolipoic acid to lipoyl acceptor
proteins suggested that this enzyme may exhibit plasticity toward small-molecule substrates
while retaining specificity for its protein or peptide substrate. Fern ndez-Suarez et al. found
that this is indeed the case, and that wild-type LpIA can ligate a series of functionalized probes,
39
including an alkyl azide, to its LAP1 acceptor peptide.[112] The alkyl azide was used to label
LAP1-tagged cell-surface proteins with cyclo-octyne-bearing probes and fluorophores.[112]
Perhaps the most interesting feature of LpIA is the capacity for mutants of the enzyme to
accommodate interesting probe structures as substrates. Specifically, mutations at W37, which
lies deep in the binding pocket and interacts with the dithiolane ring of lipoic acid, [113-115]
increase the size of the binding pocket and permit large probes to bind. First, a mutant of LplA
have been demonstrated to ligate a probe bearing an aryl azide photo-activatable cross-linker
site-specifically to the LAP1 peptide, which was subsequently utilized for cross-linking
interacting proteins.[116]
Most excitingly for the field of protein imaging, mutations at W37 have been shown to
accommodate a bright blue fluorescent 7-hydroxycoumarin probe and to ligate this probe to
LAP2-tagged proteins.[117] Despite its blue emission, the fluorescence spectrum of 7-
hydroxycoumarin is compatible with imaging of cultured cells (excitation 387-405 nm; emission
448 nm).[118] Furthermore, despite its small size, the anionic form of 7-hydroxycoumarin is a
brighter fluorophore (with a E of 36,700 M 1 cm' and quantum yield of 0.7)[118] than the
enhanced blue fluorescent protein (EBFP), which is commonly used for protein imaging in cells
(with a E of 31,500 M1 cm' and quantum yield of 0.2).[119] Therefore, LAP2-conjugated
coumarin represents an advantage over EBFP for protein imaging, not only because of its
improved brightness, but because of the small total size of this tag. LplA-mediated coumarin
labeling has been put to use in site-specific protein labeling and fluorescence imaging both on
the surface and in the cytoplasm of living cells.[117]
Importance of protein-protein interactions in cell biology
While the importance of site-specific protein labeling cannot be overstated, as we still have
much to learn about the localization, trafficking, and dynamic behavior of many proteins inside
living cells, we can also apply our enzyme-mediated labeling technologies to more complex
problems. In particular, we are interested in studying the occurrence and dynamics of protein-
protein interactions inside living mammalian cells.
Proteins rarely function individually in cellular processes.[120] The recent characterization of
several interactomes, or sets of all protein-protein interactions (PPIs) occuring in a cell,
demonstrates not only that many proteins undergo PPIs, but that those interactions are
fundamental to the biological function of these proteins.[121-125] Some proteins exist in stable
complexes inside cells, such as RNA polymerase and the nuclear pore complex.[126] Other
proteins form transient associations, which form the basis of signaling pathways inside cells.
Protein-protein interactions convey information from the extracellular environment into the
cell interior, beginning with ligand-receptor interactions at the cell surface, then propagating
the signal into the cell via short-lived associations of protein partners in the signaling pathway,
including kinases and phosphatases.[127] It is therefore clear that the functions of many
proteins are governed by their interactions with other proteins, and where and when those
interactions occur inside the cell.
Reductionist methods for identifying PPIs rely on characterization of interactions between
purified proteins, protein domains, or peptides in vitro. While such methods provide
information about dissociation constants and the effects of inhibitors, they cannot report on
whether the interaction occurs in cells, where such processes are regulated by spatially and
temporally regulated, and where other biomolecules may compete for binding. Therefore we
focus on methods that detect interactions within the cellular milieu, be it cell lysates, fixed cells,
or living cells.
In this section we will discuss current methods for the study of PPIs in the cellular context,
beginning with biochemical methods used in cell lysates, then moving to methods used to
identify PPIs in the heterologous context of yeast cells, then to methods used to detect
interactions in fixed mammalian cells, and finally to methods for use in living mammalian cells.
We will discuss the strengths and weaknesses of these methods as well as examples of their
applications in order to motivate the need for improved methods.
Biochemical methods
Co-immunoprecipitation and tandem affinity purification
The most commonly used method to identify PPIs in cells is co-immunoprecipitation, or co-IP. In
this experimental paradigm, a protein is precipitated from a cell lysate using resin conjugated to
an antibody specific to the protein of interest. Any proteins that interact with the target protein
will remain complexed during the precipitation step, and can be eluted from the beads and
subsequently identified.[128] In its modern incarnation, co-IP is combined with mass
spectrometry (MS)-based proteomics to identify interacting proteins.[129, 130] The assignment
can then be confirmed by immunoblotting against the co-precipitated protein with an antibody
specific to its suspected identity.
An advantage of co-IP is that if a specific and high-affinity antibody against a protein of interest
exists, the method can be used to pull down and interrogate binders of endogenous proteins.
Barring the existence of such an antibody, the protein of interest can be fused either to an
epitope tag for which a high-affinity antibody exists, or to a protein such as glutathione-S-
transferase that can bind a resin-conjugated small molecule to facilitate specific, high-affinity
pull-downs.
Co-IP is, however, subject to false positives. First, the antibody utilized for precipitation of the
protein of interest may bind to and precipitate other proteins in off-target events.[126] Second,
cell lysis can generate false positive results for proteins that would normally not be co-
compartmentalized or co-localized in an intact cell, but that can interact once the cell is
lysed.[126] Therefore, an independent method must be used to demonstrate that any
detected interaction is physiologically relevant. Finally, proteins co-precipitated may not
directly interact with the protein of interest, but may be part of a larger multi-protein
complex.[126]
Additionally, co-IP suffers from false negatives. In particular, due to the dilution effect of cell
lysis and washing steps, as well as the lengthy purification protocols, transient and/or low-
affinity interactions may not be detected.[131] Since protein concentrations inside cells can
vary from 0.3pM to 1 mM, the dissociation constants of intracellular PPIs must occur over that
range; but even the most sensitive purification-based methods applicable to lysates are limited
to detecting interactions with dissociation constants of less than or approximately equal to 10
p.M.[126]
Tandem affinity purification, or TAP-tagging, has been developed more recently to reduce the
false positives that plague co-IP. The noise reduction arises from two sequential purification
steps.[132] Generally, two affinity tags are fused to the protein of interest; the tags are
separated by a tobacco etch virus (TEV) protease recognition sequence. The protein and its
associated interaction partners are first purified by binding to an affinity resin specific to the
first part of the TAP tag; elution is performed by adding TEV protease. The complex is then
purified on a resin specific for the second part of the TAP tag.[132] Unfortunately, tandem
affinity purification is prone to low sensitivity due to the multiple dilution and washing steps
involved, necessitating the use of very large amounts of starting material to achieve sufficient
signal for analysis.[133] It therefore suffers the same limited ability to detect transient and low-
affinity interactions that characterizes co-IP. Despite these limitations, TAP-tagging has recently
been used to construct an interactome network of Saccharomyces cerevisiae.[123]
Chemical cross-linking and photo-cross-linking
In order to solve the false-negative problem of affinity purification methods due to dissociation
events, covalent cross-linking methods have been developed. Classical methods for protein
cross-linking utilize a reagent such as formaldehyde or a di-N-hydroxysuccinimide ester with a
linker between the reactive groups, which can react with two proteins in close proximity to one
another in biological samples (i.e., intact cells or cell lysates).[131, 132] The covalent complexes
are then affinity purified from the sample and subjected to immunoblotting or MS-based
analysis. Because cross-linking reagents react non-specifically with protein functional groups in
a proximity-dependent manner, cross-linking approaches are amenable to analysis of
interactions of a protein of interest with endogenous proteins.
The utility and sensitivity of the chemical cross-linking approach have been demonstrated by an
elegant method for covalently trapping kinases that interact with a particular phosphorylation
substrate.[134, 135] A cysteine is engineered into the phosphorylated protein of interest near
the phosphorylation site; all kinases have a lysine in the active site that is mechanistically
required for phosphate group transfer. A cross-linking probe was designed to bind specifically in
the kinase active site, either utilizing an adenine moiety or a small-molecule kinase inhibitor,
bearing an o-phthaldialdehyde moiety. The cross-linker can then react with the kinase lysine
residue and the substrate cysteine to create a cross-linked product. This approach is amenable
to kinase cross-linking in cell lysates, demonstrating that cross-linking strategies can be applied
to the some of the most labile of biologically relevant PPIs, kinase-substrate interactions. (Of
course, the labeling chemistry is still relatively slow, requiring that the cross-linking probe be
designed around a very high-affinity kinase inhibitor in order to achieve cross-linking in cell
lysates, so the sensitivity and generality of this method remain to be demonstrated.) Thus
cross-linking approaches can be utilized to capture transient interactions that would never be
detected by co-IP or affinity purification.
Additional sensitivity in PPI detection can be achieved through the use of photo-activatable
cross-linkers. While chemical cross-linking reagents are limited to reaction with electrophilic
and nucleophilic substitutents of amino acids, photo-activatable cross-linkers generate highly
reactive intermediates that can react with essentially any functional group, including C-H
bonds.[136] Because photo-cross-linking probes can be site-specifically incorporated into
proteins, they offer the additional advantage (over chemical cross-linking methods) of
generating relatively few cross-linked products, simplifying analysis. Unnatural amino acid
mutagenesis was the first method reported for site-specific incorporation of photo-cross-linkers
into proteins, including aryl azides and benzophenones.[11] A method to enzymatically attach
an aryl azide to a small peptide tag using the E. coli lipoic acid ligase enzyme has been recently
reported by our research group.[116] Both of these methods have been demonstrated to
specifically cross-link known interaction partners in cell lysates. Of course, aryl azides (and the
smallest photo-activatable cross-linkers, diazirines) are inefficient cross-linkers because their
photo-activation involves dissociation of nitrogen, producing nitrene or carbene intermediates,
respectively; which can react non-productively with solvent, producing very low cross-linking
yields[112, 116]. Benzophenones are much more efficient photo-cross-linkers because the
reactive ketyl diradical intermediate can relax back to the ground state and be re-activated
through multiple cycles of excitation, producing greater cross-linking yields.[137] Because these
site-specific targeting methods are relatively new, application of photo-cross-linking reagents in
new PPI discovery has not yet been extensively demonstrated.
Yeast genetic methods
Yeast two-hybrid
The yeast two-hybrid is a powerful method for detecting PPIs in yeast cells. In this assay, the
transcription factor GAL4 is separated into two domains, a DNA-binding domain and an
activator domain. If interacting proteins are each fused to one of the domains, the interaction
causes the transcription factor to reassemble, translocate to the nucleus, and activate
transcription of a reporter gene.[138, 139] The yeast two-hybrid can be used either to
interrogate a suspected interaction between two proteins of interest, or to screen libraries of
prey proteins for interaction with a bait protein of interest. It is in library screening that the
yeast two-hybrid method has found its most powerful application.
The yeast two-hybrid method suffers from a high false positive rate. False positives can arise
from several sources. First, false positives can arise from off-target interactions of a particular
prey. If the prey protein binds to the promoter directly, interacts with another transcription
factor or protein involved in transcription, or if it interacts with the activator domain of the bait
fusion construct, reporter transcription can be activated.[140] Second, false positives can arise
because the proteins are being expressed in a heterologous system; if they are mislocalized or
overexpressed in yeast, they may undergo interactions which would never occur in the
mammalian cell.
Finally, the information that can be obtained about a PPI is limited in the yeast two-hybrid
system. The method cannot report on the localization of the interaction, nor can it provide
temporal information about interactions, because the readout depends on transcription and
translation of a reporter gene, which requires several hours' lag time. Furthermore, because
the reassembled transcription factor must be able to translocate to the nucleus, this method is
inapplicable to proteins that cannot undergo this translocation, in particular membrane
proteins.[141]
Despite these limitations, the yeast two-hybrid remains one of the most commonly used
methods for new PPI discovery, as evidenced by its use in delineating large-scale interactome
maps for Drosophila melanogaster,[125] Saccharomyces cerevisiae,[142] Caenorhabditis
elegans,[121] as well as partial interactome studies of human proteins.[143, 144]
Split ubiquitin
A genetic reporter of PPIs that promises to improve on the two-hybrid method is split ubiquitin.
In this system, ubiquitin is split into two halves that are not recognized by ubiquitin binding
proteins and are not cleaved when expressed individually. When the two ubiquitin halves are
fused to interacting proteins, the forced proximity (that is, the high local concentration)
induced by the interaction causes the fragments of ubiquitin to associate and fold, forming an
active, though non-covalently associated, ubiquitin molecule joining the interacting proteins.
The folded ubiquitin is recognized by ubiquitin binding proteins and cleaved.[145] If a reporter
protein is incorporated into the construct after the cleavage site, the ubiquitin cleavage event
will liberate it from the fusion construct, which can be used to read out the interaction event.
The reporter in this case is an engineered transcription factor that, upon liberation, translocates
to the nucleus and specifically activates transcription of an introduced transgene, such as beta-
galactosidase. The subsequent colorimetric response of the P-galactosidase reports on the
interaction.[146] Because the transcription factor is freed from the interacting proteins after
cleavage, the proteins of interest may reside anywhere in the cell, as long as the ubiquitin and
transcription factor are localized in the cytosol. In fact, split ubiquitin has been demonstrated to
detect interactions between membrane proteins, a significant advance over the yeast two-
hybrid.[146] While this method is powerful for detecting PPIs, it is performed in the
heterologous context of yeast cells, and so suffers the same problems of context that the yeast
two-hybrid does. Furthermore, because the readout is genetic, the method does not provide
spatial or temporal information about the interaction under study.
Methods applicable to fixed mammalian cells
In situ proximity ligation
The proximity ligation in situ assay (P-LISA) is a method for detecting endogenous PPIs in fixed
cells or tissue sections.[147] The general principle is the coupling of two DNA oligonucleotides
to antibodies against the two target proteins; when the antibodies are in close proximity, the
attached oligonucleotides template association of circularizable DNA "connectors", which can
be enzymatically ligated in situ to produce a circular DNA primer. The circular DNA can then
prime rolling-circle amplification of one of the antibody-conjugated oligonucleotides. The
amplified product remains attached to the antibody, and is then detected with DNA probes by
fluorescence in situ hybridization. This method provides both sensitivity and specificity of
detection; specificity arises because only when the DNA-conjugated antibodies are in close
proximity is the circular primer formed, and sensitivity comes from the amplification of the
rolling circle amplification product, which can produce up to several thousand repeats of the
target sequence.[148]
The P-LISA method has been utilized to detect heterodimers of the transcription factors c-Myc
and Max in cell lines and in clinical tissue sections.[147] In some cell lines, individual spots can
be observed, which may or may not be signal from single c-Myc/Max interaction events.
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The major advantages of the P-LISA method are (1) the ability to detect interactions of
endogenous proteins, and therefore applicability to clinical histological samples, as long as a
suitable antibody is available; and (2) the tremendous signal amplification arising from the DNA
replication step. However, the major disadvantage is that the method requires fixation and
therefore cannot be applied in living cells.
Proximity biotinylation
A method to detect PPIs in lysates and fixed mammalian cells has recently been reported by the
Ting lab.[149] Proximity biotinylation adapts the BirA-mediated biotinylation of the AP peptide
(see Part 11 of this chapter as well as Chapter 4 for more details) to create a PPI sensor. In this
design, BirA is fused to one protein partner, and an AP peptide to the other. When the two
proteins interact, BirA and the peptide substrate are brought into proximity, biotinylation
occurs, and the signal can be read out with streptavidin staining. In order to decrease
background from interaction-independent AP biotinylation, the peptide was engineered to
decrease its affinity for BirA, but retain a sufficiently high kcat, by deleting three amino acids
from the C-terminus; the resulting peptide is called AP(-3). Proximity biotinylation utilizing BirA
and AP(-3) generates, at best, a signal-to-background ratio of 28:1 in the presence of a PPI.
However, the method suffers from a limited dynamic range from slow background biotinylation
of AP(-3) and impaired kcat of AP(-3) relative to the original AP peptide (0.53 min-'instead of 12
min 1)[149]. Furthermore the method is limited to fixed-cell detection because of the
requirement for streptavidin staining.
Methods applicable to live mammalian cells
Co-localization imaging
A common method utilized in the study of interacting proteins in both fixed and live cells is co-
localization imaging. In this method, each protein is detected with a unique fluorophore; in
fixed cells, this can be accomplished with fluorophore-conjugated antibodies against the
endogenous proteins, while in live cells, fluorescent protein fusions can be utilized. Upon
imaging, coincidence of the two colors is taken as confirmation of co-localization of the two
proteins. Live-cell co-localization analysis has been applied, for example, to studying co-
trafficking of synaptic proteins in neurons[150] and to the discovery of the purinosome, a
presumptive complex of the proteins involved in de novo purine biosynthesis.[151]
However, the resolution of co-localization imaging in most conventional light-based
microscopes is limited by the diffraction of light. Using the shortest near-UV excitation light that
is non-toxic in cellular imaging, approximately 400 nm, the maximum theoretical achievable
resolution in the focal plane is 150 nm.[152] In practice, the real achievable resolution is 200-
300 nm.[153] This resolution limit is larger than some subcellular structures, [153] and certainly
larger than individual proteins. Therefore coincidence of fluorescence reports only that the
proteins are within the same diffraction-limited spot, not that they are directly interacting.
While several new techniques have been developed for sub-diffraction imaging, they are
technically challenging, require specialized microscopy instrumentation, and are currently
restricted to use in fixed samples.[153]
Resonance energy transfer
As an improvement to co-localization imaging, the direct interaction of two flurorophore-
tagged proteins can be detected by resonance energy transfer. The principle of resonant energy
transfer is the nonradiative transfer of energy from a donor fluorophore to an acceptor
fluorophore. The efficiency of energy transfer depends on the distance between the donor and
acceptor, decaying as a function of the sixth power of this distance and therefore only occurring
at very short donor-acceptor separation. The F6rster distance is defined as the separation
between the donor and acceptor giving 50% energy transfer efficiency, and for most organic
fluorophores is approximately 1-10 nm.[141] This distance is within the range of the distances
involved in biological protein-protein interactions.[154]
The most commonly used method to detect PPIs inside living cells, in real time and with spatial
resolution, is fluorescence resonant energy transfer, or FRET. Several biologically relevant
fluorophore pairs have been reported for FRET. The first pair used was the blue fluorescent
protein (BFP) and the green fluorescent protein (GFP), but cell autofluorescence interferes
significantly with BFP emission, generating noise.[155] The most commonly used pair is the
cyan fluorescent protein, CFP, and yellow fluorescent protein, YFP.[156] Several additional pairs
have been reported, including YFP/dsRED[154] and CFP/fluorescein (targeted using the FlAsH
methodology).[157] At its simplest, the interrogation of PPIs can be accomplished by fusion of a
donor and acceptor fluorophore to individual proteins, followed by quantitation of
intermolecular FRET. The advantage of this arrangement is that the interaction can be observed
associating and dissociating in real time due to the rapid FRET response, while obtaining spatial
information about the interaction. However, there are severe limitations in terms of signal-to-
noise attainable in intermolecular FRET. First, every reported donor-acceptor pair suffers from
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intrinsic channel cross-talk.[156] Donor excitation wavelengths often directly excite the
acceptor to some extent, producing low background acceptor fluorescence. Furthermore, the
broad emission spectra of fluorescent proteins mean that the tail of donor emission extends
into the acceptor emission channel, again producing low background signal from donor
emission. This cross-talk fundamentally limits the dynamic range of intensity-based FRET
measurements, since the background will never be zero. A secondary consequence of these
bleed-through effects is that intermolecular FRET is most sensitive if the donor and acceptor
(and thus, both interaction partners) are present in a 1:1 stoichiometry.[141] Additional copies
of either donor or acceptor contribute background that may overwhelm specific FRET signal.
The final limitation is the requirement for not only spatial proximity but proper orientation of
the donor relative to acceptor.[156] This means that FRET is exquisitely sensitive to fusion
geometry, and even in the case where proteins interact, FRET may not occur if the orientations
of and distance between the donor and acceptor are not adequate.
Several developments have attempted to address the limitations of intermolecular FRET. First,
FRET-FLIM, or fluorescence lifetime imaging, is a method of FRET quantitation that addresses
the limitations of spectral cross-talk by eliminating the measurement of acceptor emission
entirely.[155] The excited state lifetime of the donor is measured in the presence and absence
of the acceptor; if FRET occurs, the lifetime of the excited state is expected to decrease. [158]
This method retains spatial information and has a better dynamic range than intensity-based
FRET because only the donor emission is measured, but it is technically challenging. A second
method to address the stoichiometry problem is the construction of fusion proteins containing
both interaction partners for intramolecular FRET. The most important examples of this PPI
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reporter class are the cameleon calcium sensors.[159] These reporters are generally fusions of
calmodulin to M13 peptide, a peptide derived from myosin light-chain kinase that binds Ca2 ,
which interact upon calcium binding. CFP and YFP are fused at each end of the construct, and
when calcium is present, calmodulin and M13 interact, bringing CFP and YFP into proximity and
increasing FRET.156] However, as a general design principle, presenting both interaction
partners on the same molecule may promote their interaction simply because of their
increased local concentration, producing false positives.[141]
Bioluminescent resonance energy transfer, or BRET, relies on energy transfer between the
bioluminescent product of a luciferase enzyme with a fluorescent protein acceptor. Similar to
FRET, the donor-acceptor distances producing BRET are in the range of 1-10 nm.[160] Because
the donor is bioluminescent, donor excitation light is eliminated, removing background due to
autofluorescence and direct acceptor excitation.[160] The dynamic range and sensitivity of
BRET are therefore superior to FRET. The most common donor-acceptor pair utilized in BRET
studies is Renilla luciferase, which produces a blue bioluminescent product from the small-
molecule substrate coelenterazine, and YFP.[160] Recently, extension of BRET to far-red
imaging in vivo has been reported using an indocyanine dye as the acceptor;[161] to make this
method generally applicable, chemical methods for specific indocyanine targeting to proteins of
interest must be developed.
In conclusion, FRET has found widespread application for both intermolecular and
intramolecular PPI detection, though it suffers from a limited dynamic range and complicated
technical corrections for spectral overlap; BRET may begin to address these spectral limitations
in the near future.
Protein complementation assays
Protein complementation assays (PCAs) are a class of PPI detection methods that make use of
reporter protein reconstitution to report on PPIs. In general, a reporter protein (either an
enzyme or a fluorescent protein) is split in an internal loop to create two inactive fragments.
This can either be done by rational design, where known or predicted disordered regions are
chosen for dissection, or by screening libraries of truncation mutants for complementation
activity. The fragments are fused to each member of an interacting pair of proteins. Upon
interaction of the proteins of interest, the fragments of the reporter protein associate, fold, and
reconstitute the reporter functionality, be it enzymatic activity or fluorescence. The fragments
must also be designed such that in the absence of a PPI, they do not spontaneously reassemble
to generate reporter activity. This assay design has been applied to several methods of PPI
detection in living cells.
PCAs in general suffer several limitations. One drawback is that reporter reconstitution depends
on accessibility of the fragments in the interaction complex; the fusions to the proteins of
interest must be constructed such that the fragments of the PCA reporter are geometrically
accessible for folding and re-assembly, and failure to do so may result in false negative results.
Another drawback is that reporter reconstitution is generally irreversible, meaning that the
interacting proteins are trapped in complex, a non-physiological condition in which the
proteins' normal trafficking is perturbed. Finally, some suffer from background due to
spontaneous reporter re-assembly, especially at high expression levels.[162]
Many proteins have been pressed into use as PCA reporters, and we will discuss each in turn.
1. Dihydrofolate reductase
The first reported PCA utilized dihydrofolate reducutase (DHFR) as the reporter. This enzyme
can be reassembled from inactive fragments to regenerate DHFR enzymatic activity when fused
to interacting proteins.[163] The DHFR activity can then be read out either by a survival assay or
by imaging using a fluorescent probe.[164] The survival assay works by expressing the DHFR
fragment fusions to interaction partners in a cell line that lacks endogenous DHFR; if the
proteins interact, the introduced DHFR activity allows survival in nucleotide-free media. This
assay, while sensitive, provides no spatial or temporal information about the PPI under
investigation. The imaging-based method utilizes fluorescein-conjugated methotrexate, an
inhibitor that strongly binds DHFR, as a probe for active enzyme. Unfortunately, while this
method in theory has the potential to provide spatial information about interactions,
methotrexate is toxic to cells because it inhibits nucleotide biosynthesis.
Despite these limitations, the DHFR survival assay has recently been used to great effect in
elucidating a complete interaction network in Saccharomyces cerevisiae.[124] Reconstitution of
a methotrexate-resistant mutant of DHFR was utilized to interrogate interaction of the products
of over 4000 yeast ORFs, and over 2700 interactions were identified. This impressive
application demonstrates the power of PCAs for identifying new PPIs, even if additional
biological information about the interaction cannot be acquired with the method.
2. @-galactosidase
Split -galactosidase was developed next.[165] By splitting @-galactosidase into two fragments
with no enzymatic activity and also low ability to spontaneously reassemble when coexpressed,
low background is achieved; enzymatic activity is strongly induced in the context of fusion to
interacting proteins. The enzyme can utilize chemiluminescent and colorimetric substrates, but
substrate treatment must be performed in cell lysate or fixed cells, therefore eliminating any
temporal or spatial information that can be obtained about the enzyme.
3. P-lactamase
The ampicillin resistance gene product, 0-lactamase, has been utilized as a PCA sensor. The
enzyme catalyzes hydrolysis of cephalosporins. A fluorogenic substrate for @-lactamase, CCF2-
AM, has previously been developed for use in live cells.[166] A colorimetric S-lactamase
substrate, nitrocefin, can be hydrolyzed by the enzyme to produce a red product, but nitrocefin
is not membrane-permeable, so can only be used in cell lysates.[167]
In order to create a PCA reporter, the enzyme was dissected at a site shown to be amenable to
linker insertion and circular permutation.[166] Reconstitution of the reporter and enzymatic
activity were detected in the presence of both of these interactions both in vitro, using the
nitrocefin substrate, and in living cells by microscopy using the CCF2-AM substrate, when fused
to a homodimerizing leucine zipper.
The @-lactamase reporter therefore provides a colorimetric or fluorogenic response to PPI and
reporter reconstitution. However, several important limitations exist. First, the background is
low but nonzero for this method in the absence of interactions, potentially producing false
positive results. Second, the CCF2-AM substrate for use in living cells is diffusible, limiting the
spatial information that can be obtained about the interaction.
4. Luciferase
PCAs have been reported using firefly,[168] Renilla,[169] and Gaussia[170] luciferases. The
firefly luciferase utilizes molecular oxygen and ATP to oxidize a small-molecule substrate called
luciferin, producing yellow bioluminescence; the Renilla and Gaussia luciferases act on the
coelenterate luciferin (coelenterazine) substrate, oxidizing it with molecular oxygen to produce
blue bioluminescence without any additional cofactor requirement.[171] The first report of a
Renilla luciferase PCA was in 2003.[172] However, significant background was observed when
the Renilla luciferase fragments were coexpressed in cells, either alone or when fused to non-
interacting proteins. An improved Renilla luciferase PCA was reported in 2007.[169] In this
design, which splits the protein in a different location, background is low (though non-zero) and
bioluminescence recovery in the event of a PPI is high. Counter-intuitively, the formation of the
Renilla luciferase reporter from its fragments is demonstrably reversible, meaning that the
folded reporter can again dissociate into its fragments, permitting the interacting proteins to
dissociate.
The Gaussia luciferase PCA was reported in 2006.[170] Two fragments of the enzyme were
identified that could fold in less than 1 minute to generate 10% of the enzymatic activity of an
equivalent amount of intact Gaussia luciferase. This reporter also demonstrates reversibility.
Firefly luciferase has been utilized for real-time PPI detection.[168] This reporter folds within 1
minute and produces 18-fold greater bioluminescence in the presence of an interaction than in
the absence of one. The firefly luciferase fragments produce background bioluminescence
when coexpressed in mammalian cells in the absence of any fusion, though the induced
bioluminescence in the context of a fusion to an interacting pair is much higher. This reporter
was used to image the phosphorylation-dependent association of Cdc25C with 14-3-3E and the
constitutive homodimerization of the transcription factor STAT1 in cultured mammalian cells,
and the rapamycin-dependent association of FKBP with FRB, the domain of the mammalian
target of rapamycin (mTOR) that interacts with FKBP and rapamycin, in living mice.
In conclusion, split luciferase assays provide sensitive bioluminescent detection of PPIs both in
living cells and in living animals, with multiple colors and orthogonal substrates available. The
association of these reporter fragments is reversible, thus not trapping the complexes.
However, these assays suffer in general from background signal in the absence of a PPI that
could be interpreted as false positives. Furthermore, the luciferins are diffusible, limiting the
spatial information that can be obtained.
5. Fluorescent proteins
The bimolecular fluorescence complementation (BiFC) assay has found extensive application in
the detection and imaging of PPIs with high sensitivity and spatial resolution on the surface of
and inside living cells. The principle of BiFC rests on the fact that GFP and related fluorescent
proteins contain a buried fluorophore within an eleven-stranded beta-barrel.[173] The stepwise
formation of mature fluorescent GFP from a nascent polypeptide is as follows: first the protein
folds into its tertiary structure, then the fluorophore autocatalytically cyclizes, followed by
oxidation of the fluorophore by molecular oxygen. If the barrel structure is not properly folded
or denatured, the chromophore is non-fluorescent. In order to turn GFP into a PPI sensor, the
protein is split into two pieces which do not fluoresce individually because the barrel structure
is incomplete. Each piece is fused to one member of an interacting pair or proteins. When the
proteins interact, the fragments of GFP associate and fold; subsequent to protein folding, the
fluorophore forms and becomes oxidized, and fluorescence is reconstituted.[174]
The first and still most widely applied fluorescence complementation method was split GFP.GFP
is split in the loop between beta-strands 10 and 11, leaving strands 1-10 forming the larger N-
terminal fragment, and the strand 11 peptide forming the small C-terminal fragment of GFP.
Split GFP has been reported to detect PPIs with affinities as weak as 1 mM.[175] The first report
of split GFP reconstitution was by Ghosh et al., who demonstrated that two non-fluorescent
fragments of GFP could reconstitute fluorescence when fused to artificial leucine zippers and
either refolded from aggregates in vitro or expressed inside E. coli.[176] These leucine zipper
fusions were subsequently demonstrated to recombine in mammalian cells and allowed
visualization of the subcellular localization of the interaction when directed to various
organelles.[177] Ozawa et al. also reported recontsitution of split GFP by a slightly different
method, wherein each fragment of GFP was fused to a split intein, as well as calmodulin and
M13. Upon calcium-induced interaction, the intein was reconstituted and covalently
recombined the fragments of GFP, yielding fluorescence. [178] Since these initial reports, split
GFP has been used to image protein-protein interactions across the synaptic junction[179] and
the trafficking and co-compartmentalization of bacterial pathogen proteins with various
60
endogenous mammalian proteins during infection;[180] it has also been used to screen
randomized protein libraries for the design of new peptide binding activity, [181] among many
other applications.
YFP BiFC has been developed specifically for use in visualizing PPIs inside living cells. The first
report of YFP BiFC came from the Kerppola lab, who described fragments of enhanced YFP split
at residue 155 to generate a large N-terminal and small C-terminal fragment, which could
produce fluorescence complementation in living mammalian cells when fused to leucine zipper
domains of the transcription factors Fos and Jun and accurately reported the subcellular
(nuclear) localization of the interaction.[174]
Multicolor BiFC has recently been reported. Cyan fluorescent protein (CFP),[182] several red
fluorescent proteins (mCherry[183] and mRFP1[184]), and a far-red fluorescent protein,
mLumin,[185] have been demonstrated to support fluorescence complementation upon PPI-
mediated reconstitution. Because the small C-terminal fragment of CFP and YFP used for BiFC
are nearly identical, a fusion of the C-terminal CFP peptide to one interacting partner can
complement either the N-terminal fragment of CFP or YFP on another interacting partner,
facilitating the interrogation of competing interactions with a single protein.
BiFC displays excellent sensitivity, even to transient interactions, accurately reports subcellular
localization of PPIs, works in living cells, and is available in many colors. As such it is well suited
to microscopy as well as FACS-based applications. However, there are several limitations to the
technique that speak to the need for new methods to image PPIs in living cells. First,
fluorescence recovery for split YFP after a PPI is induced is detectable after 10 minutes, but only
quantifiable after about 1 hour and maximal 8 hours after the interaction is induced;[186] the
in vitro half-time for fluorescence maturation is about an hour.[127] This slow maturation limits
the application of the method to inducible or dynamic PPIs. Second, reconstitution of the
fluorescent protein reporter from its constituent fragments is irreversible, trapping interacting
proteins in complex.[175] Third, both the large and small fragments of fluorescent proteins
used as reporters are generally insoluble and tend to cause aggregation of the protein to which
they are fused.[186, 187] Well-folded fragments of split superfolder GFP were selected from a
library generated by DNA shuffling; these fragments produce fluorescence only ten minutes
after complementation, but they spontaneously reassemble, precluding their use as a reporter
of PPIs.[187] Reporter misfolding presents several serious problems in detecting inducible PPIs,
which we will discuss in detail in Chapter 4. Finally, the method has been reported to be prone
to false positive results that arise from association, folding, and subsequent fluorescence in the
absence of a PPI, especially when the constructs are expressed at very high levels (though this is
dependent on the fluorescent protein employed in the reporter design, occurring, for example,
for Venus but not EYFP).[162, 186]
Conclusion
From the sheer number of PPI detection methods discussed in this chapter, it should be clear
that the study of known PPIs and the discovery of new PPIs are of tremendous interest to cell
biologists and protein biochemists. Despite the repeated application of high-throughput co-
purification and two-hybrid approaches to interactome mapping, very little overlap between
detected interactions has been observed between similar studies. This is due to the high false
positive and negative rates of current methods; it has been estimated that up to 60% of the
interactions detected in these studies are false positives that have not been verified by
independent methods.[132] Therefore, the yeast and human interactomes are estimated to be
only 50% and 10% complete, respectively,[132] and new methods to discover and characterize
these remaining PPIs are needed.
The pertinent features of each PPI detection method described in this section are summarized
in Table 1-3. While biochemical methods have proven historically powerful in identifying and
characterizing PPIs, and indeed are still utilized to confirm any new PPI that has been putatively
identified by other methods, they cannot provide information about whether an interaction
occurs in intact cells, and certainly cannot provide spatial or temporal information about the
interaction. Yeast genetic methods are amenable to high-throughput screening but notoriously
subject to false positives. Histological methods cannot provide dynamic information about PPIs.
FRET suffers from limited dynamic range and BRET cannot assess subcellular localization.
Protein complementation assays suffer either high background, lack of spatial resolution, or
aggregation problems. While each of these methods is powerful in its own right, no method yet
satisfies all the requirements of an ideal PPI detection method. It is clear, then, that new
methods are required to improve on the sensitivity and specificity of existing methods, as well
as to provide improved PPI imaging modalities to gain spatial and temporal information about
an interaction without significantly perturbing it. Finally, we note that even new methods for
PPI detection will not likely address all limitations of current methods, and that any new
interaction must be interrogated by multiple methods, because they provide different and
synergistic information about PPIs.
While proximity biotinylation represented an advance in PPI detection in mammalian cells
relative to PCAs because of its good sensitivity, low background, and because it does not trap
interacting proteins, its dynamic range is limited and it can only be used for PPI detection in
fixed cells. In Chapter 4 of this thesis, we will describe our efforts to improve on this method by
utilizing LpIA and the LAP peptide to create new sensors for visualizing PPIs.
Biochemical methods
Co- No No No No No Yes
immunoprecipitation
and TAP tagging
Chemical and photo- No No No No No Yes
cross-linking
Yeastgentic Methods
Yeast two-hybrid No No No No No No
Split ubiquitin No No No No No Yes
Fixed manmaflan cell methods
Proximity ligation in No No Yes No No Yes
situ (P-LISA)
Proximity No No Yes No No Yes
biotinylation
Resonant energy transfer (live mammalian cell methods)
Fluorescence Yes Yes Yes No Yes Yes
resonant energy
transfer (FRET)
Bioluminescence No Yes Yes No Yes Yes
resonant energy
transfer (BRET)
Protein complementation assays (live mammalian cell methods)
Split dihydrofolate No No No Yes Yes Yes
reductase
Split 1-lactamase No Yes No Yes Yes Yes
Split -galactosidase No No No Yes Yes Yes
Split luciferase No Yes No No Yes Yes
BiFC No Moderate Yes Yes Yes Yes
Table 1-3. Comparison of current protein-protein interaction (PPI) detection methods. Note that the
dihydrofolate reductase (DHFR) protein complementation assay (PCA) is described in terms of the survival assay.
References
1. Shaner, N.C., P.A. Steinbach, and R.Y. Tsien, A guide to choosing fluorescent proteins. Nat
Methods, 2005. 2(12): p. 905-9.
2. Lippincott-Schwartz, J. and G.H. Patterson, Development and use offluorescent protein markers
in living cells. Science, 2003. 300(5616): p. 87-91.
3. Xie, X.S., et al., Single-molecule approach to molecular biology in living bacterial cells. Annu Rev
Biophys, 2008. 37: p. 417-44.
4. Betzig, E., et al., Imaging intracellular fluorescent proteins at nanometer resolution. Science,
2006. 313(5793): p. 1642-5.
5. Dresbach, T., et al., Synaptic targeting of neuroligin is independent of neurexin and SAP90/PSD95
binding. Mol Cell Neurosci, 2004. 27(3): p. 227-35.
6. Lisenbee, C.S., S.K. Karnik, and R.N. Trelease, Overexpression and mislocalization of a tail-
anchored GFP redefines the identity of peroxisomal ER. Traffic, 2003. 4(7): p. 491-501.
7. Marguet, D., et al., Lateral diffusion of GFP-tagged H2Ld molecules and of GFP-TAP1 reports on
the assembly and retention of these molecules in the endoplasmic reticulum. Immunity, 1999.
11(2): p. 231-40.
8. Chen, l. and A.Y. Ting, Site-specific labeling of proteins with small molecules in live cells. Curr
Opin Biotechnol, 2005. 16(1): p. 35-40.
9. Chin, J.W., et al., An expanded eukaryotic genetic code. Science, 2003. 301(5635): p. 964-7.
10. Liu, W., et al., Genetic incorporation of unnatural amino acids into proteins in mammalian cells.
Nat Methods, 2007. 4(3): p. 239-44.
11. Wang, L., J. Xie, and P.G. Schultz, Expanding the genetic code. Annu Rev Biophys Biomol Struct,
2006. 35: p. 225-49.
12. Liu, D.R., et al., Engineering a tRNA and aminoacyl-tRNA synthetase for the site-specific
incorporation of unnatural amino acids into proteins in vivo. Proc Nati Acad Sci U S A, 1997.
94(19): p. 10092-7.
13. Sasso, S.P., et al., Thermodynamic study of dihydrofolate reductase inhibitor selectivity. Biochim
Biophys Acta, 1994. 1207(1): p. 74-9.
14. Miller, L.W., et al., In vivo protein labeling with trimethoprim conjugates: a flexible chemical tag.
Nat Methods, 2005. 2(4): p. 255-7.
15. Miller, L.W., et al., Methotrexate conjugates: a molecular in vivo protein tag. Angew Chem Int Ed
Engl, 2004. 43(13): p. 1672-5.
16. Clackson, T., et al., Redesigning an FKBP-ligand interface to generate chemical dimerizers with
novel specificity. Proc Natl Acad Sci U S A, 1998. 95(18): p. 10437-42.
17. Marks, K.M., P.D. Braun, and G.P. Nolan, A general approach for chemical labeling and rapid,
spatially controlled protein inactivation. Proc Natl Acad Sci U S A, 2004. 101(27): p. 9982-7.
18. Keppler, A., et al., A general method for the covalent labeling offusion proteins with small
molecules in vivo. Nat Biotechnol, 2003. 21(1): p. 86-9.
19. Heinis, C., et al., Evolving the substrate specificity of 06-alkylguanine-DNA alkyltransferase
through loop insertion for applications in molecular imaging. ACS Chem Biol, 2006. 1(9): p. 575-
84.
20. Los, G.V., et al., HaloTag: a novel protein labeling technology for cell imaging and protein
analysis. ACS Chem Biol, 2008. 3(6): p. 373-82.
21. Bonasio, R., et al., Specific and covalent labeling of a membrane protein with organic
fluorochromes and quantum dots. Proc Natl Acad Sci U S A, 2007. 104(37): p. 14753-8.
22. Chattopadhaya, S., et al., Site-specific covalent labeling of proteins inside live cells using small
molecule probes. Bioorg Med Chem, 2009. 17(3): p. 981-9.
23. Lockless, S.W. and T.W. Muir, Traceless protein splicing utilizing evolved split inteins. Proc Nati
Acad Sci U S A, 2009. 106(27): p. 10999-1004.
24. Griffin, B.A., S.R. Adams, and R.Y. Tsien, Specific covalent labeling of recombinant protein
molecules inside live cells. Science, 1998. 281(5374): p. 269-72.
25. Martin, B.R., et al., Mammalian cell-based optimization of the biarsenical-binding tetracysteine
motiffor improved fluorescence and affinity. Nat Biotechnol, 2005. 23(10): p. 1308-14.
26. Adams, S.R., et al., New biarsenical ligands and tetracysteine motifs for protein labeling in vitro
and in vivo: synthesis and biological applications. J Am Chem Soc, 2002. 124(21): p. 6063-76.
27. Gaietta, G., et al., Multicolor and electron microscopic imaging of connexin trafficking. Science,
2002. 296(5567): p. 503-7.
28. Adams, S.R. and R.Y. Tsien, Preparation of the membrane-permeant biarsenicals FIAsH-EDT2 and
ReAsH-EDT2 forfluorescent labeling of tetracysteine-tagged proteins. Nat P rotoc, 2008. 3(9): p.
1527-34.
29. Gaietta, G.M., et al., Golgi twins in late mitosis revealed by genetically encoded tags for live cell
imaging and correlated electron microscopy. Proc Nati Acad Sci U S A, 2006. 103(47): p. 17777-
82.
30. T our, 0., et al., Calcium Green FlAsH as a genetically targeted small-molecule calcium indicator.
Nat Chem Biol, 2007. 3(7): p. 423-31.
31. Roberti, M.J., et al., Fluorescence imaging of amyloid formation in living cells by afunctional,
tetracysteine-tagged alpha-synuclein. Nat Methods, 2007. 4(4): p. 345-51.
32. Tour, 0., et al., Genetically targeted chromophore-assisted light inactivation. Nat Biotechnol,
2003. 21(12): p. 1505-8.
33. Stroffekova, K., C. Proenza, and K.G. Beam, The protein-labeling reagent FLASH-EDT2 binds not
only to CCXXCC motifs but also non-specifically to endogenous cysteine-rich proteins. Pflugers
Arch, 2001. 442(6): p. 859-66.
34. Guignet, E.G., R. Hovius, and H. Vogel, Reversible site-selective labeling of membrane proteins in
live cells. Nat Biotechnol, 2004. 22(4): p. 440-4.
35. Hauser, C.T. and R.Y. Tsien, A hexahistidine-Zn2+-dye label reveals STIM1 surface exposure. Proc
Natl Acad Sci U S A, 2007. 104(10): p. 3693-7.
36. Ojida, A., et al., Oligo-Asp tag/Zn(II) complex probe as a new pair for labeling and fluorescence
imaging of proteins. J Am Chem Soc, 2006. 128(32): p. 10452-9.
37. Nonaka, H., et al., Non-enzymatic covalent protein labeling using a reactive tag. J Am Chem Soc,
2007. 129(51): p. 15777-9.
38. Marks, K.M., M. Rosinov, and G.P. Nolan, In vivo targeting of organic calcium sensors via
genetically selected peptides. Chem Biol, 2004. 11(3): p. 347-56.
39. McCann, C.M., et al., Peptide tags for labeling membrane proteins in live cells with multiple
fluorophores. Biotechniques, 2005. 38(6): p. 945-52.
40. Lambalot, R.H., et al., A new enzyme superfamily - the phosphopantetheinyl transferases. Chem
Biol, 1996. 3(11): p. 923-36.
41. Yin, J., et al., Labeling proteins with small molecules by site-specific posttranslational
modification. J Am Chem Soc, 2004. 126(25): p. 7754-5.
42. Yin, J., et al., Genetically encoded short peptide tag for versatile protein labeling by Sfp
phosphopantetheinyl transferase. Proc Natl Acad Sci U S A, 2005. 102(44): p. 15815-20.
43. Kropf, M., et al., Subunit-specific surface mobility of differentially labeled AMPA receptor
subunits. Eur J Cell Biol, 2008. 87(10): p. 763-78.
44. Yin, J., et al., Single-cell FRET imaging of transferrin receptor trafficking dynamics by Sfp-
catalyzed, site-specific protein labeling. Chem Biol, 2005. 12(9): p. 999-1006.
45. Carrico, I.S., B.L. Carlson, and C.R. Bertozzi, Introducing genetically encoded aldehydes into
proteins. Nature Chemical Biology, 2007. 3(6): p. 321-322.
46. Wu, P., et al., Site-specific chemical modification of recombinant proteins produced in
mammalian cells by using the genetically encoded aldehyde tag. Proceedings of the National
Academy of Sciences of the United States of America, 2009. 106(9): p. 3000-3005.
47. Duckworth, B.P., et al., Selective labeling of proteins by using protein farnesyltransferase.
Chembiochem, 2007. 8(1): p. 98-105.
48. Lin, C.W. and A.Y. Ting, Transglutaminase-catalyzed site-specific conjugation of small-molecule
probes to proteins in vitro and on the surface of living cells. Journal of the American Chemical
Society, 2006. 128(14): p. 4542-4543.
49. Chapman-Smith, A. and J.E. Cronan, Jr., Molecular biology of biotin attachment to proteins.
J.Nutr., 1999. 129(2S Suppl): p. 477S-484S.
50. Beckett, D., The Escherichia coli biotin regulatory system: a transcriptional switch.
J.Nutr.Biochem., 2005. 16(7): p. 411-415.
51. Cronan, J.E., Jr., Biotination of proteins in vivo. A post-translational modification to label, purify,
and study proteins. J.Biol.Chem., 1990. 265(18): p. 10327-10333.
52. Xu, Y. and D. Beckett, Kinetics of biotinyl-5'-adenylate synthesis catalyzed by the Escherichia coli
repressor of biotin biosynthesis and the stability of the enzyme-product complex. Biochemistry,
1994. 33(23): p. 7354-7360.
53. Xu, Y. and D. Beckett, Biotinyl-5'-adenylate synthesis catalyzed by Escherichia coli repressor of
biotin biosynthesis. Methods Enzymol., 1997. 279: p. 405-421.
54. Stanley, J.S., J.B. Griffin, and J. Zempleni, Biotinylation of histones in human cells. Effects of cell
proliferation. Eur.J.Biochem., 2001. 268(20): p. 5424-5429.
55. Healy, S., et al., Nonenzymatic biotinylation of histone H2A. Protein Sci., 2009. 18(2): p. 314-328.
56. Healy, S., et al., Biotin is not a natural histone modification. Biochim.Biophys.Acta, 2009.
1789(11-12): p. 719-733.
57. Chapman-Smith, A., et al., Molecular recognition in a post-translational modification of
exceptional specificity. Mutants of the biotinylated domain of acetyl-CoA carboxylase defective
in recognition by biotin protein ligase. J.Biol.Chem., 1999. 274(3): p. 1449-1457.
58. Beckett, D., E. Kovaleva, and P.J. Schatz, A minimal peptide substrate in biotin holoenzyme
synthetase-catalyzed biotinylation. Protein Sci., 1999. 8(4): p. 921-929.
59. de Boer, E., et al., Efficient biotinylation and single-step purification of tagged transcription
factors in mammalian cells and transgenic mice. Proc.Natl.Acad.Sci.U.S.A, 2003. 100(13): p.
7480-7485.
60. Chen, I., Y.A. Choi, and A.Y. Ting, Phage display evolution of a peptide substrate for yeast biotin
ligase and application to two-color quantum dot labeling of cell surface proteins.
J.Am.Chem.Soc., 2007. 129(20): p. 6619-6625.
61. Chen, L., et al., Site-specific labeling of cell surface proteins with biophysical probes using biotin
ligase. Nat.Methods, 2005. 2(2): p. 99-104.
62. Howarth, M., et al., Targeting quantum dots to surface proteins in living cells with biotin ligase.
Proc.Natl.Acad.Sci.U.S.A, 2005. 102(21): p. 7583-7588.
63. Howarth, M., et al., A monovalent streptavidin with a singlefemtomolar biotin binding site.
Nat.Methods, 2006. 3(4): p. 267-273.
64. Howarth, M., et al., Monovalent, reduced-size quantum dots for imaging receptors on living cells.
Nat Methods, 2008. 5(5): p. 397-9.
65. McNeill, E., i. Chen, and A.Y. Ting, Synthesis of a ketone analogue of biotin via the intramolecular
Pauson-Khand reaction. Org.Lett., 2006. 8(20): p. 4593-4595.
66. Sletten, E.M. and C.R. Bertozzi, Bioorthogonal chemistry: fishing for selectivity in a sea of
functionality. Angew.Chem.Int.Ed Engl., 2009. 48(38): p. 6974-6998.
67. Rostovtsev, V.V., et al., A stepwise huisgen cycloaddition process: copper(l)-catalyzed
regioselective "ligation" of azides and terminal alkynes. Angew.Chem.Int.Ed Engl., 2002. 41(14):
p. 2596-2599.
68. Wang, Q., et al., Bioconjugation by copper(l)-catalyzed azide-alkyne [3 + 2] cycloaddition.
J.Am.Chem.Soc., 2003. 125(11): p. 3192-3193.
69. Saxon, E. and C.R. Bertozzi, Cell surface engineering by a modified Staudinger reaction. Science,
2000. 287(5460): p. 2007-10.
70. Kiick, K.L., et al., Incorporation of azides into recombinant proteins for chemoselective
modification by the Staudinger ligation. Proc NatI Acad Sci U S A, 2002. 99(1): p. 19-24.
71. Agard, N.J., et al., A comparative study of bioorthogonal reactions with azides. ACS Chem.Biol.,
2006. 1(10): p. 644-648.
72. Liu, W., et al., Compact biocompatible quantum dots functionalized for cellular imaging. J Am
Chem Soc, 2008. 130(4): p. 1274-84.
73. Jaiswal, J.K., et al., Long-term multiple color imaging of live cells using quantum dot
bioconjugates. Nat Biotechnol, 2003. 21(1): p. 47-51.
74. Ruan, G., et al., Imaging and tracking of tat peptide-conjugated quantum dots in living cells: new
insights into nanoparticle uptake, intracellular transport, and vesicle shedding. J Am Chem Soc,
2007. 129(47): p. 14759-66.
75. Derfus, A.M., W.C.W. Chan, and S.N. Bhatia, Intracellular delivery of quantum dots for live cell
labeling and organelle tracking. Advanced Materials, 2004. 16(12): p. 961-+.
76. Janes, P.W., et al., Cytoplasmic Relaxation of Active Eph Controls Ephrin Shedding by ADAM10.
Plos Biology, 2009. 7(10): p. -.
77. Chen, X., et al., A cell nanoinjector based on carbon nanotubes. Proc Natl Acad Sci U S A, 2007.
104(20): p. 8218-22.
78. Kim, B.Y., et al., Biodegradable quantum dot nanocomposites enable live cell labeling and
imaging of cytoplasmic targets. Nano Lett, 2008. 8(11): p. 3887-92.
79. Chan, W.C. and S. Nie, Quantum dot bioconjugates for ultrasensitive nonisotopic detection.
Science, 1998. 281(5385): p. 2016-8.
80. Schroeder, J.E., et al., Folate-mediated tumor cell uptake of quantum dots entrapped in lipid
nanoparticles. J Control Release, 2007. 124(1-2): p. 28-34.
81. Bharali, D.J., et al., Folate-receptor-mediated delivery of InP quantum dots for bioimaging using
confocal and two-photon microscopy. J Am Chem Soc, 2005. 127(32): p. 11364-71.
82. Murriel, C.L. and S.F. Dowdy, Influence of protein transduction domains on intracellular delivery
of macromolecules. Expert Opin Drug Deliv, 2006. 3(6): p. 739-46.
83. Cronican, J.J., et al., Potent Delivery of Functional Proteins into Mammalian Cells in Vitro and in
Vivo Using a Supercharged Protein. ACS Chem Biol, 2010.
84. McNaughton, B.R., et al., Mammalian cell penetration, siRNA transfection, and DNA transfection
by supercharged proteins. Proc Natl Acad Sci U S A, 2009. 106(15): p. 6111-6.
85. Delehanty, J.B., et al., Self-assembled quantum dot-peptide bioconjugates for selective
intracellular delivery. Bioconjug Chem, 2006. 17(4): p. 920-7.
86. Nitin, N., et al., Tat peptide is capable of importing large nanoparticles across nuclear membrane
in digitonin permeabilized cells. Ann Biomed Eng, 2009. 37(10): p. 2018-27.
87. Mattheakis, L.C., et al., Optical coding of mammalian cells using semiconductor quantum dots.
Anal Biochem, 2004. 327(2): p. 200-8.
88. Chang, J.C., H.L. Su, and S.H. Hsu, The use of peptide-delivery to protect human adipose-derived
adult stem cellsfrom damage caused by the internalization of quantum dots. Biomaterials, 2008.
29(7): p. 925-36.
89. Rozenzhak, S.M., et al., Cellular internalization and targeting of semiconductor quantum dots.
Chem Commun (Camb), 2005(17): p. 2217-9.
90. Biju, V., et al., Quantum dot-insect neuropeptide conjugates forfluorescence imaging,
transfection, and nucleus targeting of living cells. Langmuir, 2007. 23(20): p. 10254-61.
91. Delehanty, J.B., et al., Delivering quantum dot-peptide bioconjugates to the cellular cytosol:
escaping from the endolysosomal system. Integr Biol (Camb), 2010. 2(5-6): p. 265-77.
92. Akinc, A., et al., Exploring polyethylenimine-mediated DNA transfection and the proton sponge
hypothesis. J Gene Med, 2005. 7(5): p. 657-63.
93. Sonawane, N.D., F.C. Szoka, Jr., and A.S. Verkman, Chloride accumulation and swelling in
endosomes enhances DNA transfer by polyamine-DNA polyplexes. J Biol Chem, 2003. 278(45): p.
44826-31.
94. Duan, H. and S. Nie, Cell-penetrating quantum dots based on multivalent and endosome-
disrupting surface coatings. J Am Chem Soc, 2007. 129(11): p. 3333-8.
95. Mok, H., J.W. Park, and T.G. Park, Enhanced intracellular delivery of quantum dot and adenovirus
nanoparticles triggered by acidic pH via surface charge reversal. Bioconjug Chem, 2008. 19(4): p.
797-801.
96. Derfus, A.M., et al., Targeted quantum dot conjugatesfor siRNA delivery. Bioconjug Chem, 2007.
18(5): p. 1391-6.
97. Yoo, J., et al., Intracellular imaging of targeted proteins labeled with quantum dots. Exp Cell Res,
2008. 314(19): p. 3563-9.
98. Kam, N.W. and H. Dai, Carbon nanotubes as intracellular protein transporters: generality and
biologicalfunctionality. J Am Chem Soc, 2005. 127(16): p. 6021-6.
99. Dhar, S., et al., Targeted single-wall carbon nanotube-mediated Pt(IV) prodrug delivery using
folate as a homing device. J Am Chem Soc, 2008. 130(34): p. 11467-76.
100. Bottini, M., et al., Full-length single-walled carbon nanotubes decorated with streptavidin-
conjugated quantum dots as multivalent intracellular fluorescent nanoprobes.
Biomacromolecules, 2006. 7(8): p. 2259-63.
101. Okada, C.Y. and M. Rechsteiner, Introduction of macromolecules into cultured mammalian cells
by osmotic lysis of pinocytic vesicles. Cell, 1982. 29(1): p. 33-41.
102. Courty, S., et al., Tracking individual kinesin motors in living cells using single quantum-dot
imaging. Nano Letters, 2006. 6(7): p. 1491-1495.
103. Pierobon, P., et al., Velocity, processivity, and individual steps of single myosin V molecules in live
cells. Biophys J, 2009. 96(10): p. 4268-75.
104. Sandvig, K. and B. van Deurs, Delivery into cells: lessons learned from plant and bacterial toxins.
Gene Ther, 2005. 12(11): p. 865-72.
105. Chakraborty, S.K., et al., Cholera toxin B conjugated quantum dots for live cell labeling. Nano
Letters, 2007. 7(9): p. 2618-26.
106. Tekle, C., et al., Cellular trafficking of quantum dot-ligand bioconjugates and their induction of
changes in normal routing of unconjugated ligands. Nano Lett, 2008. 8(7): p. 1858-65.
107. W alev, I., et al., Delivery of proteins into living cells by reversible membrane permeabilization
with streptolysin-0. Proc Natl Acad Sci U S A, 2001. 98(6): p. 3185-90.
108. Xing, Y., et al., Molecular profiling of single cancer cells and clinical tissue specimens with
semiconductor quantum dots. Int J Nanomedicine, 2006. 1(4): p. 473-81.
109. Morris, T.W., K.E. Reed, and J.E. Cronan, Jr., Lipoic acid metabolism in Escherichia coli: the IplA
and lipB genes define redundant pathways for ligation of lipoyl groups to apoprotein.
J.Bacteriol., 1995. 177(1): p. 1-10.
110. Green, D.E., et al., Purification and properties of the lipoate protein ligase of Escherichia coli.
Biochem.J., 1995. 309 ( Pt 3): p. 853-862.
111. Puthenveetil, S., et al., Yeast display evolution of a kinetically efficient 13-amino acid substrate
for lipoic acid ligase. J.Am.Chem.Soc., 2009. 131(45): p. 16430-16438.
112. Fernandez-Suarez, M., et al., Redirecting lipoic acid ligase for cell surface protein labeling with
small-molecule probes. Nat.Biotechnol., 2007. 25(12): p. 1483-1487.
113. Kim, D.J., et al., Crystal structure of lipoate-protein ligase A bound with the activated
intermediate: insights into interaction with lipoyl domains. J.Biol.Chem., 2005. 280(45): p.
38081-38089.
114. McManus, E., B.F. Luisi, and R.N. Perham, Structure of a putative lipoate protein ligase from
Thermoplasma acidophilum and the mechanism of target selection for post-translational
modification. J.Mol.Biol., 2006. 356(3): p. 625-637.
115. F uj iwara, K., et al., Crystal structure of lipoate-protein ligase A from Escherichia coli.
Determination of the lipoic acid-binding site. J.Biol.Chem., 2005. 280(39): p. 33645-33651.
116. Baruah, H., et al., An engineered aryl azide ligase for site-specific mapping of protein-protein
interactions through photo-cross-linking. Angew.Chem.int.Ed Engl., 2008. 47(37): p. 7018-7021.
117. Uttamapinant, C., et al., Afluorophore ligase for site-specific protein labeling inside living cells.
Proc Natl Acad Sci U S A, 2010. 107(24): p. 10914-9.
118. Sun, W.C., K.R. Gee, and R.P. Haugland, Synthesis of novel fluorinated coumarins: excellent UV-
light excitable fluorescent dyes. Bioorg Med Chem Lett, 1998. 8(22): p. 3107-10.
119. Yang, T.T., et al., Improved fluorescence and dual color detection with enhanced blue and green
variants of the green fluorescent protein. J Biol Chem, 1998. 273(14): p. 8212-6.
120. More|l, M., S. Ventura, and F.X. Aviles, Protein complementation assays: Approaches for the in
vivo analysis of protein interactions. Febs Letters, 2009. 583(11): p. 1684-1691.
121. Li, S., et al., A map of the interactome network of the metazoan C. elegans. Science, 2004.
303(5657): p. 540-543.
122. Butland, G., et al., Interaction network containing conserved and essential protein complexes in
Escherichia coli. Nature, 2005. 433(7025): p. 531-537.
123. Krogan, N.J., et al., Global landscape of protein complexes in the yeast Saccharomyces cerevisiae.
Nature, 2006. 440(7084): p. 637-643.
124. Tarassov, K., et al., An in vivo map of the yeast protein interactome. Science, 2008. 320(5882): p.
1465-1470.
125. Giot, L., et al., A protein interaction map of Drosophila melanogaster. Science, 2003. 302(5651):
p. 1727-1736.
126. Phizicky, E.M. and S. Fields, Protein-protein interactions: methods for detection and analysis.
Microbiol.Rev., 1995. 59(1): p. 94-123.
127. Kerppola, T.K., Bimolecularfluorescence complementation (BiFC) analysis as a probe of protein
interactions in living cells. Annu.Rev.Biophys., 2008. 37: p. 465-487.
128. Elion, E.A., Detection of protein-protein interactions by coprecipitation. Curr Protoc Mol Biol,
2006. Chapter 20: p. Unit20 5.
129. Downard, K.M., Ions of the interactome: the role of MS in the study of protein interactions in
proteomics and structural biology. Proteomics, 2006. 6(20): p. 5374-84.
130. Chang, \.F., Mass spectrometry-based proteomic analysis of the epitope-tag affinity purified
protein complexes in eukaryotes. Proteomics, 2006. 6(23): p. 6158-66.
131. Miernyk, J.A. and J.J. Thelen, Biochemical approaches for discovering protein-protein
interactions. Plant Journal, 2008. 53(4): p. 597-609.
132. Berggard, T., S. Linse, and P. James, Methods for the detection and analysis of protein-protein
interactions. Proteomics, 2007. 7(16): p. 2833-2842.
133. Collins, M.O. and J.S. Choudhary, Mapping multiprotein complexes by affinity purification and
mass spectrometry. Current Opinion in Biotechnology, 2008. 19(4): p. 324-330.
134. Maly, D.J., J.A. Allen, and K.M. Shokat, A mechanism-based cross-linkerfor the identification of
kinase-substrate pairs. J Am Chem Soc, 2004. 126(30): p. 9160-1.
135. Statsuk, A.V., et al., Tuning a three-component reaction for trapping kinase substrate complexes.
J Am Chem Soc, 2008. 130(51): p. 17568-74.
136. Brunner, J., New photolabeling and crosslinking methods. Annual Review of Biochemistry, 1993.
62: p. 483-514.
137. Dorman, G. and G.D. Prestwich, Benzophenone photophores in biochemistry. Biochemistry,
1994. 33(19): p. 5661-73.
138. Fields, S. and 0. Song, A novel genetic system to detect protein-protein interactions. Nature,
1989. 340(6230): p. 245-6.
139. Chien, C.T., et al., The two-hybrid system: a method to identify and clone genesfor proteins that
interact with a protein of interest. Proc Natl Acad Sci U S A, 1991. 88(21): p. 9578-82.
140. Luban, J. and S.P. Goff, The yeast two-hybrid system for studying protein-protein interactions.
Curr Opin Biotechnol, 1995. 6(1): p. 59-64.
141. Villalobos, V., S. Naik, and D. Piwnica-Worms, Current state of imaging protein-protein
interactions in vivo with genetically encoded reporters. Annual Review of Biomedical
Engineering, 2007. 9: p. 321-349.
142. Yu, H., et al., High-quality binary protein interaction map of the yeast interactome network.
Science, 2008. 322(5898): p. 104-110.
143. Stelz\, U., et al., A human protein-protein interaction network: A resource for annotating the
proteome. Cell, 2005. 122(6): p. 957-968..
144. Rual, J.F., et al., Towards a proteome-scale map of the human protein-protein interaction
network. Nature, 2005. 437(7062): p. 1173-1178.
145. Johnsson, N. and A. Varshavsky, Split Ubiquitin As A Sensor of Protein Interactions In-Vivo.
Proceedings of the National Academy of Sciences of the United States of America, 1994. 91(22):
p. 10340-10344.
146. Stagljar, i., et al., A genetic system based on split-ubiquitin for the analysis of interactions
between membrane proteins in vivo. Proceedings of the National Academy of Sciences of the
United States of America, 1998. 95(9): p. 5187-5192.
147. Soderberg, 0., et al., Direct observation of individual endogenous protein complexes in situ by
proximity ligation. Nature Methods, 2006. 3(12): p. 995-1000.
148. Baner, J., et al., Signal amplification of padlock probes by rolling circle replication. Nucleic Acids
Res, 1998. 26(22): p. 5073-8.
149. Fernandez-Suarez, M., T.S. Chen, and A.Y. Ting, Protein-protein interaction detection in vitro and
in cells by proximity biotinylation. J.Am.Chem.Soc., 2008. 130(29): p. 9251-9253.
150. Gerrow, K., et al., A preformed complex of postsynaptic proteins is involved in excitatory synapse
development. Neuron, 2006. 49(4): p. 547-562.
151. An, S., et al., Reversible compartmentalization of de novo purine biosynthetic complexes in living
cells. Science, 2008. 320(5872): p. 103-6.
152. Hell, S.W., M. Dyba, and S. Jakobs, Concepts for nanoscale resolution in fluorescence microscopy.
Current Opinion in Neurobiology, 2004. 14(5): p. 599-609.
153. Huang, B., M. Bates, and X.W. Zhuang, Super-Resolution Fluorescence Microscopy. Annual
Review of Biochemistry, 2009. 78: p. 993-1016.
154. Ciruela, F., Fluorescence-based methods in the study of protein-protein interactions in living cells.
Curr.Opin.Biotechnol., 2008. 19(4): p. 338-343.
155. Truong, K. and M. Ikura, The use of FRET imaging microscopy to detect protein-protein
interactions and protein conformational changes in vivo. Curr.Opin.Struct.Biol., 2001. 11(5): p.
573-578.
156. M iyawaki, A., Visualization of the spatial and temporal dynamics of intracellular signaling.
Developmental Cell, 2003. 4(3): p. 295-305.
157. Hoff mann, C., et al., A FlAsH-based FRET approach to determine G protein-coupled receptor
activation in living cells. Nat Methods, 2005. 2(3): p. 171-6.
158. Wallrabe, H. and A. Periasamy, Imaging protein molecules using FRET and FLIM microscopy. Curr
Opin Biotechnol, 2005. 16(1): p. 19-27.
159. Miyawaki, A., et al., Fluorescent indicators for Ca2+ based on green fluorescent proteins and
calmodulin. Nature, 1997. 388(6645): p. 882-7.
160. Pfleger, K.D. and K.A. Eidne, Illuminating insights into protein-protein interactions using
bioluminescence resonance energy transfer (BRET). Nat Methods, 2006. 3(3): p. 165-74.
161. Wu, C., et al., In vivo far-red luminescence imaging of a biomarker based on BRET from Cypridina
bioluminescence to an organic dye. Proc.Natl.Acad.Sci.U.S.A, 2009. 106(37): p. 15599-15603.
162. Kerppola, T.K., Visualization of molecular interactions by fluorescence complementation. Nature
Reviews Molecular Cell Biology, 2006. 7(6): p. 449-456.
163. Pelletier, J.N., F.X. Campbell-Valois, and S.W. Michnick, Oligomerization domain-directed
reassembly of active dihydrofolate reductase from rationally designed fragments. Proceedings of
the National Academy of Sciences of the United States of America, 1998. 95(21): p. 12141-
12146.
164. Remy, 1. and S.W. Michnick, Clonal selection and in vivo quantitation of protein interactions with
protein-fragment complementation assays. Proceedings of the National Academy of Sciences of
the United States of America, 1999. 96(10): p. 5394-5399.
165. Rossi, F., C.A. Charlton, and H.M. Blau, Monitoring protein-protein interactions in intact
eukaryotic cells by beta-galactosidase complementation. Proc Natl Acad Sci U S A, 1997. 94(16):
p. 8405-10.
166. Zlokarnik, G., et al., Quantitation of transcription and clonal selection of single living cells with
beta-lactamase as reporter. Science, 1998. 279(5347): p. 84-88.
167. Remy, I., G. Ghaddar, and S.W. Michnick, Using the beta-lactamase protein-fragment
complementation assay to probe dynamic protein-protein interactions. Nat.Protoc., 2007. 2(9):
p. 2302-2306.
168. Luker, K.E., et al., Kinetics of regulated protein-protein interactions revealed with firefly
luciferase complementation imaging in cells and living animals. Proc.Natl.Acad.Sci.U.S.A, 2004.
101(33): p. 12288-12293.
169. Stefan, E., et al., Quantification of dynamic protein complexes using Renilla luciferase fragment
complementation applied to protein kinase A activities in vivo. Proc.Natl.Acad.Sci.U.S.A, 2007.
104(43): p. 16916-16921.
170. Remy, \. and S.W. Michnick, A highly sensitive protein-protein interaction assay based on Gaussia
luciferase. Nat.Methods, 2006. 3(12): p. 977-979.
171. Prescher, J.A. and C.H. Contag, Guided by the light: visualizing biomolecular processes in living
animals with bioluminescence. Current Opinion in Chemical Biology, 2010. 14(1): p. 80-89.
172. Paulmurugan, R. and S.S. Gambhir, Monitoring protein-protein interactions using split synthetic
renilla luciferase protein-fragment-assisted complementation. Anal Chem, 2003. 75(7): p. 1584-
9.
173. Tsien, R.Y., The green fluorescent protein. Annu.Rev.Biochem., 1998. 67: p. 509-544.
174. Hu, C.D., Y. Chinenov, and T.K. Kerppola, Visualization of interactions among bZIP and Relfamily
proteins in living cells using bimolecular fluorescence complementation. Mol.Ce||, 2002. 9(4): p.
789-798.
175. Magliery, T.J., et al., Detecting protein-protein interactions with a green fluorescent protein
fragment reassembly trap: scope and mechanism. J.Am.Chem.Soc., 2005. 127(1): p. 146-157.
176. Ghosh, I., A.D. Hamilton, and L. Regan, Antiparallel leucine zipper-directed protein reassembly:
Application to the green fluorescent protein. Journal of the American Chemical Society, 2000.
122(23): p. 5658-5659.
177. Zhang, S.F., C. Ma, and M. Chalfie, Combinatorial marking of cells and organelles with
reconstituted fluorescent proteins. Cell, 2004. 119(1): p. 137-+.
178. Ozawa, T., et al., A fluorescent indicatorfor detecting protein-protein interactions in vivo based
on protein splicing. Analytical Chemistry, 2000. 72(21): p. 5151-5157.
179. Feinberg, E.H., et al., GFP Reconstitution Across Synaptic Partners (GRASP) defines cell contacts
and synapses in living nervous systems. Neuron, 2008. 57(3): p. 353-363.
180. Van Engelenburg, S.B. and A.E. Palmer, Imaging type-Ill secretion reveals dynamics and spatial
segregation of Salmonella effectors. Nat.Methods, 2010. 7(4): p. 325-330.
181. Jackrel, M.E., et al., Screening Libraries To Identify Proteins with Desired Binding Activities Using
a Split-GFP Reassembly Assay. ACS Chem Biol, 2010.
182. Hu, C.D. and T.K. Kerppola, Simultaneous visualization of multiple protein interactions in living
cells using multicolorfluorescence complementation analysis. Nat. Biotechnol., 2003. 21(5): p.
539-545.
183. Fan, J.Y., et al., Split mCherry as a new red bimolecularfluorescence complementation system for
visualizing protein-protein interactions in living cells. Biochem.Biophys.Res.Commun., 2008.
367(1): p. 47-53.
184. Jach, G., et al., An improved mRFP1 adds red to bimolecular fluorescence complementation.
Nat.Methods, 2006. 3(8): p. 597-600.
185. Chu, J., et al., A novelfar-red bimolecular fluorescence complementation system that allows for
efficient visualization of protein interactions under physiological conditions.
Biosens.Bioelectron., 2009. 25(1): p. 234-239.
186. Robida, A.M. and T.K. Kerppola, Bimolecularfluorescence complementation analysis of inducible
protein interactions: effects offactors affecting proteinfolding on fluorescent protein fragment
association. J.Mol.Biol., 2009. 394(3): p. 391-409.
187. Cabantous, S. and G.S. Waldo, In vivo and in vitro protein solubility assays using split GFP.
Nat.Methods, 2006. 3(10): p. 845-854.
Chapter 2: Expanding the substrate tolerance of biotin ligase through exploration of enzymes
from diverse species
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Destihobiotin azide and propargyl biotin were synthesized by Dr. Irwin Chen. lodouracil valeric
acid and thiouracil valeric acid were synthesized by Dr. Yoon-Aa Choi.
Introduction.
E. coli biotin ligase, BirA, has been previously utilized by the Ting research group for labeling
cell-surface proteins with biotin, followed by detection with streptavidin-conjugated quantum
dots for single-molecule imaging, and with ketone biotin, which can be derivatized in
chemoselective fashion with hydroxylamine probes.[1, 2] The enzyme selectively ligates biotin
and ketone biotin to its 15-amino acid acceptor peptide, the AP, which can be genetically fused
to proteins of interest (Figure 2-1). These reactions, much like the natural reaction catalyzed by
BirA, attachment of biotin to the biotin carboxyl carrier protein (BCCP) of acetyl CoA
carboxylase, proceed in two Mg 2'-dependent steps, where the small molecule acid is first
activated using ATP as the adenylate ester, followed by attack of the activated intermediate by
a specific lysine residue of the peptide of protein substrate to form the amide bond in the
product.
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Figure 2-1. E. coli biotin ligase
(BirA)-mediated ligation of
biotin and ketone biotin to the
acceptor peptide (AP). Top,
biotin ligation; bottom, ketone
biotin ligation. The sequence of
the acceptor peptide is
provided; the unique lysine is
the point of attachment. Both
reactions require ATP for
generation of the reactive
adenylate intermediate.
While these two labeling schemes have proved useful for the study of cell surface proteins, they
cannot currently be applied to intracellular proteins. The ketone derivatization will be
inefficient inside the cell, where many ketones and aldehydes are present in metabolites;
streptavidin and quantum dots are too large to cross the cell membrane. We therefore sought
new labeling chemistries to expand the utility of biotin ligase-mediated protein labeling.
E. coli BirA has low tolerance for biotin analog ligation to the AP peptide
In this project we sought to incorporate a wider variety of functional groups, such as azides and
alkynes, which can be derivatized with probes using bio-orthogonal chemistry, as well as probes
containing fluorophores and photo-crosslinkers for one-step labeling, using BirA. However, the
efforts of many members of the Ting research group failed to identify BirA activity toward a
wide variety of probes.[3, 4] Furthermore, efforts to mutagenize the BirA active site, as well as
selections using randomized BirA libraries and in vitro compartmentalization, failed to produce
an enzyme that could ligate any new probes from a library of biotin analogs onto the AP.[3, 4]
This strong preference of BirA for biotin, as well as our difficulty in engineering BirA to be more
permissive for its small-molecule substrate, eventually led us to a different approach: we
decided to screen biotin ligase enzymes from other species to see if we could identify an
enzyme with increased small-molecule permissivity. Such differential substrate specificity
among homologous enzymes from different species has been previously observed.[5, 6]
Designing our study required advance knowledge of the general properties of biotin ligase
enzymes, including their biochemical properties, structures, and substrate specificity, which we
will review here.
Properties of biotin ligase enzymes across evolutionary space
I. Specificity of biotin ligase enzymes toward protein substrates
Despite exhibiting extremely high specificity toward the proteins they modify (discussed in
detail in Chapter 1), biotin ligase homologs have the fascinating property of biotinylating
carboxylase domains from other species.[7] This is a result of the extremely high sequence
conservation among both biotinyl domains and biotin ligase catalytic domains across
evolution.[7] The functional equivalence of biotin ligases from multiple species in biotinylating
each other's BCCPs has been demonstrated by complementation assays, in which a
temperature-sensitive mutation of E. coli BirA is rescued by biotin ligases from other species, as
well as direct detection of biotinylation of the E. coli BCCP by other biotin ligase enzymes (vide
infra for more details).
II. Monofunctional and bifunctional biotin ligases
In some species, the biotin ligase enzyme has a second function, transcriptional regulation of
biotin biosynthesis. The best-studied example is the E. coli system. E. coli BirA, in addition to its
large and strongly conserved catalytic domain, contains a small winged helix-turn-helix N-
terminal domain that can bind the biotin operator, a specific DNA sequence upstream of the
biotin biosynthetic operon.[8] Because of the ordered stepwise mechanism of BirA, discussed in
detail in Part II of Chapter 1, free biotin is constantly converted to the reaction intermediate
biotinyl-5'-AMP, or bio-5'-AMP. If excess free biotin is present but all BCCP present in the cell is
biotinylated, the bio5'-AMP intermediate remains bound with high affinity in the enzyme active
site. The intermediate-bound enzyme then dimerizes, and the dimer binds the biotin operator
78
to repress transcription of the biotin biosynthetic operon.[9] Because bio-5'-AMP-bound BirA
homodimerizes along the same interface at which apo-BCCP (that is, unbiotinylated BCCP)
binds during catalysis, the kinetic partitioning between catalytic turnover and
homodimerization, followed by DNA binding, is controlled by competing protein-protein
interactions, and therefore depends on the concentration of apo-BCCP in the cell.[10]
Therefore BirA acts as a sensor of biotin status and creates negative feedback to prevent excess
biotin biosynthesis when the vitamin levels are adequate.
Not all biotin ligases are bifunctional: two classes of enzymes exist, monofunctional enzymes
that catalyze biotin transfer and bifunctional enzymes that also have a DNA-binding domain. A
computational analysis of all sequenced bacterial and archaeal genomes revealed that
orthologs of bifunctional biotin ligase (that is, BirA orthologs with predicted DNA-binding
domains) are common among archaea as well as several groups of bacteria, such as the
Bacillus/Clostridium group, and the gamma-proteobacteria .[11] Several species were also
found to encode two biotin ligase paralogs, one monofunctional and one bifunctional.
Therefore it is clear that there is tremendous variation across evolution in the regulatory
function of biotin ligases. While DNA-binding capacity does not directly affect the catalytic
function of biotin ligases, it exemplifies the structural and functional diversity of these enzymes
across species.
Ill. Previously reported biotin ligase enzymes from other species: similarities and
differences in biochemical properties
While E. coli BirA is by far the best-characterized biotin ligase, many homologs have been
reported. All biotin ligase enzymes contain a strongly conserved catalytic domain (vide infra for
an alignment of biotin ligase catalytic domains relevant to this project). However, they vary
widely in other biochemical parameters, including substrate specificity (toward both protein
and small molecule substrates), domain structure and DNA binding properties, oligomerization
properties, and known rate constants. We briefly summarize the previously reported biotin
ligase homologs here, and provide a summary of their relevant biochemical properties in Table
2-1.
Several bacterial biotin ligases have been previously reported. The previously cloned, though
not purified, biotin ligase from Bacillus subtilis, a widely distributed bacterium that can be
found in many soils and aquatic environments,[12] has 27% sequence identity with the E. coli
BirA, and is also bifunctional.[13, 14] The monomeric, monofunctional biotin ligases from
Mycobacterium tuberculosis[15], the bacterium that causes tuberculosis, and Aquifex
aeolicus,[16, 17] a hyperthermophilic bacterium, have been cloned and purified. The biotin
ligase enzymes from Propionibacterium shermanii,[18] the bacterium utilized in fermenting
Swiss cheese,[19] and Bacillus stearothermophilus [20] a thermophilic bacterium, have been
purified from the organisms and biochemically characterized, though their DNA-binding
capacity has not been directly investigated. Interestingly, while most biotin ligase enzymes
require Mg2+ to support catalysis, the P. shermanii enzyme preferentially utilizes Zn 2.[18]
Leuconostoc mesenteroides is a bacterium used in industrial dextran production;[21] it is also
used in starter cultures for Manchego cheese production.[22] While its biotin ligase enzyme,
which has no predicted DNA-binding domain, has not been previously cloned or purified, the
growth requirements of the bacterium toward biotin and various biotin analogs have been
investigated.[23] While most organisms can utilize desthiobiotin, or DTB, in place of biotin, both
as a substrate for biotin ligase and as a cofactor in carboxylation reactions, DTB usually supports
at least two times slower growth of the organism in culture. Furthermore, the biotin analog y-
(3,4-ureylenecyclohexyl)butyric acid, in which the thiophene ring of biotin has been replaced
with a cyclohexyl ring, normally inhibits growth. However, in Leuconostoc, DTB supports a
growth rate equivalent to biotin, and the organism can grow in y-(3,4-
ureylenecyclohexyl)butyric acid when this analog is supplied at a sufficiently high concentration
(100 times the minimal concentration of biotin required for growth). While this does not report
directly on the substrate specificity of Leuconostoc biotin ligase, it is clear that the organism has
a uniquely relaxed tolerance for growth on biotin analogs, and we hoped that its biotin ligase
could potentially have interesting substrate specificity.
One monofunctional archaeal biotin ligase, lacking any N-terminal domain, has been previously
cloned, purified, and biochemically investigated. This enzyme is from Pyrococcus horikoshii, an
archaeon originally isolated from deep-sea vents that grows optimally at 980C.[24]
Representing the lower eukaryotes, two yeast biotin ligase enzymes have been cloned, purified,
and biochemically characterized. The baker's yeast Saccharomyces cerevisiae biotin ligase
(yeast biotin ligase, yBL) gene was first isolated in 1995.[25] The protein does not have DNA
binding capacity, though it does have a large N-terminal domain of ill-defined function. Deletion
of this domain severely curtails the enzyme's catalytic activity, up to 3500-fold relative to full-
length enzyme.[26] Another monofunctional fungal biotin ligase gene was recently isolated
from Candida albicans, a causative agent of human yeast infections.[27] C. albicans biotin ligase
is closely related to the S. cerevisiae enzyme, having 39% sequence identity with its fungal
relative.
In higher eukaryotes, biotin ligase is generally called holocarboxylase synthetase, in reference
to its activity in biotinylating carboxylase enzymes. Arabidopsis thaliana, the flowering plant
used as a model system for plant biologists, encodes two biotin ligase (in this case, referred to
as holocarboxylase synthetase, or HCS) genes targeted to either the cytosol or to chloroplasts.
Both have been cloned, purified, and characterized. This enzyme has no DNA binding domain
and fails to regulate the biotin biosynthetic operon in E. coli.[28-32] Two isoforms of
monofunctional HCS from the pea plant Pisum sativum have also been purified from the
plant.[31, 33]
Several mammalian HCS enzymes from have been purified and subjected to preliminary
characterization. The dimeric rat HCS was purified from rat liver.[34] The monomeric bovine
HCS was similarly purified from bovine liver.[35] Interestingly, this enzyme can utilize CTP with
an equivalent efficiency to the canonical biotin ligase nucleotide substrate, ATP.
Finally, the human HCS has been extensively characterized because mutations in the biotin-
binding region of HCS decrease the affinity of the enzyme for biotin and can cause multiple
carboxylase deficiency, a rare recessive disorder characterized by rashes, seizure, and death if
untreated.[36] The enzyme consists of a conserved catalytic domain as well as a large N-
terminal domain of ill-characterized function; expression of N-terminally truncated constructs
in E. coli revealed that the minimum functional enzyme consists of the last 348 amino acids of
the protein and contains the catalytic domain, but that the N-terminal domain is required for
full activity and substrate recognition.[37] HCS is expressed in human cells as two isoforms.[38]
Both isoforms are monomeric and have no DNA binding capacity.
Many of these enzymes have been functionally and biochemically characterized, and a
summary of their biochemical properties relevant to the current study is presented in Table 2-1.
Species N- Bi- Biotin ATP Km Activity Endo- Ordered Sensitivity to
terminal functional Km toward E. genous substrate biotin
domain coli BCCP BCCP binding analogs
Km
E. coli [1, 2, Yes Yes 490 0.3 Yes 4.39 liM Yes Uses
39] nM mM desthiobiotin
(DTB) and
ketone biotin
as substrates
B. subtilis Yes Yes NR NR Yes NR NR NR
(13, 14]
M. No No 420 21 pM NR 5.2 pM NR Does not use
tuberculosis nM DTB as
[15] substrate
A. aeolicus No No 440 15 pM NR NR No NR
[16, 17] nM
L. NR NR NR NR NR NR NR Growth not
dextranicum inhibited by
[23] DTB or
cyclohexyl
biotin analog 3
B.stearo- NR NR 75 nM 300 NR NR NR NR
thermophilus nM
{20]
P. shermanii NR NR 2 pM 38 pM NR 900 nM NR NR
[18]
P. horikoshii No No NR; KD NR; KD NR NR No NR
[40, 41] is 200 is 240
nM pM
S. cerevisiae Yes No 67 nM 20 pM Yes2; Km is 1 pM Yes Not inhibited
[26] 11 pM by biotin
analogs4
C. albicans NR No NR NR Yes' NR NR NR
[27]
A. thaliana NR No 130 4.4 pM Yes1'2  30 pM Yes Does not use
[29, 31, 32] nM DTB;not
inhibited by
biotin
analogs4
P. sativum NR No 28 nM 1 mM Yes NR NR Not inhibited
[31, 33] by biotin
analogs
4
Rat [34] NR No 50 nM NR NR NR NR NR
Cow[35] NR No 113nM NR NR NR NR NR
2Human [37, Yes No 800 47 pM Yes 21 pM Yes NR
38] nM
Table 2-1. Comparison of some biochemical properties of previously reported biotin ligase enzymes.
NR, not reported.
IE. coli BCCP utilization assayed by complementation of conditionally lethal heat-sensitive E. coli BirA strain.
2 E. coli BCCP utilization assayed directly in vitro.
3 Cyclohexyl biotin analog is y-(3,4-ureylenecyclohexyl)butyric acid.
4 Biotin analogs assayed for inhibition are biocytin, desthiobiotin, diaminobiotin and iminobiotin.
The biochemical properties of these enzymes are in some cases very similar and in other cases
interestingly variable. For example, it is clear from both complementation studies and in vitro
assays that these enzymes are similar in their general ability to modify biotinyl domains from
other species, in particular the E. coli BCCP. These reactions appear to be kinetically efficient; in
the case of the S. cerevisiae ligase, the apparent Km for E. coli BCCP is only about ten times
worse than its endogenous substrate. The Km values of these enzymes for biotin vary over two
orders of magnitude. Oligomerization states and the existence and function of N-terminal
domains vary and have no obvious correlation to mono- or bifunctionality or kinetic
parameters. As discussed in the text, examples of differential divalent cation (Zn2+ in place of
the canonical Mg2+ for the P. shermanii enzyme) or nucleotide (CTP rather than the canonical
ATP for the bovine liver enzyme) substrate specificities can be found in the literature. Most
interestingly of all, while the Leuconostoc biotin ligase has not been previously isolated, the
organism can utilize desthiobiotin and a cyclohexyl analog of biotin for growth, indicating that
some organisms may have interesting flexibility in biotin metabolism. We conclude that this
similarity in protein substrate specificity, but variability in structure as well as affinity for small
molecule substrates, portends potential room to discover new small molecule reactivity while
preserving specificity for protein and peptide substrates.
IV. Biotin ligase crystal structures
To date, biotin ligases from four species have been crystallized: E. coli BirA, P. horikoshii biotin
ligase, M. tuberculosis biotin ligase, and A. aeolicus biotin ligase. The first structure determined
was that of E. coli BirA, in its unliganded,[42] biotin bound,[42] and biotinyl-lysine bound[43]
forms. The structure of E. coli bound to biotinol-adenylate, an analog of the biotinyl-5'-
AMPreaction intermediate, was subsequently determined.[44] The protein consists of the N-
terminal DNA binding domain, a central catalytic domain housing the active site, and a C-
terminal domain that has been proposed to be involved in protein substrate binding. [45] The
biotin binding site features many hydrogen-bonding and hydrophobic interactions with biotin.
The side chains of residues S89, T90, and Q112, as well as a backbone carbonyl group from
R116, hydrogen-bond with the ureido ring of biotin.[42] The aliphatic sidechain of biotin is
bound in a hydrophobic pocket.[42] In the unliganded and biotin-bound enzyme, a Gly-Arg-Gly-
Arg-Arg-Gly loop is disordered; when the intermediate analog biotinol-adenylate is bound,
mimicking the conditions under which BirA serves its DNA-binding function, the loop becomes
ordered and is involved in high-affinity retention of the intermediate, forming a "cap" over the
active site.[44] K183 is required for reaction of biotin and ATP to form the biotinyl-5'-AMP
intermediate. [43]
The crystal structure of the P. horikoshii enzyme has been solved in its unliganded state, with
biotin bound, and with various other ligands bound. While this monofunctional enzyme
obviously lacks an N-terminal DNA binding domain, and furthermore dimerizes along a
completely different interface than does BirA, the sequence and structure of the catalytic
domain are highly conserved; in fact, the P. horikoshii enzyme has 31% sequence identity with
the catalytic and C-terminal domains of E. coli BirA.[40] The P. horikoshii biotin ligase structure
is superimposable on the catalytic and C-terminal domains of BirA with a r.m.s.d. value of 2.41
A.[40] The catalytic lysine is conserved (K111 in P. horikoshii biotin ligase), as is the threonine
involved in interaction with the biotin ureido ring (T90 in BirA, T22 in P. horikoshii biotin ligase),
as well as the glycine-rich loop that becomes ordered upon biotin binding. [40]
The crystal structure of the A. aeolicus biotin ligase enzyme has similarly been solved with
biotin bound. Again, the disordered glycine-rich loop involved in intermediate binding is
observed, as well as conservation of active-site residues including T14 (which aligns with T90 of
BirA and interacts with the ureido ring of biotin).[17]
Because such high sequence and structural similarity is observed in the active sites and catalytic
domains of these enzymes, we anticipate that any differences in their biochemical properties
would be difficult to predict from structural analysis.
V. Study design
The varied biochemical properties of biotin ligases from across evolution made us optimistic
that we might observe differences in their specificity for small-molecule substrates, and
potentially discover new catalysts for ligation of our probes of interest to proteins. However,
due to the similarity of reported biotin ligase structures, the basis of these differences
remained mysterious, so we adopted a screening strategy wherein we would select a panel of
distantly related biotin ligase enzymes in hopes of interrogating structural and functional
diversity. We were also encouraged to note that we could potentially design a relatively high-
throughput screening method using a single protein substrate, since biotin ligases from multiple
species can recognize the E. coli BCCP. We next explain the probes, enzymes, and substrates
that we chose for our screen, as well as the results of our screening strategy.
Results and discussion
Panel of biotin analogs
Our first prerogative was to choose a panel of probes that would extend the utility of site-
specific labeling to new functional groups, but that would also be likely to be accommodated by
the enzyme active site. This presumably requires significant structural similarity to biotin.
Members of the Ting lab prepared the panel of probes depicted in Figure 2-2 to meet these two
design goals.
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Figure 2-2. Structures of biotin
analogs used in this study.
Compounds 2 and 3 were
prepared by Dr. Irwin Chen, and
compounds 7 and 8 were
prepared by Dr. Yoon-Aa Choi.
Compound 1, included here for structural comparison, is d-biotin, which consists of a puckered
bicyclic structure containing a ureido functionality atop a thiophene ring and an aliphatic valeric
acid sidechain. Several classes of biotin analogs are represented among the remaining probes.
We first sought to incorporate bio-orthogonal functional group handles onto our probe, which
would allow secondary derivatization with a wide variety of reporter structures. These
functional handles are represented in compounds 2 and 3 (Figure 2-2), synthesized by Dr. Irwin
Chen. Compound 2, desthiobiotin azide, contains an azide moiety in place of the thiophene
ring of biotin. Azides are absent from cells and can react, as discussed in the introduction, with
alkynes, phosphines, and cyclooctynes. Compound 3, cis- and trans-propargyl biotin, bears a
propargyl group on the cis- and trans-ureido nitrogen atoms. Alkynes are also absent from cells
and can be derivatized via the [3+2] azide-alkyne cycloaddition. The synthesis of these probes
has been described and is summarized in Figure 2-3.[46]
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Figure 2-3. Synthetic routes to (A) desthiobiotin azide and (B) cis-propargyl biotin.
MeOH, methanol; AcCi, acetyl chloride; Me, methyl; TFAA, trifluoroacetic anhydride;
TEA, triethylamine; MsCl, mesyl chloride.
We also sought to directly incorporate probes with interesting functionality. The commercially
available probes 4 and 5 (Figure 2-2), iminobiotin and diaminobiotin, display pH-dependent
(strept)avidin binding properties and can be used for protein purification.[47]This pH-
dependence is due to the presence of protonatable groups with acid dissociation constants in
or near the physiological range. These molecules bind (strept)avidin in their deprotonated form,
and upon titration to lower pH, become protonated and dissociate.[47] The pKa of the
guanidino nitrogen of iminobiotin is 11.9, though it has been found to stoichiometrically bind
avidin at pH 9.0.[47]The pKa values for the two amino nitrogens of diaminobiotin are 5.1 and
8.3, and are presumably so low because of the proximity of these groups to each other.[47]
Probe 6, nitrobenzoxadiazole (NBD) y-amino butyric acid, contains the environmentally
sensitive fluorophore NBD (Figure 2-2). Though NBD is planar while biotin is puckered, we
hoped that the small bicyclic fluorophore could be accommodated by the enzyme active site.
Probes 7 and 8, iodouracil valeric acid and thiouracil valeric acid (Figure 2-2), synthesized by Dr.
Yoon-Aa Choi, contain the photo-activatable cross-linkers iodouracil and thiouracil.[48] Such
probes are useful for the study of protein-protein interactions; a complete discussion of this
application can be found in Part Ill of Chapter 1.
For the purposes of intracellular labeling, all of these probes would have to be able to cross the
cell membrane. We expect them all to have similar hydrophobicity to, if not greater
hydrophobicity than, biotin, which enters cells by passive diffusion at concentrations greater
than 2 pM.[49] At lower concentrations, biotin is actively transported into cells by the sodium-
dependent multivitamin transporter (SVMT); the SVMT has been shown to take up
desthiobiotin, so our biotin analogs stood a chance of being recognized as well.[50] Therefore
we hypothesized that these probes could potentially be membrane permeable.
We note here that the utility of these probes inside cells would be limited by competition with
endogenous free biotin, which has been demonstrated to be of approximately equivalent
concentrations in bacterial and mammalian cells,[51] and in the range of 10-100 nM.[8, 52]
While free biotin in cultured mammalian cells can be depleted with overnight biotin
starvation,[53] it would be preferable not to subject cells to this non-physiological stress.
Therefore we began our study with the knowledge that only kinetically efficient enzyme-probe
pairs could become candidates for use in intracellular protein labeling.
Panel of enzymes
Our next task was to select a set of biotin ligase enzymes to probe for new reactivity toward our
probes. We wished to select enzymes with maximal diversity in the hope of probing as much
functional BirA sequence space as possible. We therefore selected the previously reported
human, Saccharomyces cerevisiae (yeast), Pyrococcus horikoshii, and Bacillus subtilis biotin
ligases, all of which are described in the introduction to this chapter, as well as five additional
species (Methanococcus jannaschii, Leuconostoc mesenteroides, Trypanosoma cruzi, Giardia
lamblia, and Propionibacterium acnes). We chose these species because (1) their genomes are
sequenced, facilitating PCR cloning of their biotin ligase enzymes, (2) they are common model
organisms or well-studied disease agents, and therefore genomic or cDNA was available, (3) at
least one, Leuconostoc mesenteroides, had been previously been reported to have relaxed
tolerance for growth on biotin analogs, and (4) they represent distantly related organisms, by
the broad measure of coming from different kingdoms of life. These species include archaea,
bacteria, two protists (and infectious disease agents), a fungus, and a higher eukaryote.
We performed a ClustalW alignment[54] of all the biotin ligase enzymes utilized in this study. A
portion of the alignment contained within the (though not comprising the entire) conserved
central catalytic domain of each enzyme is presented in Figure 2-4. Several interesting
conserved sequence elements are highlighted in the alignment. First, the disordered glycine-
rich loop involved in binding the biotinyl-5'-AMP intermediate (discussed in the introduction to
this chapter) is highlighted in red. A sequence involved in biotin binding, KWPND, is highlighted
in blue. Finally, the catalytic lysine residue required for formation of the intermediate from
biotin and ATP is highlighted in green. This alignment supports our previous assertion that the
catalytic domains of these enzymes are highly conserved, and also gives us confidence that the
previously unreported enzymes we chose to investigate were annotated correctly in their
genome sequences.
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Figure 2-4. ClustalW alignment of a portion of the catalytic domain of biotin ligase enzymes
utilized in this study. Species (or genus) names are provided to the right of the sequence. Red
and green text highlight conserved sequence elements important in catalysis; blue highlights a
conserved sequence element required for biotin binding. Starred residues are identical in all
sequences; two dots represent conserved residues, based on considerations of charge, polarity,
and size; a single dot represents a weakly conserved residue.
We obtained expression plasmids for the human, yeast, and P. horikoshii enzymes. We cloned
the Giardia biotin ligase from a cDNA library; the M.jannaschii, Leuconostoc, and P. acnes
genes were cloned directly from cell lysates; and the T. cruzi and B. subtilis enzyme s were
cloned from purified genomic DNA. Each coding sequence was inserted into a bacterial
expression plasmid with a C-terminal hexahistidine tag for affinity purification. (In a cautionary
note for future scientists who wish to append affinity or epitope tags to uncharacterized
proteins, our C-terminally tagged Leuconstoc construct was insoluble and produced inclusion
bodies upon expression in E. coli; subsequent construction of an N-terminally hexahistidine
tagged Leuconostoc enzyme afforded soluble, active protein upon purification.) We
subsequently over-expressed each biotin ligase in E. coli, and purified them as described in the
Methods section. Each enzyme was obtained in acceptable yield and purity (Figure 2-5), except
for the human enzyme, which was significantly degraded. Nevertheless, we observed enzymatic
activity in this sample (vide infra), so we made use of it for our study. We also note that the
enzymes cover a satisfyingly broad range of sizes, indicating that they probably span a range of
different domain structures and organizations, as desired.
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Figure 2-5. SDS-PAGE characterization of purified biotin ligases. In lanes 1-9, the major band
represents the full-length ligase. In lane 10, most of the human enzyme is proteolyzed (the
arrow indicates the full-length ligase), but biotinylation activity is still detected.
Substrate selection and assay design
We next had to identify suitable protein or peptide substrates for screening our enzymes. We
preferred to identify a single substrate that could be recognized by all of our enzymes, in order
to simplify our screening and analysis. We used an HPLC-based assay to test several of our
biotin ligase enzymes for biotinylation activity toward the engineered BirA peptide substrate,
the acceptor peptide (AP), and confirmed and extended what we and others had previously
reported: the AP is not recognized by biotin ligase enzymes from other species, including
human, yeast, and Spodopterafrugiperda.[55-58] We additionally observe that the B. subtilis,
T. cruzi, and P. horikoshii enzymes do not modify the AP peptide (Figure 2-6). We therefore
investigated BCCP protein substrates; it was more likely that we could identify a BCCP that
could be utilized by all of our enzymes, because, as discussed above, sequence conservation
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among biotinylated proteins is extremely strong at the site of biotin attachment, and biotin
ligases generally recognize and biotinylate BCCPs from other species.
We first investigated the P. shermanii BCCP,[18] but found that it degraded after biotinylation;
we then tested BCCP-87, a biotinylation-competent fragment of E. coli BCCP,[59] but found that
it co-purified with full-length endogenous E. coli BCCP (data not shown). We then moved to
p67, a 67-amino acid fragment of the C-terminal domain of human pyruvate carboxylase which
is competent for biotinylation on a single lysine residue, K61.[60] We obtained an expression
plasmid for this construct (a kind gift from the laboratory of Roy Gravel), which we found to be
isolable in excellent yield and purity from E. coli. This protein and its modification products can
be easily analyzed by HPLC and native gel-shift assays.
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Figure 2-6. The AP peptide is not recognized by biotin
ligases from other species. HPLC traces for analysis of AP
reaction products with various biotin ligase enzymes in
the presence of biotin are shown. Absorbance in
arbitrary units is plotted on the y-axis. Each trace is
labeled according to the biotin ligase enzyme used in
that reaction. A negative control reaction using BirA with
ATP omitted is used as a genuine standard for
unmodified AP peptide. Unmodified AP peptide elutes
from the column at approximately 20 minutes, while
biotinylated AP peptide elutes at approximately 22
minutes. Product is formed only in the presence of BirA,
and no detectable product is formed for the other
enzymes.
Our assays are based on the change in charge that occurs in substrate peptides and proteins
upon modification with biotin or biotin analogs. As discussed in Part 11 of Chapter 1, biotin ligase
covalently attaches biotin to a specific lysine residue of its substrates, producing a neutral
amide product. We find this change in charge to be sufficient to cause a large retention time
shift in both AP peptide and p67 protein when analyzed by reversed-phase HPLC. (Though
positively charged molecules like iminobiotin and diaminobiotin would not produce an overall
change in charge upon ligation, they could ostensibly cause changes in polarity of the product
that would be sufficient for HPLC-based resolution.) Similarly, a native gel-shift assay has been
previously reported for analysis of BCCP-87.[61] Migration of BCCP-87 is governed in a native
gel both by its charge and its conformation; biotinylated protein migrates more quickly due to
the elimination of a positive charge after reaction, and also possibly due to conformational
change. We confirmed that the same gel-shift is observable for p67 (vide infra). We would
subsequently utilize both assays for analysis of p67 reaction products.
Having our biotin ligase enzymes, a suitable substrate, and working assays in hand, we needed
to confirm that all of our enzymes could biotinylate our p67 substrate. We therefore tested
each of our biotin ligase enzymes for biotinylation activity toward p67 using the HPLC assay, as
described in the Methods section (Figure 2-7).
First, we observed that the Giardia enzyme did not display activity toward p67; we also tested it
with our other substrates, P.shermanii BCCP and BCCP-87, and found that it was inactive
toward all three (data not shown). We therefore eliminated the Giardia enzyme from our
subsequent analysis. We note that the only putative annotated biotinylation substrate in the
Giardia genome, a putative transcarboxylase, diverges significantly in sequence from the
canonical biotinylation sequence,[62] which could easily explain why it does not recognize a
canonical substrate; it would be interesting in the future to determine if the Giardia enzyme is
capable of biotinylating this substrate, and to try to elucidate the reason for this rare sequence
divergence.
Second, we observed that all of our other biotin ligases were active toward p67, but to varying
degrees. Under identical reaction conditions, the E. coli, B. subtilis, and yeast biotin ligases were
highly active toward p67, with their reactions going to completion within minutes. The P. acnes,
Leuconostoc, and P. horikoshii enzymes displayed intermediate activity, with their biotinylation
reactions going to completion on a time scale of hours. The M. jannaschii, T. cruzi, and human
ligases displayed low, but detectable, activity. Rough estimates of the initial rates of these
reactions span a 700-fold range of velocities. The reasons for these differences could be many;
the reactions were conducted under conditions optimized for BirA activity, but buffers were not
individually optimized for each enzyme; reactions were conducted at 30"C, which is certainly
sub-optimal for the thermophilic enzymes; and each enzyme probably varies in its affinity for
p67. Regardless, we were encouraged by this result and concluded that we observed sufficient
activity of each enzyme toward p67 to screen our panel of probes under sufficiently forcing
reaction conditions.
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Figure 2-7. Biotinylation time courses of all enzymes under identical conditions.
Reaction conditions: 1 pM ligase, 100 iM p67 acceptor protein, 1 mM biotin, 5 mM
ATP, 5 mM Mg(OAc) 2, and 50 mM bicine pH 8.3 at 35 *C. Percent conversion to
biotinylated p67 was measured by HPLC. Each point represents the average of three
measurements. Error bars, 1 standard deviation.
Probe screening by HPLC; product identification and assessment of ligation specificity by gel-
shift assay and LC-MS
Using p67 as a substrate, we assayed our eight active biotin ligase enzymes against each probe
in our panel using either our HPLC assay or the gel-shift assay (Table 2-2). Notably, none of our
enzymes incorporated iminobiotin, diaminobiotin, NBD y-amino butyric acid, iodouracil valeric
acid or thiouracil valeric acid. Presumably the shape or charge state of these probes precluded
their association with the enzymes. However, we did observe product formation (which we
simply define as any product formation above our detection limit, which for the HPLC assay is
approximately 2% completion, or 2 pM) in the reactions of P. horikoshii biotin ligase (PhBL) with
desthiobiotin azide (DTB-Az) and propargyl biotin (PB) (a mixture of cis and trans isomers), as
well as yeast biotin ligase (yBL) with PB. (We were disappointed to find that the Leuconostoc
enzyme did not display any new activity, despite the previously reported propensity for this
organism to grow in the presence of biotin analogs; we conclude that this observation must be
the result of other metabolic features of the organism than direct biotin analog ligation to
carboxylase proteins.)
Human Bacillus Propioni- Leuconostoc Trypano- Methano- Pyro- Saccharo-
subtilis bacterium mesenter- soma coccus coccus myces
acnes oides cruzi jannaschii horikoshii cerevisiae
(yeast)
Biotin
DTB-Az
- +
cis-PB
trans-PB
Imino-
biotin -
Diamino-
biotin - - - -
NBD y-
amino
butyric
acid
IU valeric
acid - -
TU valeric
acid - - - - -
Table 2-2. Results of screening biotin ligase enzymes against probes. 1 pM of each enzyme was
incubated with 1 mM probe and 100 pM p67 acceptor protein for 14 h at 30 *C in the presence of ATP.
Formation of product (indicated by "+") was detected by HPLC or native gel-shift assay. For screening,
probe 3 (PB) was provided as a mixture of cis and trans isomers. Abbreviations: DTB-Az, desthiobiotin
azide; PB, propargyl biotin; NBD, nitrobenzoxadiazole; IU, iodouracil; TU, thiouracil.
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Significantly more product was formed under identical conditions in the PB reaction with yBL
than PhBL, so we proceeded to further characterize the yBL reaction with PB. The synthetic
route to PB affords both the cis isomer, with the N-propargyl group on the same side of the ring
system as the alkyl side chain, and the trans isomer. Initial reactions were performed with this
regioisomeric mixture, but we wished to determine which isomer yBL prefers in order to gain
more insight into the structure of the active site. We purified the regioisomers by HPLC, then
tested their yBL-mediated incorporation onto p67 separately using the native gel-shift assay
(Figure 2-8).We utilize biotin as a positive control for product formation, and observe that 100%
of the reaction product is a higher-mobility species on the gel (lanes 1 and 6). In negative
control reactions where probe, ATP, and yBL enzyme were individually omitted, no product is
formed, and all of the p67remainsin its lower-mobility apo form (lanes 3-5 and 8-10). In the
presence of trans-PB, no product formation is formed within the detection limit of this assay
(lame 7); in the presence of cis-PB, after a 14-hour reaction, we observe 100% conversion to
product (lane 2). The enzyme clearly exclusively utilizes cis-PB, so we can conclude that, despite
the lack of structural information about this enzyme, trans substituents on the biotin ring
system are probably sterically excluded from binding, while the cis face of the biotin ring
system has fewer steric clashes with the binding pocket.
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Figure 2-8. Native gel shift assay showing preferential ligation of cis-PB over trans-PB by yeast biotin
ligase. Ligation products have a greater mobility in the gel than unmodified p67. Reaction conditions: 1
pM yBL, 100 pM p67, 1 mM cis- or trans-PB, 5 mM ATP, 5 mM Mg(OAc)2, 50 mM bicine pH 8.3, 30 *C, 14
hours.
We then confirmed that enzymatic activity is required for our product formation in both
reactions of interest, using our HPLC assay (Figure 2-9). Omission of either ATP or PhBL prevents
product formation with DTB-Az; omission of ATP or yBL prevents product formation with cis-PB.
For comparison, reactions were performed with biotin, and by inspecting the HPLC traces we
observe that the p67-biotin conjugate has a unique, shorter retention time as compared to the
p67-DTB-Az and p67-cis-PB conjugates.
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Figure 2-9. HPLC detection of (A)
DTB-Az and (B) cis-PB ligation to p67
acceptor protein by PhBL and yBL,
respectively. Negative controls are
shown with ATP or enzyme omitted.
The biotin-p67 conjugate has a
shorter retention time than the DTB-
Az or cis-PB conjugates. The starred
peaks were collected and analyzed by
mass spectrometry in a separate
experiment (Figure 7). Absorbance in
arbitrary units is plotted on the y-axis.
We further wished to structurally characterize our reaction products, in particular to confirm
our expectation that exactly one molecule of DTB-Az or cis-PB had been ligated to p67, and that
the reaction occurred site-specifically on the single reactive lysine residue of p67.We therefore
collected the starred peaks shown in Figure 6 from our HPLC analyses and analyzed them by
mass spectrometry. A comparison of the observed mass of the P. horikoshii ligation product of
DTB-Az to p67 to apo-p67 (purified from our control reaction lacking ATP) revealed a difference
consistent with exactly one DTB-Az molecule (Figure 2-10A, left). Similarly, comparison of our
yBL-catalyzed cis-PB conjugate to apo-p67 was consistent with addition of exactly one cis-PB
molecule to p67 by the enzyme (Figure 2-9B, left). We additionally compared the mass of the
yBL-catalyzed p67 biotinylation product to our cis-PB conjugate, and gratifying found that they
were distinguishable in our mass spectrometer, lending confidence to our structural assignment
(Figure 2-10B, left).
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In order to assay site specificity of the ligation, we generated a point mutant of p67, K61A
(which we call p67(Ala)), in which the reactive lysine residue is mutated to alanine, preventing
amide bond formation and eliminating site-specific ligation. We could therefore use p67(Ala) to
assay for off-target modification events. Such non-specific reactivity has previously been
reported for mutants of BirA at high concentrations and over long reaction times, probably due
to release of the activated biotin-5'-adenylate (bio-5'-AMP) intermediate;[63] in fact, free bio-
5'-AMP has been demonstrated to slowly react with the physiologically modified lysine of BCCP-
87 and also the N-termini of proteins in solution due to the relatively low pKa of these primary
amines.[64] Though we had already confirmed that only one probe molecule was being
incorporated onto p67 in each reaction, since we were using long reaction times and high
concentrations of probes, we had to further demonstrate that non-site-specific modification
events were not occurring.
We therefore performed parallel reactions in which PhBL reacted with DTB-Az and p67, or in
which p67 was replaced with p67(Ala); identical reactions were performed with yBL and cis-PB.
Each reaction product was purified by HPLC (data not shown), and then analyzed by mass
spectrometry. Again PhBL produces the expected 1:1 adduct of DTB-Az to wild-type p67;
however, the single product of the p67(ala) reaction was identical to unmodified p67(Ala)
(Figure 2-10A, right). Similarly, under conditions in which yBL catalyzes formation of the cis-PB-
p67 adduct, p67(Ala) remains unmodified (Figure 2-10B, right). No additional peaks are visible
in either p67(Ala) HPLC trace or mass spectrum.
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Figure 2-10. ESI-MS analysis of p67 conjugates to (A) DTB-Az and (B) cis-propargyl biotin. Products of
negative control reactions with ATP omitted or p67(Ala) mutant in place of p67 are also shown. Charge states
in each spectrum are labeled.
We therefore conclude that our ligation reactions are site-specific and dependent on enzyme
activity, and therefore likely proceed by the same reaction mechanism as biotinylation.
Secondary derivatization of DTB-Az by the Staudinger ligation
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Having identified and validated these new ligation reactions, we needed to demonstrate their
utility for protein labeling. While alkynes can be derivatized using azide-functionalized probes
via Click chemistry, a copper-mediated [3+21 cycloaddition reaction, as discussed in Chapter 1,
this reaction was too toxic to be compatible with live-cell labeling at the time of this project;
recently reported improvements have reduced toxicity from reactive oxygen species
generation.[65] We therefore focused on the DTB-Az probe, as azides can be derivatized either
by Click chemistry with alkynes, copper-free cycloaddition with strained cyclooctynes,[66] or
Staudinger ligation with phosphines.[67]
We chose the Staudinger ligation for our in vitro azide derivatization. DTB-Az-p67 conjugate
was enzymatically prepared, then reacted with a peptide comprising the FLAG epitope
(DYKDDDDK) conjugated to a phosphine (FLAG-phosphine), which has been previously
reported.[68] Subsequent immunoblotting with anti-FLAG antibody reveals the presence of the
labeled protein (Figure 2-11, left). Parallel single-reagent-omission reactions were run as
negative controls; treatment of these mixtures with FLAG-phosphine reveals no product
formation, again confirming the specificity of our enzymatic ligation as well as the secondary
derivatizaztion step. It is important to note that the immunoreactive product runs as a slightly
larger protein than the starting material visualized by Coommassie staining of the reaction
mixture (Figure 2-11, right), as expected due to the addition of the octapeptide FLAG epitope.
We also note that the reaction product is present at such small quantities as to be undetectable
by Coommassie staining, due to the inefficiency both of the first enzymatic step (vide infra) and
of the secondary Staudinger ligation.[66] Nevertheless, labeled product is produced and can be
detected, demonstrating that we can use this chemistry for protein labeling in vitro.
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DTB-Az: + + - +
ATP: + - + +
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Figure 2-11. Functionalization of ligated DTB-Az by Staudinger
ligation. PhBL was used to ligate DTB-Az to p67 protein. The
azide was then functionalized with FLAG-phosphine. The FLAG
epitope was detected with anti-FLAG immunostaining. Negative
controls show omission of ligase, DTB-Az, or ATP from the
reactions (lanes 2-4). Coomassie staining (right) demonstrates
equal protein loading.
Kinetic analysis
We observed low yields of product formation in our initial screens, and we needed to
determine the kinetics of these ligation reactions in order to determine if they would be useful
for cellular labeling applications. We attempted to investigate the concentration dependence of
the ratio of DTB-Az utilization by PhBL, but we were unable to saturate the initial rate of the
reaction even with the maximal DTB-Az concentration that we could experimentally provide
(data not shown). Therefore rather than determining kcat for this reaction, we compared the
rate of DTB-Az ligation to the rate of biotin ligation by PhBL under identical reaction conditions.
Under these conditions, we obtained a DTB-Az ligation rate of (1.34 ± 0.11) x 10-4 tM s1 (Figure
2-12A), three orders of magnitude slower than the biotinylation rate of 0.20 ± 0.02 piM s~1
(Figure 2-12B).
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We obtained saturation of the initial rate of yBL-catalyzed cis-PB ligation to p67 at cis-PB
concentrations above 1 mM (data not shown). Under these saturating conditions, we obtained
a kcat for cis-PB ligation to p67 of (2.07 ± 0.10) x 10-2 S-2 (Figure 2-12C). We also measured the
kcat for yBL-catalyzed ligation of biotin to p67 (Figure 2-12D); this rate is 0.28 ± 0.4 s1, 14-fold
faster than the rate of ligation for the unnatural probe.
Of course, these kinetic parameters are not suitable for cellular labeling. First, such high
(millimolar) concentrations of probe would almost certainly be toxic to cells. Since saturating
concentrations of probe would have to be delivered in order to out-compete endogenous
biotin, as previously discussed, toxicity would probably be severe. Second, even if sufficient
concentrations of probe could be delivered, the kcat is probably still too slow to afford
significant labeling except after very long incubation times. We therefore examined whether
use of a different protein substrate could enhance kinetics of DTB-Az ligation by PhBL.
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Figure 2-12. Kinetic analysis of DTB-Az and cis-PB ligation reactions. 1 IM PhBL, 100 tM p67, 5 mM
ATP, 5 mM Mg(OAc) 2, and 50 mM bicine pH 8.3 were incubated at 35 *C with 1 mM DTB-Az (A) or 1
mM biotin (B). Samples at various timepoints were analyzed by HPLC, to determine the reaction
velocities. (C) Measurement of kcat for yBL-catalyzed ligation of cis-PB to p67. 400 nM yBL was
incubated with 100 pM p67, 5 mM cis-PB, 5 mM ATP, 5 mM Mg(OAc) 2, and 50 mM bicine pH 8.3 at
35 *C. (D) Measurement of kcat for yBL-catalyzed biotinylation of p67. 45 nM yBL was incubated with
100 pM p67, 1 mM biotin, 5 mM ATP, 5 mM Mg(OAc) 2, and 50 mM bicine pH 8.3 at 35 *C.
Attempt to improve ligation kinetics: assaying the P. horikoshii biotin carboxyl carrier protein
We first hypothesized that PhBL may exhibit improved reactivity toward its endogenous
substrate, the P. horikoshii BCCP (PhBCCP), derived from P. horikoshii acetyl CoA carboxylase.
We cloned, expressed, and purified this protein, and found that its modification products could
be analyzed by gel shift assay in much the same manner as p67. Much to our surprise, when
assayed with PhBL for DTB-Az turnover, under conditions providing 100% conversion of biotin
to product, only a small fraction of p67 became modified in the DTB-Az reaction (Figure 2-13).
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While we could detect this product in our gel-shift assay (though its intensity above background
was barely measurable), and later confirmed presence of the azide in the product via
Staudinger ligation and immunoblotting (data not shown), it was clear that this reaction is not
more efficient than DTB-Az ligation to p67 by PhBL. The reason for this low activity toward
PhBCCP is unclear, though it is possible that the reaction may be accelerated at the higher
temperatures at which P. horikoshii grows, a hypothesis that we left untested because we are
interested only in physiologically relevant conditions for mammalian cell labeling.
PhBL: + + + + 
-
Biotin: 
- + + 
- +
Figure 2-13. Gel-shift assay for P.DTB-Az: + 
-horikoshii biotin ligase-catalyzed DTB-Az
ATP: + + + + ligation to P. horikoshii BCCP (PhBCCP).
Products have a greater mobility in the
gel than apo-PhBCCP. Negative controls
areshown with ATP or enzyme omitted.
Product
Conclusion
In conclusion, we have discovered new reactivity of PhBL and yBL toward DTB-Az and cis-PB,
respectively. These biotin analogs are suitably functionalized for secondary derivatization with
bio-orthogonal probes, which we demonstrated via Staudinger ligation of DTB-Az with a
phosphine-functionalized probe. Unfortunately, the kinetic parameters of these reactions are
unsuitable for cellular labeling applications. No easy solution to this problem presents itself,
aside from extensive in vitro evolution.
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The similarity of the previously reported crystal structures of BirA, PhBL, and A. aeolicus biotin
ligase renders the differences in small-molecule reactivity that we observe among our panel of
biotin ligases toward biotin analogs somewhat mysterious, at least from a structural point of
view. As more biotin ligase enzymes are crystallized in the future, it will be interesting to
compare their binding sites to see if structural conservation is a general rule, and to determine
any more obvious differences in active site organization.
Perhaps the most interesting differences among these enzymes come at the level of their
protein and peptide substrate specificity. We have confirmed that the AP is recognized uniquely
by BirA, and not by biotin ligases from several other species. We speculate that the AP may
exhibit a different mode of binding to BirA than does BCCP, and that a similar binding interface
is not available on other biotin ligase enzymes. This makes every enzyme in our panel a
candidate for development of a peptide substrate orthogonal to the BirA-AP pair for multicolor
labeling, as was reported for the yeast enzyme.[56] Perhaps the best candidate would be the
Giardia enzyme, pending confirmation of its enzymatic activity, as it does not even recognize
canonical BCCP sequences. It also confirms that the BirA and AP pair can be used for site-
specific protein labeling in the context of cells from many different species.
Subsequent to this work, we serendipitously discovered that, while attempting to use E. coli
BirA as a negative control for DTB-Az and cis-PB ligation, that BirA actually does ligate these
probes to the p67 protein. In addition, BirA was found to ligate iminobiotin to p67. These
reaction products were confirmed by HPLC and ESI-MS (data not shown). We never previously
observed this reactivity because all previous BirA assays with biotin analogs were performed
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with the AP peptide. We confirmed that, according to our initial observations, BirA does not
detectably ligate these probes to the AP peptide. We speculate that the differential reactivity of
BirA toward the AP peptide and p67 protein with respect to biotin analogs may be due to our
proposed different binding modes of peptide and protein. More specifically, p67 probably binds
to the enzyme in a similar manner to BCCP due to high sequence similarity, while the AP
probably binds differently. If our biotin analogs are also oriented slightly differently in the active
site than biotin, they may be incompetent for reaction with the AP. Unofortunately these BirA
ligation reactions are still too kinetically inefficient to be utilized for cellular labeling. While this
result was surprising to us, it does not invalidate the major conclusions of our study, which is
that the enzyme homologs from different species can have differential substrate permissivity.
In parallel with this work, the Ting research group developed the enzyme E. coli lipoic acid
ligase, or LpIA, for site-specific protein labeling applications, as described in Chapter 1. Since
LplA has proved to be an efficient and highly specific catalyst for labeling peptide-tagged
proteins with azides as well as photo-affinity probes and coumarins (see Chapters 1 and 4 for a
complete discussion), and our biotin ligase enzymes were found to be inefficient catalysts, we
chose not to continue to pursue biotin ligases as an approach to developing new small-
molecule probes for cellular labeling.
Methods
Cloning of biotin ligases
The expression plasmid for human biotin ligase (also called holocarboxylase synthetase), fused
to glutathione S transferase, in the pDEST15 vector, was a gift from Roy Gravel. The Pyrococcus
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horikoshii biotin ligase (PhBL) gene in pET11a was a gift from Mitsuaki Sugahara and Naoki
Kunishima. The Saccharomyces cerevisiae (yeast) biotin ligase (yBL) gene in pET16b was a gift
from Stephen Polyak and John Wallace. The expression plasmid for E. coli biotin ligase (BirA)
has been described.[69]
The bacterial expression plasmids for biotin ligases from Trypanosoma cruzi, Bacillus subtilis,
Giardia lamblia, and Propionibacterium acnes were prepared by PCR-amplifying the genes and
cloninginto the Nhel and Xhol sites of the pET21a vector. This cloning introduces a C-terminal
hexahistidine tag (from the pET vector). Methanococcusjannaschii biotin ligase was cloned in a
similar fashion, between Nhel and Xhol of pET21a, but a stop codon was introduced before the
hexahistidine tag. Leuconostoc mesenteroides biotin ligase was cloned into the Ndel and BamHl
sites of pET15b. This introduced an N-terminal hexahistidine tag from the vector. Primers used
for all the PCR reactions are given in the table below. The following PCR program was used for
amplification of all genes: 95 C for5 minutes, followed by 30 rounds of [95 "C for 30 seconds,
55 "C for 60 seconds, and 72 "C for 90seconds]. PCR reactions contained 2 IM of each primer,
500 p.M dNTPs, 25 ng template DNA or a minimal inoculation of cells, 1X Thermo pol buffer
(New England Biolabs), and 5 units of Taq polymerase (New England Biolabs).
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Species Forward Primer Reverse Primer Template
Source
Trypanosoma cruzi 5'cctagctagcatgccaatggatgtgccgcca 5'aaaaaagcttaaaaaggtattccgccatgag genomic
Y strain DNA, a gift
from Barbara
Burleigh
Bacillus subtiis 5'cctagctagcatgcggtcaacattaagaaaa 5'aaaactcgaggcccaattcgatatcggcaga genomic
PY79 DNA, a gift
from Alan
Grossman
Giardia lamblia 5'cctagctagcatggaaagggtaattagcgca 5'aaaactcgagacagactggcgaaagatcctg cDNA library,
WB/1267 (ATCC a gift from
50582) Heidi
Elmendorf
Propionibacterium 5'cctagctagcgtgccgtccacaccttcgcct 5'aaaactcgagcctggttcgcaaatgatgaac heat-
acnes (ATCC 11827) generated
cell lysate
Methanococcus 5'cctagctagcatggaaattatacatttaagt 5'aaaactcgagttatcttacatggatgcaaat cell lysatejannaschii (DSMZ generated by
2661) autolysis
after
exposure to
air
Leuconostoc 5'aaaacatatgagtacagctgataaactgttag 5'aaaaggatccctaaccctggtattcattatttgg heat-
mesenteroides generated
(DSMZ 20241) cell lysate
Table 2-3. Cloning primers and template sources for biotin ligase enzymes.
Expression and purification of biotin ligases
In general, expression plasmids were transformed into E. coli BL21 DE3 cells, and individual
colonies were amplified in 500 mL Luria Broth (LB) supplemented with 10 pg/mL ampicillin until
OD(optical density) 0.6. Protein expression was induced with 420 ptM isopropylthiogalactoside
(IPTG) for3 hours at 30 0C. Cells were harvested and stored overnight at -80 "C. For yBL,
expression was induced with 42 lpM instead of 420 ptM IPTG, for 2 hours at 30 "C. For human
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holocarboxylase synthetase and PhBL, expression was induced with 420 pM IPTG for 12 hours
at 25 C. For hexahistidine-tagged proteins, cells were lysed by sonication in binding buffer (50
mM Tris-HCI pH 7.8, 300 mM NaCl) in the presence of 1 mM phenyl-methyl-sulfonyl fluoride
(PMSF). Clarified lysate was loaded onto 1 mL nickel-nitrilotriacetic acid agarose resin (Qiagen)
by gravity flow, then washed with binding buffer followed by washing buffer (binding buffer +
30 mM imidazole). An exception was yBL, for which the washing buffer contained only 10 mM
imidazole. Fractions containing the highest concentrations of ligase were pooled and dialyzed
into phosphate-buffered saline (PBS) pH 7.4. Purified ligases were stored in aliquots at -80 "C.
For M. jannaschii and P. horikoshii biotin ligases, purification was carried out by heat-selective
precipitation following the protocol of Bagautdinov et al.[40] Briefly, cells were resuspended in
20 mM Tris-HCI pH 8.0, 500 mM NaCl, 1 mM DTT, and 1 mM PMSF, then lysed by sonication.
Clarified lysate was heated to 90 0C for 11.5 minutes, then denatured proteins were removed
by centrifugation at 17,000 g for 20 minutes. Supernatant containing the desired enzyme was
dialyzed into PBS pH 7.4, then aliquoted and stored at -80 "C.
For human holocarboxylase synthetase, cells were lysed by sonication in loading buffer (50 mM
HEPES pH 7.4, 300 mM NaCI) in the presence of 1 mM PMSF. Clarified lysate was loaded onto
glutathione agarose resin (Sigma), washed with loading buffer, then eluted with loading buffer
containing 6.4 mg/mL reduced glutathione. Concentrated fractions were pooled and dialyzed
into PBS.
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HPLC analysis of AP peptide modification
The following reaction conditions were used: 1 pM enzyme was incubated with 1 mM biotin, 4
mM ATP, 50 ptM K3AP (a previously reported AP peptide with 3 lysine residues appended to
improve HPLC peak shapes),[2] 5 mM Mg(OAc) 2, 50 mM bicine buffer (pH 8.0). Reactions were
incubated for 15 hours at 30*C. 50 pL of the reaction mixture was injected onto a C18 reverse
phase column (Microsorb-MV 300-5, 250 x 4.6 mm, Varian) and separated with a mobile phase
gradient of 10 to 40 % acetonitrile in water with 0.1% trifluoroacetic acid over 25 minutes.
Absorption was monitored at 210 nm. Unmodified K3AP had a retention time of 20 minutes,
and biotinylated K3AP had a retention time of 22 minutes.
Expression and purification of p67 acceptor protein
p67 is a protein domain comprising the 67 C-terminal amino acids of human propionyl CoA
carboxylase.[60] The p67 expression plasmid, in pDEST11 vector, was a gift from Roy Gravel.
The plasmid was transformed into E. coli BL21 DE3 cells and individual colonies were amplified
in 6 litersof LB with 100 pg/mL ampicillin, until OD 0.8. Expression was induced with 420 IM
IPTG for 3hours at 30 "C. Cells were harvested and lysed as described above, and p67 was
purified using nickel affinity chromatography with 200 mM imidazole for the final elution.
Before use in biotinylation assays, we removed pre-biotinylated p67 (caused by endogenous
BirA during the protein expression) by incubating the entire batch of purified p67 with 750 pL
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streptavidin-agarose resin (Novagen) at 4 'C for 1 hour with rocking. The slurry was then
filtered through a fritted column (Biorad) by gravity. Biotinylated p67 was retained on the
column, and the non-biotinylated p67 was stored in aliquots at -80 0C.
The K61A mutant of p67, called p67(Ala), was generated by QuikChange with the primer
5'ggtcaagaaatttgtgtgattgaagccatggcaatgcagaatagtatgacagc and its reverse complement.
Screening of biotin ligases against biotin analogs
The following reaction conditions were used in the screening assays: 1 ptM of biotin ligase
enzyme, 1 mM biotin analog, 100 lM p67 protein, 5 mM Mg(OAc) 2, 5 mM ATP, and 50 mM
bicine pH8.3. The reaction mixture was incubated for 14 hours at 30 "C. Formation of product
was detected by either HPLC (for P. acnes, yeast, human, M. jannaschii, P. horikoshii, T. cruzi,
and B. subtilis biotin ligases) or native gel shift assay (for L. mesenteroides and yeast biotin
ligases), as described below.
HPLC assay to detect probe conjugation to acceptor protein
Reactions for DTB-Az ligation contained 5 ptM of P. horikoshii biotin ligase, 10 mM DTB-Az,
100 lpM p67, 5 mM Mg(OAc) 2, 5 mM ATP, and 50 mM bicine pH 8.3. Reactions for cis PB ligation
contained 1 lpM of yeast biotin ligase, 8 mM cis-PB, 100 lpM p67, 5 mM Mg(OAc) 2, 5 mM ATP,
and 50mM bicine pH 8.3. Reactions were incubated for 14 hours at 30 *C. 50 p1 of the reaction
mixture was injected onto a C18 reverse phase column (Microsorb-MV 300-5, 250 x 4.6 mm,
Varian) and separated with a mobile phase gradient of 30 to 50 % acetonitrile in water with
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0.1% trifluoroacetic acid over 30minutes. Absorption was monitored at 210 nm. Unmodified
p67 had a retention time of 14.9 minutes, and the probe-p67 conjugates ranged from 16.9 to
17.9 minutes.
Native gel shift assay to detect probe conjugation to acceptor protein
20 pL of each reaction mixture, prepared as above, was loaded onto a non-denaturing 20%
polyacrylamide gel and electrophoresed at 100 V for 3.5 hours. The electrophoresis apparatus
was submerged in ice to prevent protein unfolding. Gels were stained with Coomassie brilliant
blue. Modified p67 demonstrated a characteristic shift toward greater mobility relative to
unmodified p67.
Mass-spectrometric analysis of probe conjugation to acceptor protein
Reactions of P. horikoshii biotin ligase with DTB-Az contained 1 [tM enzyme, 100 p.M p67, 10
mM DTB-Az, 5 mM Mg(OAc) 2, 5 mM ATP, and 50 mM bicine pH 8.3. Reactions of S. cerevisiae
biotin ligase with cis-PB contained 1 p.M enzyme, 100 p.M p67, 5 mM cis-PB or 1 mM biotin, 5
mM Mg(OAc) 2, 5 mM ATP, and 50 mM bicine pH 8.3. Reactions of P. horikoshii biotin ligase with
DTB-Az and K61A p67 (to test site specificity) contained 5 p.M enzyme, 100 p.MK61A p67, 10
mM DTB-Az, 5 mM Mg(OAc)2, 5 mM ATP, and 50 mM bicine pH 8.3. Reactions of yeast biotin
ligase with cis-PB and K61A p67 contained 1 pM enzyme, 8 mM cis-PB, 100 P.M p67, 5mM
Mg(OAc) 2, 5 mM ATP, and 50 mM bicine pH 8.3. Reactions were incubated at 30 'C for 14
hours, and separated by HPLC as described above. Product fractions were collected by hand
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then injected directly onto an Applied Biosystems 200 QTRAP mass spectrometer with
electrospray ionization at a flow rate of 10 lL/min with detection in positive ion mode.
Staudinger ligation to detect ligated DTB-Az
PhBL was used to label p67 with DTB-Az in a reaction containing 1 pM ligase, 100 p.M p67,
500 p.M DTB-Az, 5 mM Mg(OAc) 2, 5 mM ATP, and 50 mM bicine pH 8.3. Reactions were
incubated at 30 C for 14 hours. For the Staudinger ligation, FLAG-phosphine[68] was directly
added to the reaction mixture to a final concentration of 1.5 mM, then incubated at 25 *C for
12 hours. The reaction mixture was divided in half and analyzed on two 20% SDS-PAGE gels.
One gel was stained with Coomassie brilliant blue to demonstrate equal protein loading. The
contents of the other gel were transferred to nitrocellulose. The FLAG epitope was detected by
staining with anti-FLAG (M2) antibody-horseradish peroxidase conjugate (Sigma, 1:2000
dilution). The blot was developed with SuperSignal West Pico Chemiluminescent Substrate
(Pierce).
Kinetic analysis of DTB-Az and cis-PB ligations
We compared the rates of DTB-Az and biotin ligations to p67, catalyzed by PhBL under
identical conditions. The measured DTB-Az ligation rate does not represent the maximal ligation
velocity (Vmax), because we found that we could not saturate the ligase with DTB-Az at the
highest experimentally achievable DTB-Az concentration (10 mM) (data not shown). Reactions
contained 1p.M PhBL, 100 p.M p67, 1 mM biotin or DTB-Az, 5 mM Mg(OAc) 2, 5 mM ATP, and 50
mM bicine pH8.3. Reactions were incubated at 35 *C, then quenched at various time points and
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analyzed by HPLC as described above. Measurements were performed in triplicate, and error
bars represent one standard deviation.
The Vmax and kcat of cis-PB and biotin ligations to p67, catalyzed by yBL, were determined as
follows. For biotin, reactions contained 45 nM yBL, 100 p.M p67, 1 mM biotin, 5 mM Mg(OAc) 2,
5mM ATP, and 50 mM bicine pH 8.3. For cis-PB, reactions contained 400 nM yBL, 100 p.M p67, 5
mMcis-PB, 5 mM Mg(OAc) 2, 5 mM ATP, and 50 mM bicine pH 8.3. Reactions were incubated at
35 2C, then quenched at various time points and analyzed by HPLC as described above.
Measurements were performed in triplicate, and error bars represent one standard deviation.
Cloning, purification, and assay for P. horikoshii BCCP
Purified P. horikoshii genomic DNA (ATCC) was obtained and used as the cloning template. P.
horikoshii BCCP was PCR-amplified from the genomic DNA using the forward primer
AAAAGGATTCATGATGAGGATGAAAGTGAAAGTTGT and the reverse primer
TTTTAAGCTTCCCCAATTCTATTAGTGGTTGTCCT, and cloned into the BamHI and HindIll sites of
pET21a to append a C-terminal hexahistidine tag. PhBCCP was overexpressed in E. coli and
purified as described for hexahistidine-tagged biotin ligase enzymes and its concentration was
determined using the BCA assay.
PhBL was used to label PhBCCP with DTB-Az in a reaction containing 1 p.M PhBL, 100 p.M
PhBCCP, 500 p.M DTB-Az, 5 mM Mg(OAc) 2, 5 mM ATP, and 50 mM bicine pH 8.3. Reactions
were incubated at 30 *C for 14 hours. As a positive control for mobility, biotin replaced DTB-Az
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in the reaction mixture; single-omission negative controls were performed. Reaction products
were analyzed by gel shift assay exactly as described above.
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Chapter 3: Delivering quantum dots into the cytosol of living cells
Dr. Takashi Kawakami performed intracellular protein labeling with quantum dots delivered
using streptolysin 0.
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Introduction
Single-molecule imaging using quantum dots (QDs) has proved exceptionally powerful in the
study of the trafficking of cell-surface receptors. The advent of biotin ligase (BirA)-mediated
targeting of streptavidin-functionalized QDs to biotinylated acceptor peptide (AP)-tagged
proteins has simplified QD targeting and facilitated long-term single molecule imaging.[1, 2]
However, because QDs are large (at least 20 nm in diameter for commercial dots), [3] they
cannot cross the cell membrane, so their potential for investigating intracellular proteins at the
single-molecule level remains untapped. As discussed in Chapter 1, many methods have been
explored for delivery of QDs into living cells; however, most methods are subject to toxicity, QD
aggregation, or trapping of QDs in endocytic vesicles. Microinjection is currently widely utilized,
and microinjected QDs have begun to make contributions to intracellular single-molecule
imaging.[4, 5] However, microinjection is technically difficult and requires specialized
equipment, so is generally accessible only to the accomplished cell biologist. Aside from
microinjection, only osmotic lysis of pinocytic vesicles, and streptolysin 0 permeabilization have
thus far afforded freely diffusible QDs that are well-distributed in the cytosol, and then with
varying degrees of characterization and confidence.[6-9] However, pinosome lysis and
streptolysin 0 are subject to toxicity and are relatively poorly characterized as QD delivery
systems. Therefore a simple, inexpensive, non-toxic method to efficiently deliver QDs into cells,
then target them to biotinylated proteins, is still needed. In this chapter we describe our efforts
toward finding a method to deliver non-cell permeable imaging reagents, and in particular QDs,
into the cytosol of living cells as a step toward this goal. We present this chapter in two parts,
each describing one delivery method we investigated. In Part I, we discuss our attempts to
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harness viral cell entry mechanisms for delivery of QDs. In Part 11, we discuss our validation,
carried to fruition by Dr. Takashi Kawakami, of the bacterial pore-forming toxin streptolysin 0
for QD delivery into the cytosol of living cells.
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Part I: Investigation of influenza Virosomes for Quantum Dot Delivery
Introduction
Viral delivery has been used extensively in transfection and gene therapy. This is because
viruses are exceedingly adept at efficiently accessing the interior of cells. During infection,
viruses must be internalized into a host cell, escape into the cytosol, then translocate their
genetic material into the nucleus in order to activate host cell transcription and translation of
the viral genome. The mechanism of this process has been particularly well characterized for
influenza virus.[10]
Influenza is an enveloped virus, consisting of a ribonucleoprotein genome encapsulated in a
lipid bilayer derived from the host cell. The major protein substitutents of the lipid bilayer are
hemagglutinin (HA) and neuraminidase, which are both required for infectivity.[11] Enveloped
viruses enter cells via membrane fusion, either at the cell surface or with endosomal
membranes. The influenza viral particle, or virion, binds to the surface of a host cell through
interaction of HA with sialic acid residues on cell-surface glycoproteins.[12] The virus is then
internalized via both clathrin-dependent and -independent endocytosis.[13] As the endosome
matures, the pH decreases, causing HA to undergo a conformational change,[14, 15] exposing
the HA2 fusion peptide that inserts into the endosomal membrane.[16] The viral membrane
then fuses with the endosomal membrane, first forming a hemi-fusion intermediate in which
the outer layers of both membranes fuse, followed by collapse to the fully fused, mixed
membrane.[17] This fusion allows the internal contents of the virion to escape into the cytosol.
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The mechanism of influenza virus cell entry has previously been exploited in delivering non-cell-
permeable cargo into cells by creating artificial viruses called virosomes. Virosomes have been
prepared by inserting purified hemagglutinin into artificial liposomes, by fusing viruses with
liposomes, and by reconstituting viral membranes.[18] By encapsulating cargo inside virosome
membranes, intracellular delivery can be affected; virosomes have been prepared containing
and used to deliver DNA, siRNA, and protein toxins into cells.[19-22] We note that cell
transfection and killing by protein toxins requires only very low delivery efficiencies into the
cytosol, so the real efficiency of cargo delivery by virosomes remained ill-characterized.
Furthermore, to our knowledge, no attempt to deliver QDs into cells by viral means has been
reported; we therefore proposed to utilize influenza virosomes to deliver QDs, as depicted in
Figure 3-1. We expected that it is physically possible for at least one QD to be encapsulated per
virosome, as reconstituted virosomes have been measured by electron microscopy to be 100-
200 nm in diameter.[23] Because we had access to the assistance of kind collaborators in the
laboratories of Xiaowei Zhuang at Harvard and Antoine van Oijen at Harvard Medical School
who were at the time beginning to investigate influenza virosomes, we elected to begin our
investigation of QD delivery methods with the influenza virosome system.
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Figure 3-1. Proposed mechanism of virosome-mediated quantum dot (QD) delivery. (A) Virosomes, or re-
constituted influenza viral envelopes, containing QDs bind to cell surface glycoprotein-displayed sialic acid
residues and become internalized in endocytic vesicles (B). (C) As endosomes mature, the pH decreases,
causing a conformational change in the influenza hemagglutinin protein. (D) The hemagglutinin
conformational change causes fusion of the virosome membrane with the endosomal membrane, freeing
the contents of the virosome into the cytosol.
While cell entry by influenza virus is efficient, it is not perfect; approximately 25-50% of virions
that initially attach to the cell surface eventually reach the cytosol.[13] Since viral delivery,
along with most delivery methods, was originally formulated for gene delivery, the actual
efficiency of cargo release from endosomes is ill-characterized; for gene transfection, only one
copy of DNA needs to reach the nucleus, and any trapped material remains invisible. Recalling
that any imaging reagents that remain trapped in endocytic vesicles will be a source of
background that cannot be removed in imaging experiments, any virosomes that cannot escape
from vesicles could potentially be problematic. We therefore approached this project with an
eye toward determining whether influenza virosomes produce endocytically trapped QDs, or
free cytosolic QDs.
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Results, discussion, and conclusions
In order to prepare QD-containing virosomes, we utilized a protocol originally reported by
Stegmann et al. in 1987,[11] with the kind assistance of the laboratory of Professor Xiaowei
Zhuang at Harvard and the laboratory of Professor Antoine van Oijen at Harvard Medical
School. The protocol is described in detail in the Methods section of this chapter. Briefly,
influenza virus is solubilized in non-denaturing detergent and the viral ribonucleprotein particle
is removed by ultracentrifugation; this removal of the viral genome eliminates infectivity. A
rhodamine green-stearic acid conjugate (a kind gift from Professor Antoine van Oijen) or
fluorescein-phosphatidylethanolamine is added to the solubilized membranous material; these
dyes become incorporated into the membrane upon reconstitution and act as markers for viral
particles. Commercial red CdSe core QDs with polyethylene glycol-conjugated, amine-
functionalized ligands for biocompatibility and solubilization (Invitrogen) are also added to this
solubilized mixture. The viral membranes are then reconstituted by vortexing in the presence of
sorbent beads that rapidly remove the detergent, forcing the membrane substituents (e.g.
lipids and membrane proteins such as hemagglutinin) to associate via hydrophobic interactions.
Cargo, in this case QDs, should be encapsulated randomly. The intact virosomes are then
purified by ultracentrifugation on a sucrose step gradient. We determined through
experimentation that the optimal concentration of QDs to add to the reconstitution mixture is
50 nM (data not shown); lesser concentrations produce little apparent encapsulation, and
higher concentrations interfere with membrane reconstitution. A schematic of the virosome
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preparation protocol is provided in Figure 3-2.
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Figure 3-2. Schematic of virosome preparation protocol. (A) Native influenza virus consists of a lipid
bilayer containing hemagglutinin protein, represented as a U-shaped molecule, enveloping a
ribonucleoprotein (RNP) genome (shown in gray). (B) Solubilization of the virion with non-denaturing
detergent affords (C) a mixture of viral membrane lipids (shown as wavy lines), membrane proteins
including hemagglutinin, and the RNP. (D) Ultracentrifugation affords removal of the RNP and
elimination of infectivity. (E) The resulting mixture of lipid and protein is doped with a green lipophilic
membrane dye to report on eventual membrane reconstitution as well as QDs. (F) Addition of sorbent
beads facilitates rapid removal of the non-denaturing detergent, yielding (G) a mixture of re-formed
viral envelopes, viral envelopes that stochastically encapsulated QDs (the desired result), and free QDs
and membrane substituents. (H) Ultracentrifugation on a sucrose step gradient purifies virosomes and
QD-containing virosomes at the interface, depicted here on a schematic centrifuge tube (1); optimizing
the amount of QDs added gives the maximal yield of virosome-encapsulated QDs at this step and
minimizes contaminating free QDs. The final product (K) is intended to be primarily QD-containing viral
envelopes, labeled with the green membrane dye and containing fusion-active hemagglutinin.
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If we successfully reconstituted virosomes, then imaging should show that the products of our
preparation are individual particles. Furthermore, if the products of our preparation protocol
are exactly the virosomes reported in the literature, we expect them to be 100-nm-diameter
particles, and so we would expect to see monodisperse, diffraction-limited spots under the
microscope; these spots would be green, because of incorporation of the green membrane dye.
Finally, imaging could tell us whether the virosome particles are associated with QDs; this
would be visualized as co-localization of the green particles with the red QD fluorescence. We
therefore used an imaging assay to determine if we had successfully produced individual
virosome particles, and if QDs were associated with, and hopefully encapsulated within, our
virosomes (Figure 3-3). First, we note that we observe green particles, as expected; however,
their size is not monodisperse. Some spots are larger than single pixels under the 40x objective,
indicating that they are larger than diffraction-limited spots; smaller particles are also present.
This indicates that larger aggregates may be formed by this protocol. Essentially complete co-
localization of green and red spots indicates that most of the virosomes are associated with
QDs. Finally, while individual QDs exhibit a phenomenon known as blinking,[2] in which their
fluorescence spontaneously turns on and off, we note that we do not observe blinking of our
virosomes, meaning that each is associated with more than one QD.
We note that this assay does not report on QD encapsulation in well-formed lipid bilayers, by
any means; co-localization could be due to QDs associating with the outside of lipid bilayers, or
alternatively QDs sticking to aggregates of lipid and protein. Indeed, the varied size of the
virosomes indicates inhomogeneity in the products of the preparation, probably including some
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larger aggregates. (For semantic ease we continue to refer to the products of our preparation
as virosomes while acknowledging this inhomogeneity.)
Overlay
Figure 3-3. Imaging virosomes reconstituted in the presence of QDs. Influenza
viral membranes were purified and reconstituted in the presence of Oregon
Green-derivatized stearic acid, to dye the virosome membrane, and QD605. The
QD channel is shown on the left in red, the virosome membrane channel is shown
in the center in green, and an overlay of the two is shown on the right. Imaging
reveals that the preparation affords individual virosome particles (Oregon Green
channel), and that many of these virosomes have QD signal associated (QD605
channel and overlay). However, the presence of (1) larger and (2) smaller spots
indicates inhomogeneity and potential aggregation in the preparation. Scale bar,
10 uM.
Since virosomes are reported to be smaller than the diffraction limit (~100 nm, whereas the
diffraction limit is ~250 nm, as discussed in Chapter 1), further structural characterization (e.g.,
confirming QD encapsulation, comparing virosome sizes, and determining if they consist of
well-formed, circularized lipid bilayers) would require electron microscopy. Rather than further
structurally characterizing the virosomes, we elected to characterize their activity in terms of
membrane fusion and quantum dot delivery, as we reasoned that, whatever their composition,
the most important characteristic is whether than can fuse with biological membranes and
deliver QDs into the cytosol.
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The first question to ask of our virosomes is whether they have membrane fusion activity,
presumably mediated by the hemagglutinin protein. In order to simplify this question, we
utilized a surface fusion assay, in which artificial acidification is used to force the viral
membrane to fuse with the plasma membrane of the cell (Figure 3-4). This simplifies analysis by
eliminating endocytosis steps. The first step of the experiment is to allow virosomes to bind to
the surface of HEK cells, which we do by treating the cells with virosomes in ice-cold phosphate-
buffered saline (PBS), such that endocytosis does not occur. Then any unbound material is
gently washed away using more ice-cold PBS, so that only virosomes that can specifically bind
to the cell surface remain. If these cells are then incubated in PBS at pH 7.5 on ice, imaging
reveals that the virosomes remain bound to the cell surface (Figure 3-4, top panels). Both the
red fluorescence from the QDs and the green membrane dye are clearly localized to the plasma
membrane. This serves as our negative control, showing that virosomes can remain stably
bound to the cell surface at physiological pH if cells are kept at 4"C. Then, to induce fusion, we
allowed virosomes to bind to the cell surface on ice and washed away unbound material as
previously, but then switched the cells into ice-cold PBS at pH 5.5. In other words, these cells
were treated identically to the negative control cells except that the pH of the incubation buffer
was decreased to 5.5. This decreased pH forces hemagglutinin to undergo its fusogenic
conformational change while still bound to the cell surface, and should force membrane fusion
to occur at the plasma membrane. Imaging (Figure 3-4, bottom panels) surprisingly reveals that,
after this treatment, the green fluorescence from the virosome membrane dye has is no longer
detectable under identical imaging conditions. We expect this to be the case if membrane
fusion has occurred and the dye has been diluted into the HEK cell membrane, although we do
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not have direct evidence that this has occurred. Second, we observe that, while some QD
fluorescence appears to remain at the cell surface, there are QDs observable in the cytosol
(indicated by white arrows, Figure 3-4, bottom left). Note that, because of their large size, these
QDs are excluded from passive diffusion into the nucleus and remain localized in the cytosol.
We conclude from this experiment that, under harsh and forcing conditions, a fraction of our
virosomes (though probably not the entire population) is capable of binding to the cell surface
and fusing with biological membranes.
We note that there is batch-to-batch variation in fusogenicity of our virosomes. For example, a
subsequent batch of virosomes exhibited cell surface binding, but clearly remained exclusively
bound to the cell surface and un-fused (in particular because the green dye signal remained,
un-attenuated) after cold acidification (data not shown). We will discuss possible sources of this
batch-to-batch variability and propose methods to address it in the future in more detail at the
end of this section (vide infra).
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Figure 3-4. Cell-surface acidification assay for virosome fusogenicity. HEK cells
were treated with QD-containing influenza virosomes on ice to prevent
endocytosis. Incubating the cells on ice at physiological pH causes the virosomes
to remain bound at the cell surface, as evidenced by the membrane localization
of the QD and virosome membrane dye puncta (top row). Exchanging the cells
into ice-cold buffer at pH 5.5 artificially forces the virosome membranes to fuse
with the plasma membrane, as evidenced by the disappearance of the green
membrane dye (possibly due to dilution into the plasma membrane of the HEK
cells) and the intracellular localization of the QD fluorescence (bottom row).
Some intracellular ODs are indicated bv white arrows (bottom left)
137
......................... ...... ..........  
10 umn
10 umn
Having established that some fraction of our virosomes has apparent fusogenic activity, we
then wanted to see if QDs could be delivered into HEK cells by our virosomes during the course
of normal endocytosis. We therefore interrogated the ability of our virosomes to be
internalized after binding to the cell surface, and examined what happens to the QDs during
this process (Figure 3-5). As in the previous experiment, in order to effect specific binding and
remove unbound material, QD-containing virosomes were applied to cells on ice, allowing cell-
surface binding to occur but preventing endocytosis, then unbound material was washed off on
ice. (This was important because, at physiological temperatures, ill-formed, non-fusogenic
virosomes that cannot associate with the cell surface could nonetheless be non-specifically
pinocytosed, showing up as background in endosomes and preventing us from querying what
happens to any cell-surface-bound virosomes, which presumably have active hemagglutinin.) As
a negative control, as previously, cells were incubated in ice-cold PBS for 5 minutes and then
imaged. Under these conditions, as seen in the top row of images in Figure 3-5, virosomes can
associate with the cells and remain primarily bound to the cell surface (though during the
imaging time, which is conducted at room temperature, some internalization does occur). The
effects of endocytosis were then investigated. Another set of cells was treated with virosomes
on ice, then washed and incubated in room-temperature PBS for 5 minutes. As seen in the
second panel row of Figure 3-5, some of the virosomes have been internalized after this
treatment, while most remain at the cell surface, much like our cold control, probably because
endocytosis is occurring very slowly at this temperature. Finally, a third set of cells was treated
with virosomes on ice, then incubated in 37"C PBS for 5 minutes. Under these conditions,
essentially all of the virosomes are internalized (though some remain at the cell surface), as
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seen in the third row of Figure 3-5. Importantly, under all conditions, the green fluorescence of
the virosome membrane dye remains visible, unlike in our forced fusion experiment. As a
negative control, HEK cells were treated with free quantum dots under identical conditions
(that is, loading with quantum dots on ice, washing, and incubation at 37"C). Under these
conditions, no free quantum dots bound to the cell surface or were internalized (Figure 3-5,
bottom). The localization of the virosomes (apparently perinuclear, in many cells in the third
row of Figure 3-5) after internalization at 37*C provides evidence that they are internalized
rather than simply aggregated on the cell surface, as we will discuss in our next experiment.
These experiments demonstrate that the viral membrane components of our virosome
preparation are necessary to promote QD binding to and internalization into cells.
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Figure 3-5. Internalization of QD-containing virosomes into HEK cells. The QD channel is shown in red
superimposed on the DIC image, left. The virosome membrane dye channel is shown in green on the right. Top,
QD-containing virosomes were allowed to bind to the surface of HEK cells on ice to prevent internalization.
Imaging reveals primarily cell-surface-associated virosomes, as indicated by arrow 1. Second row, virosomes
were bound to the surface of HEK cells, then incubated at 25*C for five minutes prior to imaging. Virosomes
remaining bound to the cell surface are indicated by arrow 2. Bottom row, virosomes were bound to the
surface of HEK cells, then incubated at 37"C for five minutes. Internalized virosomes are indicated with arrows
3 and 4.
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We then sought to determine whether these internalized quantum dots are freely distributed in
the cytosol, as desired, or if they are trapped in endocytic vesicles, at sufficiently long times
after internalization. In order to determine QD localization, we needed a bonafide marker of
endocytic vesicles. For this purpose we utilized FM 1-43, a styryl dye that emits green
fluorescence.[24] FM 1-43 can intercalate into the plasma membrane, then be internalized into
endosomal membranes; subsequent wash-out of excess dye from the plasma membrane allows
selective visualization of endocytic vesicles.[25] Treatment of our HEK cells with FM 1-43 under
this protocol generates perinuclear fluorescence, as expected for a population of late
endosomes (Figure 3-6). We then allowed virosomes to bind to HEK cells on ice, washed away
unbound material, and allowed internalization to occur for a longer time, 30 minutes at 37"C.
(As compared to the previous experiment, this longer internalization time not only allows for
endocytosis, but also for the virosomes to get to their final destination inside the cell.) The
virosomes exhibited a clear perinuclear localization (Figure 3-6), identical to our late endosomal
marker. Again, the green fluorescence of the virosome membrane dye is visible as internalized
puncta, which we interpret as an indication that membrane fusion and subsequent dye dilution
has not occurred. While it is possible that individual virosomes are fusion-active and release a
small proportion of the total population of QDs into the cytosol, it is clear that the vast majority
remain localized in endosomes.
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Figure 3-6. Comparison of internalized virosome localization to a marker of late endosomes reveals
endosomal trapping. Left, HEK cells were labeled with FM1-43 to visualize late endosomes, which display a
punctuate, perinuclear localization. The perinuclear FM1-43 fluorescence is indicated by white arrow 1, and
the nucleus of that cell is indicated with white arrow 2. FM1-43 fluorescence is shown in green
superimposed on the DIC image. Right, HEK cells were allowed to endocytose cell surface-bound QD-
containing virosomes, which are restricted to a perinuclear localization, indicating that they are trapped in
late endosomes. QD (red) and virosome membrane dye (green) fluorescence are superimposed on the DIC
image.
We therefore conclude that our functional assays on these virosomes indicate that they are not
fusion-active during endocytosis, as we had hoped. Under artificial, forcing conditions, some
fraction of our virosomes seem to be able to fuse with the plasma membrane, but this cannot
be used as a general delivery method, as treating cells with cold acidic buffer is certainly not a
step one would wish to employ prior to investigating biological phenomena. Furthermore, there
is high batch-to-batch variability in this fusogenic activity, indicating that virosomes are difficult
to prepare in active form and will not be a general tool for use by non-experts in QD delivery.
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Further optimization of the virosome preparation could have been carried out, and would
certainly have required additional structural characterization of the virosomes. However, at this
time, personal communication with our collaborators in the Zhuang and van Oijen laboratories
indicated that virosomes proved not to have significant fusogenic activity in their hands either,
and furthermore that electron microscopy had revealed the results of this preparation not to be
well-formed lipid bilayers, but rather larger aggregates of hydrophobic membrane substituents
(Dan Floyd, personal communication). Formation of aggregates rather than lipid bilayers has
been reported for virosomes reconstituted by a similar protocol from Sendai virus. [26]
Furthermore our imaging data are indicative of aggregates, as most apparent virosomes are
larger than diffraction-limited spots. It is likely that the variation between batches of virosomes
depends on the fraction of well-formed virosomes formed relative to the amount of inactive
aggregates. The physical source of this variability is almost certainly variation in sorbent loading
and quality between preparations. We note that even the best reported data in the literature
indicate that only 25% of virosomes prepared by this method are fusion-active,[27] and further
note that influenza virosomes have not become a general tool for intracellular delivery, despite
having been first reported in 1987; unfortunately, our results go a long way toward explaining
why this is the case.
We therefore abandoned this influenza virosome formulation rather than attempting to further
optimize it. However, viral delivery may yet prove useful for delivering imaging reagents into
cultured cells and tissues. A "slow reconstitution" influenza virosome preparation protocol, in
which a short-chain phospholipid detergent is used for solubilization, then removed by dialysis
rather than sorbent beads, has recently been reported.[23] This method reportedly generates
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better-quality and more reproducible virosomes with up to 75% fusion efficiency.[23] Shortly
after this initial report, these dialyzable virosomes were reported to efficiently encapsulate and
deliver siRNA[20, 21] and plasmid DNA into cells.[19] The elimination of the sorbent-dependent
step could conceivably reduce the batch-to-batch variability and aggregate formation plaguing
the previous formulation. Therefore, this improved influenza virosome preparation may prove
more useful for the delivery of imaging reagents. However, if this slow-reconstitution influenza
virosome preparation is investigated in the future, we suggest that more complete
characterization of QD-associated virosomes be performed prior to cellular experiments; in
particular, electron microscopy should be performed prior to any functional assays in order to
verify that virosomes consist of well-formed lipid bilayers rather than hydrophobic aggregates
of membrane components, and furthermore that QDs are actually encapsulated.
Additionally, the non-enveloped adenovirus has been extensively utilized for gene delivery due
to its high efficiency of cell entry. Rather than relying on encapsulation of cargo, adenovirus
causes endosomal rupture, allowing any material, including fluorescently labeled high
molecular weight dextrans, that is co-endocytosed with the virus to escape into the cytosol.[28-
30] Despite the fact that it is no longer utilized in clinical applications due to its
immunogenicity, we anticipate that adenovirus could be developed into an efficient tool for
delivery imaging reagents into cultured cells for microscopy studies. Because convincing
imaging data for adenovirus-mediated endosomal lysis exists, this seems to be a more
promising avenue for future investigation than influenza virosomes.
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These improved viral delivery methods may be investigated in the Ting lab in the future.
However, we decided that more rigorous methods for determining the intracellular fate of
delivered QDs must be validated prior to trying to develop new delivery methods. In particular,
we needed a "positive control" of bonafide cytosolic QDs for comparison to our QDs
internalized via any newly developed delivery methods. We therefore set aside viral delivery
method development in order to validate a previously reported (but ill-characterized) method
for QD delivery, reversible permeabilizaton with the bacterial toxin streptolysin 0.
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Part II: Streptolysin 0-mediated delivery of quantum dots into the cytosol of living cells
Introduction
Streptolysin 0 (SLO) is a bacterial toxin that forms pores in biological membranes. The protein
consists of a dagger-shaped monomer which intercalates into biological membranes by binding
cholesterol.[31] After the initial binding event, additional monomers associate; oligomerization
leads to formation of large circular pores up to 35 nm in diameter.[32] If a large number of
pores are opened in a given cell, cell death inevitably occurs; however, if the number of pores is
controlled (to two or fewer per cell), re-sealing of the lesions can occur after activation of a
Ca 2 -dependent signaling pathway.[32, 33] This "reversible permeabilization" with SLO has
been utilized for delivery of macromolecules into cells.[32] Cells subjected to reversible
permeabilization followed by re-sealing have been reported to remain viable.[32, 34] It is
important to note that SLO exhibits toxicity even at doses low enough to permit significant re-
sealing; under conditions providing 70-80% of cells permeabilized, only two-thirds of the
permeabilized cells survive.[32] Therefore, SLO affords cytosolic delivery, but a careful balance
must be maintained between sufficient percentage of cells permeabilized and toxicity. Our
proposed mechanism of delivery utilizing SLO is depicted in Figure 3-7.
The mechanism of SLO lesion repair after reversible permeabilization has been investigated.
Upon pore formation, calcium from the extracellular medium enters the cell, and initiates
calcium-dependent signaling that is responsible for initiating the downstream repair
processes.[32, 33] This activates the transcription factor NF-KB, which promotes expression of
inflammatory cytokines.[33] Subsequent membrane lesion repair occurs in a microtubule-
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dependent process.[32] Evidence has been found that, although the lesions have presumably
been healed (because after re-sealing of SLO pores, cells no longer take up propidium iodide),
the SLO monomer persists in the membrane of treated cells.[32, 33] This repair process only
occurs if one to two lesions are formed per cell; if SLO is applied at high concentrations such
that more pores are formed in each cell, lesion healing cannot occur and the cells die. [32]
Therefore, the literature indicates that SLO can be used for reversible permeabilization of cells,
and furthermore that SLO pores can be healed if they are formed in limited numbers. However,
transcriptional activation and stress response signaling, as well as cytoskeletal remodeling,
occur during the healing process, so the biological relevance of the state of the cell must be
taken into consideration if the reagents delivered with SLO are intended to probe a normal
physiological function.
SLO has been reported to be an effective method for imaging reagent delivery, including dye-
conjugated RNA molecular beacons.[35] While SLO has been previously reported to deliver
monodisperse QDs into the cytosol of living cells, limited imaging data has appeared in the
literature.[8, 9] Importantly, no negative controls showing that the observed QD localization is
due to SLO treatment have been reported. Furthermore, the QDs delivered by SLO have not
been demonstrated in the literature to be able to label intracellular proteins. We wished to
investigate SLO-mediated delivery in greater detail, and to determine if streptavidin-QDs and
fluorophore-labeled streptavidin could be specifically targeted to biotinylated proteins inside
the cell.
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Figure 3-7. Proposed mechanism of streptolysin 0 (SLO)-
mediated QD delivery. (A) An individual SLO monomer
initially binds to cholesterol in the cell membrane. (B) After
the initial binding event, additional SLO monomers
associate, oligomerizing to form a pore of up to 35 nm
diameter. (C) Once pores are formed, nanoparticulate
cargo such as QDs can be added to the extracellular
medium, and enter through the pores via passive diffusion.
(D) If fewer than one or two pores are formed per cell,
calcium-dependent signaling can activate active
remodeling processes that repair SLO pores, trapping QDs
inside the cytosol and allowing cell survival. This process of
pore generation followed by re-sealing is referred to as
reversible permeabilization.
Results and discussion
C QD
Delivering cell-impermeant cargo into the cytosol of living cells with streptolysin 0
Streptolysin 0 had been previously reported to provide QD delivery into the cytosol of living
cells[9], and generally to facilitate delivery of non-cell-permeable cargo via reversible
membrane pore formation[32]. However, QD delivery by SLO was poorly characterized and no
controls were done. We reasoned, therefore, that, should we demonstrate that SLO delivery
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really does deliver QDs into the cytosol, not only would we then have in hand a positive control
for QD delivery against which to assay any future methods we should develop, we would also
have validated SLO as a method for QD delivery which could be used in the meantime, until
better methods could be developed.
We first had to develop a general protocol for SLO delivery. We noted that the previously
reported protocol called for delivery of QDs into SLO-permeabilized cells at 37"C for one
hour.[9] Because we previously observed that incubating cells with QDs at this temperature
readily leads to QD endocytosis (Mark Howarth, unpublished results), we reasoned that this
protocol would result in a mixture of endotycially trapped and free QDs inside the cells. We
therefore devised a modified SLO delivery protocol, wherein we treated cells with SLO to pre-
form pores, then incubated the permeabilized cells at 4*C with the molecule we wished to
deliver, allowing diffusion into cells while preventing endocytosis. Finally, rescue in calcium-
containing buffer should permit re-sealing of the lesions. With this modified protocol in hand,
we proceeded to query SLO-mediated delivery of various imaging reagents.
We also note that our initial experiments were conducted with commercially available SLO. This
reagent contains surface cysteines, which after purification and storage form inter-molecular
disulfides, inactivating the protein; therefore, prior to use in cell permeabilization, the protein
must be "activated" by incubating it at 37"C with concentrated reductant solutions, such as
dithiothreitol (DTT) or tris(2-carboxyethyl)phosphine hydrochloride (TCEP).[9, 32, 35] Most
reported protocols then apply this protein-reductant solution directly to cells for
permeabilization, a condition we therefore also employed.[9] We note that treating cells with
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reductant is non-physiological and obviously not ideal, and could contribute significantly to
toxicity. An alanine mutant of SLO at this position has previously been reported,[32] which
produces active protein without the disulfide formation problem. We did not at the time have
access to this clone, though subsequent experiments conducted by Dr. Takashi Kawakami in our
research group have made use of this mutant protein to great effect, as we will discuss later
(vide infra).
Because of differences between cell lines and the delicate balance between SLO
permeabilization and cell killing (requiring exactly one or two pores to be formed per cell), [32]
it is recommended that cells be titrated with varying concentrations of SLO until the optimal
balance between delivery and toxicity is achieved.[32] Additionally, SLO activities are reported
in units; one unit is usually defined in terms of the amount of hemolysis (that is, lysis of
suspended red bloods cells) it causes over a certain time.[32] However, SLO from different
sources is assayed for hemolytic activity under different conditions, so the unit definition does
not necessarily translate from source to source.[32] Therefore, each batch of SLO should be
titrated against the cells of interest to empirically determine the concentration of SLO that
provides the desired amount of permeabilization activity empirically. [32]
We therefore began our experiments by determining efficacious, non-toxic SLO concentrations
that would be required to deliver fluorescein, a small organic fluorophore that cannot cross cell
membranes due to its negative charge. We performed this SLO titration on three common
laboratory cell lines (HEK, HeLa, and COS7) and determined that concentrations of SLO between
50-100 units per mL afforded efficient fluorescein delivery (Figure 3-8). Importantly, a negative
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control demonstrates that fluorescein uptake in HeLa cells is dependent on SLO treatment.
Furthermore, after healing, no significant morphology change is evident in cells treated with
SLO relative to cells left untreated, indicating that SLO toxicity is not acute under the conditions
employed.
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Figure 3-8. Delivering fluorescein into cell lines with streptolysin O. HeLa, COS-7, and HEK cells were
permeabilized for 15 minutes with 50-100 units per mL of SLO, then fluorescein was delivered for 5 mintues at
room temperature. Cells were imaged live. Uniform, diffuse fluorsecein signal was observed in permeabilized
cells. A negative control was performed for HeLa cells with SLO omitted to show that under normal conditions,
fluorescein cannot enter cells. HeLa images are normalized on the same intensity scale. Fluorescein intensity
(green) is superimposed on the DIC image for each.
It is interesting to note that our cell lines exhibit highly variable susceptibility to SLO
permeabilization, with nearly 100% of HEK cells taking up fluorescein. It is possible that these
cell lines have differential cholesterol content in their plasma membranes, or more generally
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different membrane composition, causing differences in the ability of SLO monomers to
intercalate into their membranes.
Next we attempted to deliver proteins into HEK cells with SLO. mCherry is a monomeric red
fluorescent protein[36] that serves in this case as a model membrane-impermeant
nanoparticle. We also attempted to deliver streptavidin conjugated to Alexa Fluor 568, a
reagent commonly used for imaging biotinylated proteins.[37] Both were efficiently delivered
into HEK cells after SLO permeabilization, and displayed uniform cytoplasmic localization
(Figure 3-9). No evidence of punctuate or endocytic localization is evident.
Figure 3-9. Delivering proteins into HEK
cells with streptolysin 0. mCherry, left,
and streptavidin-Alexa Fluor 568, right,
were delivered into HEK cells after SLO
permeabilization. Diffuse cytosolic
fluorescence is observed in each case. In
each image, the protein fluorescence
(red) is superimposed on the DIC image.
DIC
DIC
We then tested QD delivery with SLO, utilizing commercial red QDs with amine-functionalized
ligands. These dots are large, approximately 20 nm, and commonly used for single-molecule
imaging.[3] QD605 were efficiently delivered into HeLa cells after permeabilization with 20
units per mL of SLO, and in the absence of SLO, no QD internalization occurred (Figure 3-10).
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We therefore confirmed that SLO affords efficient cytosolic delivery of organic fluorophores,
proteins, and QDs under conditions where endocytosis is not expected to occur, providing good
evidence that these molecules should be free in the cytosol. The next step is to use them for
labeling and single-molecule imaging of biotinylated proteins.
Targeting QDs to specifically biotinylated intracellular proteins
We then needed to demonstrate that these SLO-delivered QDs can be specifically targeted to
intracellular proteins. We reasoned that we could utilize the biotin ligase (BirA)-mediated
labeling method described in detail in Chapter 1 to specifically biotinylate intracellular proteins.
Briefly, the protein of interest could be genetically fused to the acceptor peptide (AP) tag, and
co-expressed inside cells with BirA. Treatment of the cells with biotin would then allow BirA to
biotinylate the AP-tagged protein (since ATP is available inside cells). Subsequent SLO
permeabilization and delivery of streptavidin-functionalized QDs should permit the QDs to bind
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Figure 3-10. Delivering QDs into HeLa cells
with streptolysin 0. HeLa cells were
permeabilized with SLO, then QD605 were
delivered, top. Delivered QDs are generally
disperse in the cytosol and appear to be
individual molecules rather than larger
aggregates. If SLO is omitted, QDs do not enter
cells under these conditions, bottom. The QD
channel (red) is shown on the left, and the DIC
image is shown to the right in all images. HeLa
images are normalized on the same intensity
scale.
to the biotinylated protein. It has previously been demonstrated that BirA specifically
biotinylates AP-tagged proteins (to the exclusion of mammalian proteins) in the context of
mammalian cells by various methods, including mass spectrometry, [38] immunoblotting,[2, 39]
and imaging.[39]
We reasoned that the easiest way to determine specific targeting of QDs to a protein of interest
was to select model proteins with well-characterized intracellular localizations. We initially
investigated two membrane-targeted proteins: AP-tagged cyan fluorescent protein (CFP)
targeted to the plasma membrane by appending a farnesylation sequence; and the
transmembrane receptor EphA3 bearing a C-terminal, intracellular AP tag (EphA3-AP). We
confirmed that each of these proteins can be specifically biotinylated by BirA inside cells by
immunoblotting and immunofluorescence, respectively (data not shown).
Unfortunately, in our hands, SLO-delivered streptavidin-Alexa Fluor conjugates were not
observed to be targeted to these constructs in living HEK cells. This is likely to be due to the fact
that, under the SLO-permeabilization conditions utilized, cells remained healthy and viable, but
statistically few cells received streptavidin-Alexa Fluor as well as being transfected and biotin-
labeled. More stringent permeabilizaton conditions could possibly have been employed while
still maintaining cell health to give higher permeabilization efficiencies; however, in our hands,
higher SLO concentrations were toxic (data not shown). Second, though we confirmed that
biotinylation of EphA3 was occurring, we had no assay in hand to confirm that excess biotin was
fully washed out of the cells prior to streptavidin delivery. Excess free biotin inside the cells and
in the cell growth media would occupy the streptavidin binding site and prevent targeting to
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the biotinylated protein inside the cell. Finally, SLO-mediated permeabilization is most efficient
for cells that are not contact-inhibited, so more careful optimization of confluency could have
improved our chances of observing targeting.
At this point the project was taken over by Dr. Takashi Kawakami. He performed independent
optimization of the intracellular biotinylation and SLO delivery protocols (see Methods), and
has subsequently demonstrated SLO-mediated targeting of streptavidin-functionalized QDs not
only to EphA3-AP, but also to the cytoskeletal proteins actin and vimentin (Figures 3-11 and 3-
12). Briefly, the AP-tagged protein is co-expressed with BirA, a short biotin labeling step is
employed, and excess biotin is removed by washing. Cells are then permeabilized with the
C530A mutant of SLO, which does not require activation with reducing agents, then
streptavidin-QDs are delivered and cells are imaged immediately after the delivery step in
buffer containing added calcium, which promotes lesion healing.
Dr. Kawakami has demonstrated that streptavidin-QDs to EphA3 and vimentin-AP reveals the
expected intracellular localizations (Figure 3-11). QDs targeted to EphA3-AP are localized to the
plasma membrane, as expected for this transmembrane protein, but are actually
predominantly localized in intracellular puncta, presumably endocytic vesicles containing
internalized EphA3-AP (Figure 3-11, top). This is not surprising, as QDs display many copies of
streptavidin and therefore can cross-link biotinylated EphA3-AP molecules; this type of
clustering has been previously demonstrated to promoteEphA3 internalization.[1] Targeting
streptavidin-QDs to vimentin, a cytoskeletal protein that forms intermediate filaments, reveals
wide, twisting filaments (Figure 3-11, bottom). These experiments demonstrate that
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intracellular biotinylation and QD targeting is specific, and more importantly, that SLO-delivered
QDs are freely diffusible in the cytosol of living cells and can "find" their biotinylated target
proteins.
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Figure 3-11. SLO-mediated targeting of QDs to EphA3-AP and vimentin-AP. Top, HEK cells were
transfected with EphA3-AP and BirA, as well as a yellow nuclear transfection marker. After
biotinylation and SLO permeabilization, streptavidin-functionalized QDs were targeted to this cell
surface receptor. The resulting QD localization (shown in red, top left) is distributed between the cell
surface and recycling endosomes, as expected. Bottom, COS7 cells were transfected with vimentin-
AP, BirA, and the yellow nuclear transfection marker. After biotinylation and SLO-mediated QD
delivery, the QD fluorescence (red, bottom left) delineates the large, twisted fibers characteristic of
this cytoskeletal protein. The yellow transfection marker is superimposed on the DIC image on the
right for both experiments. Scale bars, 10 pm.
Finally, Dr. Kawakami performed labeling of AP-tagged actin, a cytoskeletal protein involved in
microfilament formation, and also conducted a series of controls to demonstrate the specificity
of QD targeting. SLO-delivered QDs can be targeted to biotinylated AP-actin in HEK cells (Figure
3-12A), revealing the thin filaments characteristic of actin localization. If biotin treatment is
omitted (Figure 3-12B), BirA is not expressed in the cells (Figure 3-12C), or a mutation in the AP
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that converts the specifically biotinylated lysine to alanine is introduced (Figure 3-12D), no QD
labeling occurs; furthermore, this protocol fortuitously allows the delivered QDs to diffuse back
out of the cells if they are not bound to an intracellular protein, rather than trapping the
untargeted QDs inside the cells upon lesion healing, although this exciting result was not
expected a priori.
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Figure 3-12. SLO-mediated targeting of QDs to actin and specificity controls. HeLa cells were
transfected with AP-actin, BirA, and a yellow nuclear transfection marker. Subsequent to
biotinylation and SLO-mediated permeabilization, streptavidin-QDs were delivered into the cells.
Imaging of these cells (A) reveals QD fluorescence that is targeted to apparent actin filaments
(shown in red, left) in transfected cells (shown by the yellow transfection marker superimposed on
the DIC image, right). Negative controls reveal that this targeting is dependent on biotinylation of the
target protein. Omitting biotin (B), BirA (C), or using a mutant of AP-actin where the specifically
biotinylated lysine of the AP tag is mutated to alanine (D) abrogates QD targeting inside transfected
cells. Scale bars, 10 pm.
The work of Dr. Kawakami has therefore successfully demonstrated that intracellular proteins
can be specifically biotinylated, and that SLO-mediated delivery of streptavidin-QDs can afford
QD labeling of these intracellular proteins. This validates SLO as a delivery method that can
provide freely diffusible, targetable cytosolic QDs. Of course, SLO delivery can therefore be
utilized for QD targeting in the near term. In the longer term, we do not intend SLO to be a
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permanent solution to the delivery problem because of its limitations in terms of perturbing cell
physiology and health (see Conclusion); we can, however, use SLO delivery to be a positive
control for cytosolic QD delivery against which to evaluate any new QD delivery methods
developed in the Ting lab.
Conclusion
We have established that SLO can efficiently deliver organic fluorophores, proteins, and QDs
into living cells. Dr. Takashi Kawakami has subsequently demonstrated that SLO-delivered QDs
can be utilized for protein labeling and imaging. SLO-mediated delivery may therefore prove to
be an accessible near-term alternative to microinjection for intracellular QD targeting. This
method could be accessible to more researchers and applicable to more problems than
microinjection because the SLO reagent is relatively inexpensive and commercially available,
permeabilizes many cells at a time rather than just a few, and requires no special training prior
to use.
However, we note that this technology suffers serious problems that limit its applicability to
real biological systems. First, as discussed in the introduction to this section, the balance
between efficient permeabilization and toxicity with SLO is delicate[32], meaning that it
probably cannot be applied to primary cells or living animals. Even in robust laboratory cell
lines, SLO concentration must be carefully controlled. Second, the biological relevance of any
observations made after SLO treatment may well be questionable, as the cell is undergoing
massive cytoskeletal remodeling and membrane repair processes to repair the SLO lesions[33],
which is certainly not a normal physiological condition. Third, the commercially available SLO
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protein must be activated with reductants such as TCEP or DTT prior to use, due to inter-
molecular disulfides formed between surface cysteines that inactivate the protein; treating cells
with solutions containing reductant is, obviously, non-physiological and toxic. While the alanine
mutant of SLO at this position can be prepared,[32] the mutant protein is not commercially
available and must be recombinantly expressed and purified by the researcher; it is more likely
that the non-expert researcher will elect to utilize the commercially available reagent. These
limitations make it clear that SLO serves as a temporary solution until a more favorable delivery
system is devised. More importantly, though, SLO provides us a benchmark against which to
evaluate QD delivery methods we develop in the future. It provides us a genuine sample of QDs
delivered into the cytosol of living cells, against which we can compare the localization, fate,
and diffusion properties of QDs delivered by new methods.
Methods
Mammalian cell culture
HEK, HeLa, CHO A7 and COS-7 cells were cultured in growth media, consisting of Dulbecco's
modification of Eagle's medium (DMEM, Cellgro) supplemented with 10% fetal bovine serum
(FBS, PAA Laboratories), 50 units/mL penicillin, and 50 pg/mL streptomycin (Cellgro). Cells were
maintained at 370C under an atmosphere of 5% CO2. For cellular imaging, cells were grown on
glass coverslips. HeLa, CHO A7 and COS-7 cells were grown directly on the glass substrate. HEK
cells were grown on glass pre-treated with 50 pg/ml fibronectin (Millipore).
Fluorescence imaging
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Cells were imaged in Dulbecco's phosphate buffered saline (DPBS) on glass coverslips. A Zeiss
AxioObserver inverted microscope with a 40x or 63x oil-immersion objective was used for
epifluorescence imaging. QD605 (405 broad excitation, 585 dichroic, 605/30 emission),
Fluorescein/Oregon Green/FM1-43 (493/16 excitation, 506 dichroic, 525/30 emission),
mCherry/Alexa Fluor 568 (570/20 excitation, 585 dichroic,605/30 emission), and differential
interference contrast (DIC) images were collected and analyzed with SlideBook software
(Intelligent Imaging Innovations). Acquisition times ranged from 20 milliseconds to 5 seconds.
Virosome preparation
Purified H3N2 influenza virus (A, X31, Aichi/68) was obtained from Charles River Labs (1 mL of 2
mg/mL virus). The virus was washed by adding 4.5 mL of "Hepes 145 buffer" (consisting of 50
mM Hepes pH 7.4, 145 mM NaCl, 0.1 mM EDTA) to 500 pL virus suspension, then virus was
harvested by ultracentrifugation at 35,000 rpm and 4'C for 90 minutes. Fluorescein
isothiocyanate-phosphatidylethanolamine (FITC-PE) in methylene chloride (3.1 pL, Avanti Polar
Lipids) was dried under nitrogen and added to 1 mL 100 mM octaethylene glycol monododecyl
ether (C12E8, Anatrace) in Hepes 145 buffer; alternatively, 40 pL of 2 mg/mL ethanolic solution
of Oregon Green stearic acid, a kind gift of Dan Floyd and Antoine van Oijen, was added to 1 mL
of 100 mM C12E8 in Hepes 145. These surfactant-dye mixtures were used to resuspend the
viral pellet, followed by virion solubilization with sonification at room temperature for 20
minutes. The viral genome was then pelleted by ultracentrifugation at 43,000 rpm and 4"C for
40 minutes and discarded. The supernatant was reserved and Qdot ITK amino (PEG)
(Invitrogen) was added to a final concentration of 50 nM. BioBeads SM2 (BioRad) were washed
with Hepes 145 buffer and 30 mg wet beads were added to the supernatant-QD mixture. The
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reconstitution mixture was vortexed at 2,000 rpm for 1 hour at 4"C for detergent removal. The
reconstituted sample was layered on a sucrose step gradient of 5% to 40%, then separated by
ultracentrifugation at 43,000 rpm and 40C for 60 minutes. Reconstituted virosomes were
recovered by pipetting from the visible interface between the sucrose layers.
To assay virosome formation and QD encapsulation, virosomes were diluted 1000 times in
phosphate buffered saline (PBS) and imaged in epifluorescence mode with a 40x objective in
the fluorescein and QD605 channels.
Surface acidification assay
Purified virosomes were diluted at a 1:25 ratio in 250 pL of DPBS-Mg and incubated on 90%
confluent HEK cells at 4"C for 5 minutes. Cells were rinsed 4 times with ice-cold DPBS to remove
unbound virosomes. Cells were then either incubated in ice-cold DPBS, pH 5.5, for 5 minutes on
ice, or ice-cold DPBS, pH 7.5, for 5 minutes on ice as a negative control. Cells were exchanged
back into ice-cold DPBS-Mg, pH 7.5, for imaging.
Virosome binding and internalization assays
Purified virosomes were diluted at a 1:25 ratio in 250 pL of DPBS-Mg (Dulbecco's modification
of phosphate buffered saline with 1 mM MgCl 2 added), and incubated on 90% confluent HEK
cells at 4"C for 5 minutes. (This dilution ratio was empirically determined to produce cell-
surface virosome binding.) Cells were rinsed 4 times with ice-cold DPBS to remove unbound
virosomes. Cells were then incubated in pre-temperature-equilibrated DPBS-Mg at 4"C, room
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temperature (approximately 25"C), or 370C for 5 minutes. Imaging was performed at room
temperature in DPBS-Mg.
Visualizing late endosomes with FM1-43
Dye loading was performed by incubating 90% confluent HEK cells with 50 pg/mL FM1-43 in
DPBS-Mg for 20 minutes at 37"C. The cells were then incubated in DMEM for 10 minutes at
370C to remove excess dye from the plasma membrane prior to imaging.
SLO permeabilization and delivery
Streptolysin 0 (Sigma) was diluted in DPBS to the desired concentration, then activated by
adding 5 mM tris(2-carboxyethyl)phosphine hydrochloride (TCEP) and incubating at 37"C for 30
minutes.[35] For permeabilization, 80% confluent cells (HeLa, HEK, COS-7 or CHO A7) were
treated with 250 pL per 95 cm2 of 20-100 units per mL SLO in DPBS for 15 minutes at 370C. Cells
were then rinsed 4 times with DPBS.
For fluorescein delivery, 10 VM fluorescein in DPBS was incubated with the permeabilized cells
for 5 minutes at room temperature. Cells were rinsed three times with DPBS then immediately
imaged.
For delivery of mCherry and streptavidin-Alexa Fluor conjugates, 24 PM mCherry protein or 10
pM streptavidin-Alexa Fluor 568 in DPBS-Mg were incubated with permeabilized cells for 60
minutes at 4"C. Cells were rinsed with DPBS 4 times and imaged.
For delivery of QD605, 10 nM QD605 in DPBS-Mg was incubated with permeabilized cells for 60
minutes at 4"C. Cells were rinsed with DPBS 4 times and imaged.
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Unsuccessful QD targeting protocol
HEK cells were co-transfected with 400 ng 3YF-EphA3-AP (a kind gift of Martin Lackmann at
Monash University) along with 25 ng of mCherry-BirA (pcDNA3) using Lipofectamine 2000
(Invitrogen) according to the manufacturer's instructions, then debiotinylated overnight (12-16
hours) with 50 pg/mL streptavidin (w/v in the growth media). Labeling with 50 IM biotin was
performed for 60 minutes, then excess biotin was allowed to wash out for 60 minutes in DPBS-
Mg. SLO was then added in DPBS-Mg to a final concentration of 100 U/mL and incubated on the
cells for 15 minutes at 370C. After washing off excess SLO, streptavidin-Alexa fluor 647 was
diluted 1:25 in DPBS-Mg and incubated on the cells at 320C for 60 minutes. Cells were then
placed in DMEM (no serum) and incubated at 370C for 60 minutes to allow lesion healing, then
imaged.
Successful QD targeting protocol
HeLa, HEK, or COS7 cells were co-transfected with BirA (pcDNA3), the AP fusion protein (EphA3-
AP, AP-actin, or AP-vimentin), and H2B-YFP (a nuclear-localized co-transfection marker) using
Lipofectamine 2000 according to the manufacturer's instructions. No debiotinylation was
carried out. The following day, biotinylation was carried out by incubating the cells with 10 pM
biotin in growth media at 370C for 10 minutes. Excess biotin was washed out with 3 applications
of fresh growth media for 10 minutes each. Cells were them permeabilized with 0.1 mg/mL SLO
(C530A mutant, prepared as previously described[32]) in cold DPBS for 3 minutes, then cells
were rinsed with DPBS to remove excess SLO. Delivery of QDs (Qdot 605 streptavidin conjugate,
Invitrogen) was accomplished by incubating the permeabilized cells with 10 nM QD in cold
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DPBS with 5 mM MgCl 2 and 1 mM EGTA for 20 minutes. Cells were washed with DPBS with 1
mM CaCl 2 added (DPBS-Ca, which promotes lesion healing), then imaged in DPBS-Ca.
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Chapter 4: Imaging intracellular protein-protein interactions with proximity lipoylation and
proximity coumarin ligation
Dr. Justin Cohen performed kinetic analysis of coumarin ligation to the LAPI peptide. Dr. Amar
Thyagarajan assisted with the development of the neuron labeling protocol and performed
neuron labeling and imaging.
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Introduction
The behavior of proteins inside cells is governed by their interactions with other biomolecules,
and protein-protein interactions in particular underlie many signaling pathways. Many methods
of detecting protein-protein interactions (PPIs) in the context of the cell have been reported,
and have been powerful in both the focused study of interactions of interest as well as profiling
whole interactomes, as discussed in detail in Chapter 1. However, each method has its own set
of strengths and weaknesses. Biochemical methods, such as co-immunoprecipitation, and
yeast genetic methods, such as the yeast two-hybrid, have been extensively applied in the
identification of new PPIs, but cannot provide spatial and temporal information about PPIs in
their endogenous context. Protein complementation assays (PCAs), such as bimolecular
fluorescence complementation (BiFC), have proved powerful for this purpose, but still have
significant limitations, such as trapping the interaction complex. We therefore set out to
develop improved methods for imaging PPIs in mammalian cells.
Similar to PCAs, where each half of a split reporter is fused to interacting proteins, we can
create a two-component reporter comprised of a ligase enzyme and its substrate peptide. We
design the reporter such that labeling of the peptide by the enzyme only occurs in the case of
an interaction. We call this general concept proximity ligation. Figure 4-1 provides a schematic
of the general proximity ligation concept, and we use this figure to explain the ideal kinetic
parameters of a proximity ligation system that will produce the greatest dynamic range for PPI
detection. For two (inducibly or transiently) interacting proteins A and B, protein A is fused to
the enzyme and protein B is fused to the peptide. If A and B do not interact, no labeling should
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occur. In the case that A and B do interact, the enzyme and peptide are brought into proximity
and labeling can occur. Maximal dynamic range will occur when background labeling in the
absence of an interaction is zero or minimal, and labeling in the case of an interaction is
maximal. We accomplish this by treating the PPI as a "kinetic switch".
Enzyme
peptide
probe Interaction probeNo labeling
Figure 4-1. Schematic of proximity ligation. A and B are proteins of interest. A is fused to the enzyme
ligase and B is fused to the peptide substrate. Probe ligation occurs only if A and B interact. Probe is
represented as a blue circle.
When we say kinetic switch, we mean that we can engineer a system that kinetically
discriminates between the cases when A and B are interacting and when they are not
interacting, based on the change in local concentration created upon interaction. This can be
accomplished by specifying the appropriate Michaelis-Menten parameters for enzymatic probe
ligation to the peptide substrate. We briefly review the Michaelis-Menten treatment of steady-
state enzyme kinetics and the relevant measurable kinetic parameters. For our steady-state
system, Km is empirically the concentration of peptide at which the rate of enzymatic ligation is
half-maximal (assuming all other small-molecule substrates, i.e., probe and ATP, are provided at
saturating concentrations). The maximal rate of enzymatic probe ligation when the peptide is
provided at saturating concentrations is described by kca. When the enzyme and peptide are
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present in the reaction at low concentrations, the rate of the overall reaction is controlled by
the bimolecular rate constant kcat/Km and similarly depends on the concentration of the
peptide. When the enzyme and peptide are present at high concentrations, and the peptide
concentration is saturating, the rate of the pseudo-zero-order reaction is governed by kcat.
Let us now consider how the occurrence or absence of an interaction can provide a "kinetic
switch" for the rate of enzymatic probe ligation to the peptide. If enzyme and peptide are fused
to proteins A and B and no interaction occurs, and if both enzyme and peptide are present in
the cell at concentrations well below Kin, the reaction rate is bimolecular and depends on
kcat/Km as well as the concentration of enzyme and peptide. If Km for the enzyme and peptide is
sufficiently high, that is, much higher than the concentrations of these constructs that can be
achieved in the cell under most experimental conditions, then probe ligation under these
conditions (that is, no interaction) will be kinetically inefficient. In fact, with sufficiently low
protein concentrations and/or sufficiently high Kin, undetectable background labeling can
theoretically be accomplished because the bimolecular rate will be extremely slow. Now
consider the case of a PPI. If A and B do interact, enzyme and peptide are forcibly brought into
very high local concentration, providing the previously mentioned "kinetic switch" that creates
pseudo-zero-order conditions; under this condition, the rate of the reaction will be governed
exclusively by the value of kcat. Given a sufficiently high value for kcat, therefore, the rate of
probe ligation during the interaction will be maximally high. It is intuitive that, for labeling to
occur during the time of interaction, kcat must be fast enough that one enzymatic turnover can
occur during two half-lives of the PPI. The faster the kcat achievable for the enzyme and peptide,
the better sensitivity of labeling that can be accomplished during a given labeling time, and the
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more general the method will be, especially for transient PPIs. Therefore, in order to achieve
maximal dynamic range for our kinetic switch reporter, Km of the enzyme and peptide must be
as high as possible, which maximizes the range of enzyme and peptide concentrations under
which the bimolecular reaction is very slow (and, optimally, undetectable), providing low
background labeling in the absence of an interaction; simultaneously, kcat of probe ligation to
the peptide should be maximally high in order to provide a fast ligation rate and therefore high
sensitivity when an interaction occurs. The occurrence of a PPI therefore provides this kinetic
switching by forcibly shifting the rate of enzymatic probe ligation to the peptide from a slow
bimolecular rate to a fast pseudo-zero-order rate by providing forced proximity, or high local
concentration. We set out to create a reporter of maximal dynamic range, therefore, by
engineering Km to be as high as possible, and kcat to be as high as possible.
Our research group has previously reported a PPI sensor based on the proximity ligation
concept called proximity biotinylation.[1] Proximity biotinylation utilizes the enzyme E. coli
biotin ligase, BirA, and a truncation of its acceptor peptide, the AP(-3), as two halves of a
reporter which are fused to interacting proteins. Interaction promotes biotinylation of the AP(-
3) by BirA, which is subsequently detected with streptavidin. Design of the AP(-3) was a first
attempt to access the desirable kinetic parameters we just described. The Km of BirA for the
original AP is 25 pM,[2] and for the engineered AP(-3) is 345 pM,[1] which provides for low
background in the absence of forced proximity (that is, in the concentration regime governed
by the bimolecular rate constant). However, the kcat for this reaction is perturbed. The kcat for
biotinylation of AP by BirA is 12 min 1,[2] while the kcat for biotinylation of AP(-3) is 0.53 min~
,[1] which severely curtails the sensitivity of the method. We reasoned that we could expand
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the dynamic range of detection if we could find an enzyme-peptide pair having increased kcat,
but similarly high (or higher) Km. A second limitation to the method is that proximity
biotinylation is restricted to the surface of living cells or the cytoplasm of fixed cells due to the
requirement for streptavidin-based detection.
We therefore sought to improve on the dynamic range of proximity biotinylation, and also to
extend the applicability of enzyme-mediated proximity labeling to the cytoplasm of living cells.
Because of our extensive experience with enzyme ligases and their peptide substrates, we
chose to build on the general proximity ligation paradigm for the design of our system.
Unfortunately we cannot currently address both of these issues with one reporter design, but
we will describe two methods that attempt to address first improved dynamic range, then live-
cell imaging.
We present this chapter in three parts. Part I describes our efforts to improve on dynamic range
of PPI detection in fixed cells and lysates using the enzyme E. coli lipoic acid ligase, or LpIA, and
its ligation of its natural substrate, lipoic acid, to an engineered acceptor peptide called LAP1.
We then describe our design and validation of a reporter for imaging PPIs in living cells using a
mutant of LplA that can attach a blue fluorescent coumarin probe to the LAP1 peptide. Part 11
will delineate our application of proximity coumarin ligation to investigate the interaction of
neuroligin-1 and the post-synaptic density resident protein PSD-95 in neurons. In Part Ill we
present our conclusion for this body of work.
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Part I. Design and validation of proximity lipoylation and proximity coumarin ligation protein-
protein interaction reporters
Introduction
Kinetic advantage of lipoic acid ligation by LpIA
Our first goal was to try to improve on the dynamic range of proximity biotinylation by reducing
background and improving signal. We already had access to a system with potentially ideal
kinetics for proximity labeling. Fern ndez-Suarez et al. previously reported an engineered
peptide substrate for the enzyme LpIA. LpIA catalyzes site-specific attachment of lipoic acid to
this first-generation LplA acceptor peptide, or LAP1. LpIA lipoylates LAP1 with a kcat of 3 min-',
significantly faster than BirA modifies the AP(-3) and therefore hopefully providing an increase
in sensitivity for PPI detection. Furthermore, this system should also provide low background,
because the Km of LpIA for LAPl is extremely high, initially estimated at greater than 200 pM.[3,
4] (We later determined the Km to be 678 ptM, vide infra).
While it is clear that proximity lipoylation has the potential to provide an improved dynamic
range of detection over proximity biotinylation, due to the higher kcat and Km of LpIA for its
peptide substrate, lipoic acid must be detected using an antibodyand so is restricted to
immunoblotting and immunofluorescence detection, which must be performed on lysates or
fixed cells, respectively. We therefore additionally sought a method for live-cell imaging of PPIs.
(Note that we can rationalize the existence of a commercially available anti-lipoic antibody, as
free serum concentrations of lipoic acid are essentially too low to measure. [5] This is because
lipoic acid is biosynthesized in cells via the following pathway: octanoic acid produced by the
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fatty acid biosynthesis pathway on an acyl carrier protein scaffold is transferred to
dehydrogenase proteins via an acyl-enzyme intermediate by the enzyme LipB; the sulfur atoms
are then directly installed by the lipoyl synthetase LpIA.[6] Therefore, no free lipoic acid is
formed during biosynthesis of the cofactor.)
Live-cell labeling of PPIs with coumarin
As discussed in Chapter 1, mutants of LpIA at the W37 "gatekeeper" residue at the back of the
lipoate binding pocket of the enzyme have been shown to ligate a blue fluorescent coumarin
probe to protein targets inside living cells.[7] We therefore set out to develop a live-cell PPI
reporter using the same general experimental paradigm as depicted in Figure 1, using coumarin
as our probe.
The structure of lipoic acid and the coumarin probe are shown in Figure 4-2. Of course, the 7-
hydroxycoumarin probe depicted has up to two negative charges at physiological pH and
therefore does not efficiently cross cell membranes, so modifications to the structure are
necessary for cellular labeling. Chayasith Uttamapinant has synthesized the di-acetoxymethyl
ester derivative, denoted as (AM) 2-coumarin, which can efficiently enter cells in its uncharged
state (Figure 4-2).[7] Once inside the cell, non-specific esterases cleave the ester groups, and
subsequent spontaneous elimination of formaldehyde offers the de-protected, fluorescent
coumarin.[8] Free anionic coumarin in the cytoplasm washes out over time due to the action of
non-specific anion transporters.[8] (While it is the case that formaldehyde is toxic, this method
of delivery has been generally applied to delivery of non-cell-permeable anionic molecules,
perhaps most famously to the commercially available Fura-2 calcium dye.[9] Considering that
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these molecules could otherwise only be introduced into cells via microinjection, the researcher
must consider whether the toxicity tradeoff is acceptable.)
0
OH
OH Figure 4-2. Structures of probes utilized
HO 0 in protein-protein interaction (PPI)
H reporter design. Top, lipoic acid, the
N - , OH endogenous E. coli lipoic acid ligase, or
0 0 LplA, substrate. Center, 7-
hydroxycoumarin probe utilized by W37
' 0 0mutants of LplA. Bottom,
H
0 -Ndiacetoxymethyl ester (AM)coumarin
O 0structure utilized for cell loading.
We were faced with several choices of enzyme and peptide reporter constituents. Several
mutations of LpIA have been reported to confer efficient coumarin ligase activity, in particular
W371 and W37V. These enzymes have slightly different kinetic parameters for coumarin
ligation. LpIA(W371) turns over coumarin with a kcatOf 0.96 min-' but a very high Km of 261
pM.[7] LpIA(W37V) has more favorable parameters, a kcat of 1.14 min' and Km of 56 pM.[7]
These enzymes have similarly been shown to have differential sensitivities for cellular labeling
of proteins, with W37V providing stronger signal at low expression levels, but also higher
background under high expression levels.[7] We would empirically determine which of these
enzymes works better for proximity labeling (vide infra).
While the kinetic parameters of LAP1 should be equally suitable for proximity coumarin ligation
as they are for proximity lipoylation, it was not obvious a priori that LAP1 would work in this
system. Coumarin ligation onto LAP1 had never previously been observed by other members of
the Ting research group, in vitro or in cells, probably because both coumarin and LAP1 are both
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impaired substrates in terms of the bimolecular rate constant relative to the endogenous [plA
substrates lipoic acid and H protein (or a sub-domain of H-protein, called E2p). For this reason,
a kinetically efficient LplA peptide substrate, LAP2, was evolved using yeast display.[4] The Km of
wild-type LpIA for LAP2 is 13 p.M.[4] Coumarin labeling of LAP2 has been demonstrated in vitro
and in vivo.[7] However, we theorized that LAP2 would not suffice for our proximity labeling
reporter, because as long as both proteins are present at concentrations higher than 13 pM
(which we generally find to be the case when using transient transfection of recombinant
constructs, vide infra), interaction-independent coumarin labeling would occur; that is, this
peptide would show high background labeling. We further reasoned that, although coumarin
labeling of LAP1 had never been demonstrated due to its kinetic unfavorability, the forced
proximity of LpIA and LAP1 that would occur during a PPI might overcome the kinetic barriers to
labeling.
The relevant kinetic parameters for LpIA labeling of each previously characterized probe and
peptide, which inform our reporter design, are summarized in Table 4-1.
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Km for acceptor peptide kcat Reference
BirA + AP + biotin 25 pM 12 min- [2]
BirA + AP(-3) + biotin 345 pM 0.53 min [1]
LpIA + LAPI + 8- > 300 pM 0.048 s- [3]
azidooctanoic acid
LplA + LAP2 + lipoic acid 13 pM 0.22 s [4]
LpIA(W37V) + LAPI + vide infra vide infra This work
coumarin
LpIA(W37V) + LAP2 + Not determined 0.019 s1 [7]
coumarin
Table 4-1. Previously characterized kinetic parameters for LpIA enzymes, LpIA acceptor peptides (LAPs), and
small molecule probes.
We therefore proposed that we could construct a proximity ligation PPI sensor using ligation of
coumarin to LAP1 by a W37 mutant of LpIA. We then sought model systems in which to
investigate and validate our new PPI sensors.
Model system: Rapamycin-dependent interaction of FRB and FKBP
We began our study with a well-characterized model system, the rapamycin-dependent
association of FKBP (FK506-binding protein) with a fragment of the mammalian target of
rapamycin, mTOR, called FRB, that binds FKBP and rapamycin. Rapamycin is a small molecule
derived from Streptomyces hygroscopicus that chemically dimerizes FRB and FKBP; it is named
for Easter Island, or Rapa Nui, where it was first isolated.[10] In the presence of rapamycin, the
ternary complex is stable; the dissociation constant for FRB binding to the FKBP-rapamycin
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complex has been reported to be in the range of 2.5 nM[11] to 12 nM.[12] In the absence of
rapamycin, the association between FRB and FKBP cannot be measured. Furthermore, a crystal
structure of the ternary complex has been reported, facilitating fusion construct design (Figure
4-3). It is clear from examination of the crystal structure that the C termini of FRB and FKBP are
only 18 A apart.[13] Therefore, we expect fusions of LpIA and LAP1 at the C-termini of FRB and
FKBP to afford labeling because the enzyme and substrate should be accessible to one another.
FRB (fragment of mTor)
FKBP
Figure 4-3. Ternary complex
of FRB, FKBP, and rapamycin.
FKBP is shown in light gray,
FRB is shown in dark gray, and
rapamycin is shown in red. C-
termini (points of LpIA and
LAP peptide attachment) of
FRB and FKBP are indicated
with blue arrows. Image
generated from PDB ID 1FAP.
Results and Discussion
Proximity lipoylation to detect PPIs in vitro and in cells
Construct design and in vitro proximity lipoylation
We first attemped to create a new PPI reporter based on lipoylation of LAP1 by LplA. Our first
task was to design our FRB and FKBP fusion constructs. In particular, we had to determine the
optimal LAP sequence, because several LAP1 peptides have been reported. A minimal 17-amino
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acid sequence is required for LplA recognition; however, this peptide is recognized well as an N-
terminal fusion, but poorly as a C-terminal fusion.[3] This may be due to peptide termination
with a proline residue, which could influence its secondary structure. Therefore a 22-amino acid
LAPI peptide, with a 5-amino acid extension at its C-terminal end, has been generally utilized as
an LpIA substrate.[3, 14] However, we hypothesized that the 17-mer peptide would be
sufficient for labeling in the context of fusions to interacting proteins because any effects of
poor affinity might be overcome by high local concentration in the case of interaction. We
quantitatively confirmed the suitability of the 17-mer peptide in later studies (vide infra). The in
vitro data reported here utilize the 17-mer LAP1. The initial fusion pair we chose was FRB-LpIA,
with LpIA fused to the C-terminus of FRB, and FKBP-LAP1, with the 17-mer LAP1 fused to the C-
terminus of FKBP (Figure 4-4). We began by investigating whether proximity lipoylation can
work in vitro. FRB-LplA and FKBP-LAP1 were over-expressed in E. coli and purified by nickel
affinity chromatography (Figure 4-5).
Figure 4-4. Domain structures of proximity lipoylation
constructs. LAP1 is fused to the C-terminus of FKBP,
and LpIA is fused to the C-terminus of FRB.
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Coommassie stain Coommassie stain
Figure 4-5. Purification of FRB-LpIA and FKBP-LAP. Hexahistidine-tagged FRB-LplA and FKBP-LAP1 were
expressed in E. co/i and purified by nickel affinity chromatography as described in Methods. Purity was
analyzed by electrophoresis on 16% SDS-PAGE gels. The Coommassie-stained gels are shown.
We investigated the signal-to-noise ratio of in vitro proximity lipoylation using an
immunoblotting assay. The proteins were combined at 10 pIM and pre-incubated either with
rapamycin, to induce the interaction, or without rapamycin as a negative control. We then
performed labeling by adding lipoic acid and ATP for varying times, then quenched the reaction
with the divalent metal cation chelator ethylenediaminetetraacetic acid (EDTA). (EDTA affords
quenching because LpIA requires Mg2l for ATP hydrolysis. Subsequent blotting to nitrocellulose
and detection with anti-lipoic acid antibody revealed selective lipoic acid labeling in the
presence of rapamycin, with low (but measurable) background when rapamycin is omitted from
the reaction mixture (Figure 4-6). With labeling times of both 1 minute and 4 minutes, the
signal-to-background ratio of FKBP-LAP1 labeling, determined by spot densitometry, is
approximately 12.5:1.
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Labeling time 4 minutes 1 minute Labelingtime 4minutes Iminute
Rapamycin + - + - Rapamycin + - + -
FRB-LplA *w
FKBPLAPW-
Anti-lipoic acid immunostaining Coommassie stain
Figure 4-6. In vitro proximity lipoylation analyzed by immunoblotting. Purified FRB-LplA and FKBP-LAP1
were combined at 10 pM in the presence or absence of rapamycin, then treated with ATP and lipoic acid to
afford labeling. FKBP-LAP1 lipoylation was assessed by immunoblotting with anti-lipoic acid antibody (left).
SDS-PAGE and Coommassie staining of the same reactions serves as a loading control (right). The left-most
lane of both the immunoblot and the gel is a molecular weight ladder.
Unfortunately, we also observe significant LplA self-labeling, a general problem of both LpIA
and BirA, which may contribute background in experiments where enzyme is not separated
from substrate, as is the case in cellular imaging experiments. The mechanism of BirA and LpIA
self-labeling is unclear. In particular, the primary rate constants for the two-step reaction of
LpIA have not yet been reported in the literature, to our knowledge. However, BirA has been
reported to slowly release the weakly amine-reactive intermediate biotinyl-5'-AMP into
solution (kff of 0.00027s1), and this released intermediate can non-specifically react with
bovine serum albumin in solution.[15, 16] Purified free biotinyl-5'-AMP can react with proteins,
albeit very slowly, in solution in the absence of enzyme.[17] Furthermore, "promiscuous"
mutants of BirA have been reported that release biotinyl-5'-AMP at accelerated rates; these
enzymes exhibit greater self-biotinylation, even during their expression in E. coli.[15, 16] It has
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therefore been postulated that self-labeling is a side reaction that is the result of the slow
release of the activated intermediate; the relatively high local concentration of the activated
intermediate (either biotinyl- or lipoyl-5'-AMP) in the vicinity of the enzyme means that
enzymatic lysine residues (or the N-terminus) are more likely than other proteins (and solvent)
in the cell to react with it. While our methods would be most effective if this enzymatic self-
labeling could be entirely eliminated, in particular in the case of BirA, the rate of biotin transfer
to the peptide substrate (0.1 s-1)[2] is much faster than the rate of intermediate release
(0.00027s~').[18] This means that as long as labeling times are as short as possible (and for
biotin and lipoic acid labeling, as long as the enzyme is produced in cells under conditions of
minimal free biotin or lipoic acid as necessary, in order to prevent self-labeling during
expression), the background of enzyme self-labeling relative to the peptide labeling signal will
be minimal.
Proximity lipoylation in living cells with immunoblotting detection
Proximity lipoylation worked so well in vitro, we decided to test the method inside cells. We
further wished.to test our premise that the poor-Km LAP1 peptide is required for low
background in the absence of a PPI to provide our kinetic switch. In order to do so, we utilized
three peptide or protein fusions to FKBP: LAP1, for which LplA has a poor Km (which we
measure to be 678 pM, vide infra); LAP2, for which LpIA has a lower Km of 13 pM; and E2p, a
domain from the endogenous lipoylated E. coli protein pyruvate dehydrogenase, for which the
enzyme is expected to have low Km, though this value has not been directly measured.[4] We
reasoned that, because LpIA has high kcat for lipoylation of all three, LAP1, LAP2, and E2p, they
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should all be labeled efficiently in the case of a PPI, which provides pseudo-zero-order
conditions; however, we expected that, since transient transfection is likely to provide
expressed fusion proteins at concentrations of at least ptM inside cells, at or near the Km of LpIA
for LAP2 and E2p, these fusions should also be rapidly labeled in the absence of an interaction,
providing high background (whereas LAP1 should be labeled only very slowly in the absence of
the interaction).
We co-expressed FRB-LplA with each of FKBP-LAP1, FKBP-LAP2, and FKBP-E2p in COS-7 cells;
each of these constructs is over-expressed under control of the same strong promoter, the
cytomegalovirus (CMV) promoter. We then treated the cells with rapamycin for one hour to
promote the intracellular interaction of FRB and FKBP. Parallel cells received no rapamycin, in
order to investigate the background when no interaction occurs. The cells were then labeled
with lipoic acid, with 500 ptM lipoic acid in DPBS for 1 minute, then immediately lysed and
subjected to SDS-PAGE and immunoblotting analysis to detect the lipoic acid modification
(Figure 4-7). (While lipoic acid has been demonstrated to enter intestinal cells by active
transport through the action of a proton-linked monocarboxylic acid transporter,[19] it is likely
that at these high concentrations the primary mechanism of cell entry is passive diffusion, as
has been documented for biotin, which is also an amphiphilic monocarboxylic acid, at
concentrations greater than 2pM.[20]) The anti-lipoic acid signal was quantitated for FKBP-LAP1
by spot densitometry and reveals a signal-to-background ratio of approximately 15:1. Therefore
LAPl affords good labeling in the presence of rapamycin (i.e., when a PPI occurs) and low
background in the absence of rapamycin (i.e., the absence of a PPI). Additionally, it is clear that
FKBP-LAP2 and FKBP-E2p are equivalently labeled in the presence and absence of the PPI,
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validating our premise that high-affinity peptides create high background and cannot be used in
a PPI reporter.
FKBP fusion construct LAPI LAP2 E2p LAP1 LAP2 E2p
Rapamycin + - + - + - + - + - + -
+-endogenous
+,- FRB-LplA
+--endogenous
34kDa- FKBP-E2p
26 kDa FKBP-LAP1
FKBP-LAP2
Coommassie stain Anti-lipoic acid immunostaining
Figure 4-7. Intracellular proximity lipoylation analyzed by immunoblotting. FRB-LpIA and FKBP-LAP1 were
co-expressed in COS-7 cells; alternatively, FKBP-LAP1 was replaced with FKBP-LAP2 and FKBP-E2p to test the
effect of enzyme-peptide affinity on proximity lipoylation background. Cells were labeled with 500 pM lipoic
acid in DPBS for 1 minute, then lysed immediately with direct application of SDS-PAGE loading buffer.
Lipoylation was assessed by immunoblotting with anti-lipoic acid antibody (right). Parallel wells were run on
an SDS-PAGE gel and Coommassie stained as a loading control. Only FKBP-LAP1 exhibits signal relative to
background in the presence of rapamycin; high background is observed for FKBP-LAP2 and FKBP-E2p. FRB-
LplA self-labeling is observed. Endogenous lipoylated proteins are indicated.
Proximity lipoylation in living cells with immunofluorescence detection
Having good evidence that proximity lipoylation works inside mammalian cells, we attempted
to apply proximity lipoylation to cellular imaging. Because we had a good anti-lipoic acid
antibody in hand, we expected that we would be able to detect lipoylation by
immunofluorescence. Of course, because lipoylation can only be detected by antibody binding,
imaging-based analysis of proximity lipoylation is restricted either to the cell surface or to the
cytoplasm of fixed cells. Nevertheless, these are the same restrictions facing proximity
biotinylation, and both methods can provide information about PPIs in mammalian cells not
accessible to biochemical methods of PPI analysis.
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We transfected COS-7 cells with FRB-LpIA and FKBP-LAP1-NLS, where NLS is a nuclear
localization signal that causes the FKBP-LAP1 to be trafficked into the nucleus. FRB-LpIA is
expressed throughout the cytoplasm, and immunostaining indicates that, upon rapamycin
addition, it redistributes to the nucleus, probably due to its association with FKBP-LAP1-NLS
(data not shown). We then treated the cells with rapamycin for one hour to promote the
intracellular interaction of FRB and FKBP. The cells were then labeled with lipoic acid, as
described in the Methods section, then immediately washed with ice-cold DPBS to stop the
reaction and fixed. Immunostaining reveals that FKBP-LAP, which bears a c-myc epitope tag, is
restricted to the nucleus of these cells (Figure 4-8). In the presence of rapamycin, lipoic acid
signal is detected above background, and that signal coincides with the anti-c-myc
immunostaining, indicating that the lipoic acid labeling occurs specifically on the LAP1 tag.
Furthermore, no nuclear lipoylation signal is detected in the absence of rapamycin.
Figure 4-8. Immunofluorescence imaging of proximity
lipoylation in the nucleus of COS-7 cells. COS-7 cells
were transfected with FRB-LplA and FKBP-LAP1-NLS.
Cells were incubated with 100 nM rapamycin for 1 hour,
then labeled with lipoic acid for 1 minute, followed by
formaldehyde fixation and methanol permeabilization.
Anti-c-myc staining was performed to visualize c-myc
epitope-tagged FKBP-LAP1-NLS, and anti-lipoic acid
staining was performed to visualize the lipoic acid
labeling. Anti-lipoic acid staining is shown on the left, in
red. Anti-c-myc staining is shown on the right in pink,
merged with the differential interference contrast (DIC)
image. A negative control with rapamycin omitted
demonstrates that lipoylation signal is interaction-
specific.
+ rapamycin
rapamycmn
DIC
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Unfortunately, there are serious background problems with this immunofluorescence assay.
Endogenous lipoylated proteins in mitochondria are brightly visualized with anti-lipoic acid
antibody, and we could not identify any condition that significantly decreased this endogenous
background, including 12-hour serum starvation (data not shown). Therefore, only when the
recombinant fusions are strongly over-expressed, as is the case in our COS-7 cells, does the
proximity lipoylation signal rise significantly above the endogenous background. In fact, we
were never able to accomplish proximity lipoylation of a cytoplasmic FKBP-LAP1 construct
above the mitochondrial background. Our nuclear construct is probably more brightly labeled
because nuclear localization increases the local concentration of the labeled protein, thereby
increasing the signal; the diffuse cytoplasmic construct does not achieve a sufficiently high local
concentration to be detected above the background. Furthermore, even nuclear FKBP-LAP1
could not be reproducibly labeled above background in other cell lines, such as HEK cells, which
do not over-express it as strongly in our hands. Finally, LpIA self-labeling with high-affinity
small-molecule substrates, such as lipoic acid, is a source of background that cannot be
removed, as previously discussed, so good signal-to-background ratios are only obtained when
substrate is expressed at higher levels than enzyme. It is therefore clear that proteins of
interest expressed at near-endogenous levels probably cannot be detected with proximity
lipoylation via an imaging readout.
In conclusion, proximity lipoylation provides a good response to PPIs in terms of signal-to-noise
in vitro. However, its utility in the cellular context is limited to detection by immunoblotting
applications because endogenous lipoylated proteins in the mitochondria contribute
background to immunofluorescence detection.
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Proximity coumarin ligation for live-cell PPI imaging
Method demonstration and optimization: Identification of the optimal enzyme and peptide,
demonstration of labeling specificity
Due to the limited utility of proximity lipoylation for cellular imaging, we next sought a method
for imaging PPIs, in particular inside living cells. We attempted to create a proximity coumarin
ligation reporter for this purpose. Our first task was to determine whether proximity coumarin
ligation works in living cells, and furthermore what enzyme and peptide constructs comprise
the optimal reporter. That is, we needed to quantitatively determine which LpIA coumarin
ligase mutant (i.e., LpIA(W371) or LpIA(W37V)) and which LAP1 peptide (i.e., 17-mer or 22-mer)
give the best proximity coumarin ligation response when an interaction occurs and the lowest
background in the absence of an interaction. All other things being equal, we also require that
the enzyme and peptides are minimally perturbative in the context of the fusion constructs; in
particular, the peptide substrate should be as small as possible.
We therefore compared the efficiency of labeling for each enzyme-substrate pair under very
low expression conditions, to determine which provides the greatest labeling sensitivity.
Furthermore, the FKBP-LAP1 substrate was targeted to the nucleus with the nuclear localization
signal, allowing us to determine if either enzyme is more efficient for labeling substrates with
specific sub-cellular localization. We fixed the cells in this experiment in order to query the
expression level of our constructs by immunostaining, so that we could compare their labeling
efficiency directly. Gratifyingly, we observed coumarin ligation in the presence of rapamycin for
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all constructs, as well as extremely low background in the absence of rapamycin (representative
images are shown in Figure 4-9).
Our single-cell quantitation of this dataset is shown in Figure 4-10. First we note that there is no
significant difference in the labeling intensities for the 17-mer peptide as compared to the 22-
mer peptide in the presence of rapamycin, and that background in the absence of rapamycin
for both peptides is similarly low. Therefore we conclude that, given no difference in labeling
efficiency, the 17-mer LAP1 construct is preferable because of its smaller size. Second, we
observe a few brightly labeled cells using FRB-LpIA(W371) in the presence of rapamycin, but
that most cells are dimly labeled, invariant to expression level of the FKBP-LAP1 construct (as
measured by anti-c-myc immunofluorescence). In contrast, FRB-LpIA(W37V) displays an
essentially linear increase in coumarin labeling intensity with FKBP-LAP1 expression, reaching
the same maximal intensity values attainable with LpIA(W371). This data is consistent with a
model in which LpIA(W371) must be present in the cell above a certain threshold concentration
in order to afford any labeling, whereas LpIA(W37V) provides labeling across a range of enzyme
concentrations; since we have not detected the enzyme expression level in this experiment,
this remains a hypothesis. We can conclude that LpIA(W37V) provides better sensitivity of
labeling than LpIA(W371). We note that LpIA(W37V) has been previously reported to produce
higher background labeling at high expression levels than LpIA(W371),[7] so it may be wise
when applying proximity coumarin labeling to new proteins to test both enzymes and
empirically determine which provides the best signal-to-background ratio for that particular
PPI.
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FRB-LpIA(W37V)
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Figure 4-9. Determination of optimal enzyme and peptide for proximity coumarin labeling:
Representative images. HEK cells were transfected with FRB-LpIA(W371) or FRB-LpIA(W37V) in combination
with either FKBP-LAP1(17-mer)-NLS or FKBP-LAP1(22-mer)-NLS. Cells were treated with rapamycin, or
rapamycin was omitted to assess background. Labeling was performed with 20 ptM (AM) 2-coumarin for 20
minutes. Cells were fixed and expression of FKBP-LAP1-NLS constructs was assessed by anti-c-myc
immunostaining. Coumarin labeling is shown on the left in cyan. FKBP-LAP1-NLS anti-c-myc
immunofluorescence is shown on the right in red.
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Figure 4-10. Determination of optimal enzyme and peptide for proximity coumarin labeling: Single-cell
plots of coumarin intensity against anti-c-myc intensity. Single-cell plots of intensities from the dataset
represented in Figure 4-8 are presented, wherein average per-cell coumarin intensity is plotted against the
FKBP-LAP1-NLS expression level, as assessed by anti-c-myc immunofluorescence. No difference is observed
between the 17-amino acid and 22-amino acid LAP1 sequences, indicating that they are equally competent
for coumarin labeling. LpIA(W37V) gives better labeling at intermediate expression levels than does
LpIA(W371).
We then set out to demonstrate that coumarin proximity ligation works in living cells and that
the labeling is site-specific and interaction-dependent, using LpIA(W37V) and the 17-amino acid
LAP1 peptide. We also wanted to validate our hypothesis that LAP2 should give a poor response
to PPIs in the case of coumarin ligation as well due to high background.
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When FRB-LpIA(W37V) and FKBP-LAP1 are co-expressed in the cytoplasm of living HEK cells,
addition of rapamycin followed by coumarin labeling for only ten minutes produces bright
fluorescence in transfected cells (Figure 4-11). (In this image and all live-cell images that follow,
the green fluorescent protein, GFP, is used as a co-transfection marker to identify living cells
that are expressing our constructs.) In the absence of rapamycin, background is essentially zero
(Figure 4-10). When LAPl is replaced with LAP2, coumarin labeling is observed both in the
presence and absence of rapamycin, as expected (Figure 4-11). Furthermore, the average
labeling intensity on LAP1 and LAP2 are not significantly different, indicating that the sensitivity
of labeling is not impaired by using the low-affinity substrate. Therefore, our proposed reporter
design, requiring a high kcat for labeling sensitivity, but a low Km for minimal background, has
been validated.
We further demonstrated the specificity of proximity coumarin labeling in three ways. First, we
generated a point mutant of FKBP-LAP1, FKBP-LAP1(K--4A), in which the single lysine residue of
the LAP1 peptide that is modified by LpIA is mutated to an alanine, which we expect to
eliminate labeling. When FRB-LpIA(W37V) is coexpressed with this construct, addition of
rapamycin and coumarin fail to generate coumarin signal (Figure 4-11). This demonstrates that
our coumarin proximity labeling method is site-specific. Second, we used FRB-LpIA in place of
FRB-LpIA(W37V), as a control for enzymatic activity, since wild-type LpIA has been
demonstrated not to accept the coumarin probe as a substrate. This construct fails to label
FKBP-LAP1, demonstrating that enzymatic activity is necessary for coumarin proximity ligation
(Figure 4-11).
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Figure 4-11. Imaging proximity
coumarin ligation in the cytoplasm of
living HEK cells. HEK cells were
transfected with FRB-LpIA(W37V),
FKBP-LAP1, and GFP as a co-
transfection marker. Cell were
treated with rapamycin, then labeled
with (AM), coumarin for 10 minutes,
followed by wash-out of excess
coumarin for 60 minutes. Coumarin
signal is shown to the left in blue. GFP
signal, which denotes transfected
cells, is superimposed on the DIC
image on the right. Transfected cells
treated with rapamycin display
coumarin signal (top row). A negative
control with rapamycin omitted
shows no labeling (second row). If
FKBP-LAP1 is replaced with FKBP-
LAP2, coumarin labeling occurs
independent of rapamycin addition
(third and fourth rows) due to the
high affinity of LpIA(W37V) for this
peptide. Additional negative controls
with a lysine to alanine point
mutation in LAPi or replacement of
LpIA(W37V) with wild-type LptA are
shown in rows five and six.
+ DIC
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Third, we repeated the same experiment, but restricted all of our FKBP-LAP substrate fusions to
the nucleus by appending an NLS sequence (Figure 4-12). In this case we see only nuclear
coumarin signal; since FRB-LpIA(W37V) is not specifically localized in the cell, the nuclear
labeling demonstrates that our enzyme is only labeling the LAP substrate and not other
cytoplasmic proteins.
We further wanted to confirm that our labeling corresponds to the presence of both of our
reporter constructs in the cells, and that the localization of the coumarin signal matches the
localization of our FKBP-LAP constructs. We therefore labeled the cells as above, but performed
fixation and immunofluorescence to visualize our FRB-enzyme and FKBP-substrate proteins
(Figure 4-13). Our FRB fusion constructs all bear an HA epitope tag, and our FKBP fusion
constructs all bear a c-myc tag, facilitating immunostaining. The results indicate that coumarin
labeling requires both substrate and enzyme to be present in the cell; furthermore, coumarin
localization is coincident with FKBP-LAP, as expected. Finally, we see that the protein
expression levels in the absence of rapamycin and with our alanine and wild-type LpIA controls
are essentially identical to the expression levels we see for FRB-LpIA(W37V) and FKBP-LAP1,
indicating that our negative controls have low background because of the intrinsic properties of
the system, not because of differing expression levels.
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Figure 4-12. Imaging proximity
coumarin ligation in the nucleus
of living HEK cells. All
experimental conditions and
controls are exactly as described
in the legend for Figure 6,
except that FKBP-LAP1 is
replaced with FKBP-LAP1-NLS,
which is actively restricted to
the nucleus. Similarly, FKBP-
LAP2-NLS and FKBP-LAP1(K--A)-
NLS are utilized.
+ DIC
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Figure 4-13. Investigation of FRB-LpIA(W37V) and FKBP-LAP1 expression and localization during
proximity coumarin ligation by immunofluorescence. HEK cells were transfected with FRB-LpIA(W37V)
and FKBP-LAP1. Controls are included with FKBP-LAP2 or a point mutant of FKBP-LAP1 replacing FKBP-
LAP1, or FRB-LplA replacing FRB-LpIA(W37V). Cells were treated with rapamycin, then labeled with (AM)1
coumarin for 10 minutes, followed by wash-out of excess coumarin for 30 minutes, then formaldehyde
fixation and methanol permeabilization. Anti-c-myc staining was performed to visualize FKBP-LAP
constructs, and anti-HA staining was performed to visualize FRB-LplA constructs. Coumarin signal is shown
to the left in blue. Anti-c-myc staining is shown in red superimposed on the DIC image in the center. Anti-
HA staining is shown in pink on the right.
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Generality of proximity coumarin ligation: investigating different fusion geometries and
applying the method in other cell lines
Because many PPI detection methods, including FRET and PCAs, are sensitive to fusion
geometry, we sought to determine if changing the orientation of our LpIA and LAP fusions to
FRB and FKBP produced differences in proximity labeling. We cloned the "swapped" pair of
FKBP-LpIA(W37V) and FRB-LAP1 and tested this pair side-by-side with our original set of
constructs, FRB-LpIA(W37V) and FKBP-LAP1. The domain structures of these constructs are
shown in Figure 4-14. The cells exhibiting the highest expression levels (that is, the brightest
expression of a GFP co-transfection marker) of the transfected constructs are labeled to a
similar extent in both cases (Figure 4-15). However, we observe more labeled cells, and labeling
at intermediate expression levels, for the original pair. Both fusion pairs afford similarly low
background in the absence of rapamycin. This tells us that, while the swapped pair does afford
proximity coumarin labeling, the sensitivity under these labeling conditions is decreased.
Original pair "Swapped" pair N-terminal LpIA
Figure 4-14. Domain structures of proximity coumarin ligation constructs. In the original pair, LAPI is fused to
the C-terminus of FKBP and LpIA(W37V) is fused to the C-terminus of FRB. In the "swapped" pair, LAP1 is fused
to the C-terminus of FRB and LplA(W37V) is fused to the C-terminus of FKBP. We also cloned a construct
where LpIA(W37V) was fused to the N-terminus of FRB.
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Figure 4-15. Investigation of
geometric sensitivity of proximity
coumarin ligation. HEK cells were
transfected with FRB-LpIA(W37V) and
FKBP-LAP1, or FKBP-LpIA(W37V) and
FRB-LAP1. GFP is included as a co-
transfection marker. Cell were treated
with rapamycin, then labeled with
(AM)1 coumarin for 10 minutes,
followed by wash-out of excess
coumarin for 60 minutes. Coumarin
signal is shown to the left in blue. GFP
signal, which denotes transfected cells,
is superimposed on the DIC image on
the right. Only the brightest GFP-
expressing cells in the "swapped pair"
case are labeled. Scale bars, 10 pm.
We also cloned a construct where our enzyme is fused to the N-terminus of FRB rather than its
C-terminus, which we denote LpIA(W37V)-FRB. Examination of the crystal structure reveals
that, while the N-terminus of FRB is farther from the C-terminus of FKBP, it is still oriented in
the correct direction to potentially afford enzyme-substrate accessibility. Under gentle labeling
conditions on the cytoplasmic FKBP-LAP1 construct, which afford labeling using FRB-
LpIA(W37V), we do not observe proximity coumarin labeling using LpIA(W37V)-FRB (data not
shown). Therefore, proximity coumarin labeling works in two different orientations of enzyme
and substrate peptide, but the labeling sensitivity does remain dependent on the fusion
geometry. As a result, when investigating a new PPI where no crystal structure is available to
guide construct deisgn, every possible geometric fusion must be made.
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All proximity coumarin ligation experiments to this point had been conducted in HEK cells, an
immortal line of human embryonic kidney fibroblasts. It is, however, important to show that
the method is sufficiently general to work in multiple cell lines, because different cell lines may
show differences in expression levels, dye uptake, and wash-out efficiency. We therefore tested
proximity coumarin labeling of our FRB-LpIA(W37V) and FKBP-LAP17 constructs in COS-7 and
HeLa cells using the same labeling protocol developed for HEK cells (Figure 4-16). All three cell
lines are brightly labeled in the presence of rapamycin, show very low background labeling in
the absence of rapamycin, and exhibit no obvious changes in cell health or morphology after
labeling. We therefore conclude that proximity labeling is generally applicable in immortalized
cell lines.
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Kinetic analysis of proximity coumarin ligation
While kinetic analysis of coumarin ligation to LAP2 had been previously reported, our reaction
of LplA(W37V) with LAP1 has not been previously observed. Dr. Justin Cohen therefore
measured the steady-state kinetic parameters for LplA(W37V) ligation to FKBP-LAP1. The
concentration of FKBP-LAP1 in these reactions was varied from 200 PM to 1.5 mM, and the
reaction products were analyzed by HPLC. The subsequent Michaelis-Menten curve-fitting
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Figure 4-16. Imaging proximity coumarin
ligation in the cytoplasm of living COS-7
and HeLa cells. COS-7 and HeLa cells were
transfected with FRB-LplA(W37V), FKBP-
LAP1, and GFP as a co-transfection marker.
Cell were treated with rapamycin, then
labeled with (AM), coumarin for 10
minutes, followed by wash-out of excess
coumarin for 60 minutes. Coumarin signal is
shown to the left in blue. GFP signal, which
denotes transfected cells, is superimposed
on the DIC image on the right. Bright
coumarin signal is obtained in the presence
of rapamycin and low background is
observed in its absence for both cell lines,
as observed for HEK cells. Scale bars, 10
lpm.
.. ........................................................
.. . . . ... . . . . . .. . .. .. . .. .. . .. . .. .
(Figure 4-17) revealed a Km of LpIA(W37V) for LAP1 of 678 ± 127 pM, even higher than
previously anticipated. This is excellent news, because even proteins overexpressed to the
extent of low hundreds of micromolar in the cell should not be subject to false positive results
from our proximity labeling method, because the reaction rate will still be in the bimolecular
regime. Furthermore, the measured kcat of 0.010 ± 0.001 s4 is very similar to the previously
reported kcat of coumarin ligation onto LAP2 of 0.016 s-,[7] indicating that we have not
sacrificed labeling sensitivity by using the low-Km peptide. While this kcat is not extremely fast,
and is ten times slower than the rate of lipoic acid ligation by the wild-type enzyme, we still
expect it to be sufficient for detection of PPIs with a half-life of approximately 1 minute, similar
to the sensitivity of proximity biotinylation.
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Rapamycin dose-response for proximity coumarin ligation
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We wanted to determine if our method produces a quantitative response to the strength of a
PPI. We therefore performed a rapamycin dose-response experiment to determine if we could
quantitatively detect fractional association of the ternary complex at sub-saturating rapamycin
concentrations. We used single-cell quantitative imaging for our assay. Analysis would have
been simplified if we could perform coumarin labeling in cells, lyse the cells, then quantitate in-
gel fluorescence by spot densitometry; however, no member of our laboratory has successfully
detected coumarin signal by in-gel fluorescence after labeling in live cells. This is most likely a
problem of detection sensitivity.
Cells were co-transfected with FRB-LpIA(W37V) and FKBP-LAP1, then pre-treated with
concentrations of rapamycin varying from 0.1 nM to 300 nM, extending well beyond both the
upper and lower ends of the range of reported dissociation constants. Coumarin labeling was
performed; the cells were then fixed and stained for both FRB and FKBP constructs (Figure 4-
18). Visual inspection of the imaging data reveals that the coumarin labeling intensity generally
increases as the rapamycin concentration increases, as expected,until reaching a maximal
value.
In order to do the quantitation, transfected cells (as assessed by FKBP-LAP1
immunofluorescence) were selected as regions of interest. The intensities of coumarin, FKBP-
LAP1, and FRB-LpIA(W37V) were quantitated for each cell. The labeling yield is reported as
coumarin intensity ratioed to FKBP-LAP1 intensity in order to normalize for the cell-to-cell
variation in the expression levels of our constructs (a result of the transfection method). We
then chose cells with FRB-LpIA(W37V) intensities above a chosen cut-off value for our analysis.
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The calculated single-cell coumarin labeling yield values were averaged for each concentration
of rapamycin and plotted against the rapamycin concentration (Figure 4-19). Visual inspection
of the data reveals that the labeling intensity is saturated at and above a concentration of 10
nM rapamycin, and that the labeling decays to our detection limit at and below 1 nM
rapamycin. A single inflection point is present; data fitting to the Hill equation provides an
apparent dissociation constant of 3.1 ±0.6 nM, which agrees with the previously published
value of 2.5 nM.[11] We therefore reproduce the previously reported single-site saturable
binding of FRB to the FKBP-rapamycin complex within the range of reported dissociation
constant values, demonstrating the quantitative response of proximity coumarin ligation.
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Figure 4-18. Rapamycin
dose-response:
representative images. HEK
cells were transfected with
FRB-LpIA(W37V) and FKBP-
LAPI. 24 hours after
transfection, were treated
with varying concentrations
of rapamycin, then labeled
with (AM), coumarin for 10
minutes, followed by wash-
out of excess coumarin for
30 minutes, then
formaldehyde fixation and
methanol permeabilization.
Anti-c-myc staining was
performed to visualize FKBP-
LAP constructs, and anti-HA
staining was performed to
visualize FRB-LplA constructs.
Coumarin signal is shown to
the left in blue. Anti-c-myc
staining is shown in pink in
the center. Anti-HA staining
is shown in red on the right.
Representative images are
shown.
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Figure 4-19. Rapamycin dose-response: quantitation. Each rapamycin
concentration dataset shown in Figure 14 was utilized to generate a rapamycin
dose-response curve. Coumarin labeling as a function of both FRB-LpIA(W37V)
and FKBP-LAP1 expression levels was quantitated for individual cells as
described in the methods. The calculated intensities were averaged, then
plotted as a function of rapamycin concentration. Error bars, ± standard error of
the mean.
Wedge method to determine labeling yield and sensitivity of proximity coumarin ligation
We proceeded to estimate the sensitivity (that is, the dynamic range of protein concentrations
over which we have a signal-to-background ratio greater than 2:1) and labeling yield of our
method inside living cells. The wedge method has been developed to provide estimates of the
concentrations of fluorescent molecules in cells.[21] In general, the intensity of a fluorophore
inside a cell can be measured by imaging. The average thickness of common cell lines has been
reported. Therefore, by measuring the intensity of a standard of that fluorophore at the same
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thickness, the concentration of the intracellular molecule can be estimated. To do so, a wedge-
shaped chamber of known size is constructed from glass coverslips, and the location in the focal
plane at which it reaches desired thickness in the z-direction is calculated by triangulation from
the known wedge dimensions; the intensity of the standard is measured at that point.
In order to make these measurements, we cloned a fusion of mCherry, a red fluorescent
protein, to FKBP-LAP1. This provided a fluorescent readout of the FKBP-LAP1 concentration in
the cells; of course, we have not compared the expression level of mCherry-FKBP-LAP1 to the
untagged FKBP-LAP1 construct, so these labeling yields specifically and only apply to the yield
attained for the interaction of these two constructs, FRB-LpIA(W37V) with mCherry-FKBP-LAP1.
We expressed mCherry-FKBP-LAP1 in cells with FRB-LpIA(W37V), then pre-treated the cells with
rapamycin to induce the interaction, or omitted rapamycin to quantitate background labeling in
the absence of the interaction. We then performed coumarin labeling for either 10 or 20
minutes and imaged the cells live (Figure 4-20). For our standards, we utilized purified mCherry
protein and a purified conjugate of coumarin to FKBP-LAP1, prepared as described in the
Methods section. We used this standard rather than free coumarin because coumarin quantum
yield has been observed to decrease upon ligation to target proteins (data not shown). After
converting the cellular intensities to concentrations, coumarin concentration is plotted against
mCherry-FKBP-LAP1 concentration (Figure 4-21).
Visual inspection of the data reveals the expected trends. The signal-to-background ratio is
similar (on average approximately 5:1) at both labeling times. At very low mCherry-FKBP-LAP1
concentrations, the coumarin signal decreases below our detection limit. As the concentration
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of mCherry-FKBP-LAP1 increases, coumarin signal increases essentially linearly. However, at
very high mCherry-FKBP-LAP1 concentrations, the background coumarin signal also begins to
increase. We expect that if we could access even higher protein concentrations that approach
the Km of LpIA and LAP, the background would continue to increase to values equaling the
signal. It is clear from this experiment that even at the very high intracellular concentrations of
up to 200 pM, our signal-to-background ratio is still very high, indicating that our method
should not be prone to generating false positive results even for over-expressed proteins, as
expected.
By calculating the ratio of average coumarin concentration to average mCherry-FKBP-LAP1
concentration in all analyzed cells, we estimate the labeling yield to be approximately 8% for a
10-minute coumarin incubation, and 14% after a 20-minute coumarin incubation. However,
there is high cell-to-cell variation, probably due to variations in FRB-LpIA(W37V) expression
level, which we have not measured in this experiment (because a YFP fusion to FRB-LpIA(W37V)
significantly impaired coumarin labeling, data not shown). This variation tells us something
important: if the two proteins of interest are expressed at similar levels in the cell, and if we are
looking at a single enzymatic turnover during our labeling time (which we expect to be the case
for stable PPIs), the labeling yield can depend on either the enzyme or the peptide
concentration in individual cells, depending on which is limiting.
More importantly, we calculate the minimum concentr'ation of mCherry-FKBP-LAP1 required in
the cell to produce a measurable signal, that is, a signal-to-background ratio of 2:1. We fit linear
trend lines to the 20-minute labeling data in the presence of rapamycin (signal) and the
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absence of rapamycin (background), and from a comparison of their slopes we conclude that
the signal-to-background ratio remains greater than 2 at mCherry-FKBP-LAP1 concentrations
greater than 6 pM. Similar trendline fitting to the 10-minute data provided a signal-to-noise
ratio of greater than 2 at mCherry-FKBP-LAP1 concentrations greater than 13 piM.
We note that even if a protein is expressed at total concentrations below our estimated
detection limit, it may still be detectable using proximity coumarin ligation under certain
conditions. For example, proteins targeted to specific organelles (or sub-cellular locations) and
proteins that oligomerize may be present in sufficiently high local concentrations to increase
the coumarin signal above the detection limit.
10-minute labeling 20-minute labeling
+ rapamycin
- rapamycm
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- rapamyCin
Figure 4-20. Determination of proximity coumarin ligation labeling yield: representative images. HEK cells
expressing FRB-LpIA(W37V) and mCherry-FKBP-LAP1 were treated with rapamycin, or rapamycin was omitted
to determine background. Cells were then incubated with 20 pM (AM) 2coumarin for either 10 or 20 minutes.
Coumarin labeling is shown on the left in cyan, and mCherry-FKBP-LAP1 is shown on the right in red.
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Figure 4-21. Determination of
proximity coumarin ligation labeling
yield. For the data set containing the
representative images shown in Figure,
average coumarin and mCherry
intensities were quantitated. At least 45
cells were analyzed for each condition.
Coumarin and mCherry intensities were
converted into concentrations by
200 comparison to intensities of purified
coumarin-FKBP-LAP1 and mCherry
standards of known concentration.
Sensitivity and labeling yield were
estimated from single-cell plots of
measured concentrations. Linear fits to
the data were generated and used to
estimate labeling yield and sensitivity. A
dashed line indicates the points on each
plot at which a signal-to-noise ratio of
2:1 (the lower limit of detection) is
achieved, 13 pM after 10 minutes'
labeling and 6 pM after 20 minutes'
labeling.
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Comparing proximity coumarin ligation to bimolecular fluorescence complementation
Given that so many PPI detection methods already exist, we bear the burden of demonstrating
that our method offers some advantage over comparable methods. In particular, bimolecular
fluorescence complementation (BiFC) with the yellow fluorescent protein, YFP, has been
utilized for fluorescence imaging of hundreds of PPIs inside living cells (see Chapter 1 for a
complete discussion of this method as well as other reported PPI detection methods). [22] In
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this method, YFP is divided into two non-fluorescent fragments, and each fragment is fused to
one member of an interacting pair of proteins. If an interaction occurs, the fragments of YFP
associate and fold to produce fluorescence (Figure 4-22). Because YFP BiFC has become the
standard method in the field of cellular PPI imaging, it is the benchmark against which we must
evaluate coumarin proximity ligation.
Figure 4-22. Principle of
bimolecular fluorescence
YN155 YC155 complementation (BiFC). Two
non-fluorescent fragments of
YFP enhanced YFP (EYFP) are fused to
interacting proteins A and B; upon
interaction, the fragments of EYFP
associate, fold, and oxidation by
molecular oxygen generates the
EYFP fluorophore, producing
fluorescence.
We began with design of our split YFP reporter constructs. The literature converges on
enhanced YFP (S65G, S72A, T203Y), or EYFP, as the most favorable construct for PPI detection,
because its fragments offer extremely low background in the absence of a PPI, and good signal
upon reconstitution.[23] Other enhanced YFPs, such as Venus, produce higher background.[24]
We therefore proceeded with EYFP for our comparison.
For complementation experiments, EYFP is divided into a large N-terminal fragment, YN155,
which comprises residues 1-154, and a smaller C-terminal fragment, YC155, comprises residues
155-238.[23] We created the fusions FRB-YN155 and FKBP-YC155. We hoped that these
constructs would be sterically comparable to FRB-LpIA(W37V) and FKBP-LAP1, since the larger
"piece" of the reporter in both cases (i.e., YN155 or LpIA(W37V)) is fused to the C-terminus of
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FRB, and the smaller "piece" (i.e., YC155 or LAPI) is fused to the C-terminus of FKBP. The
domain structures of the constructs used for our YFP BiFC comparison are depicted in Figure 4-
23.
YN155
- -
Figure 4-23. Domain structures of proximity coumarin ligation and YFP BiFC constructs. The "smaller piece"
of each reporter, LAP1 for proximity coumarin ligation and YC155 (comprising residues 155-238 of EYFP) for
BiFC, is fused to the C-terminus of FKBP. The "larger piece" of each reporter, LpIA(W37V) for proximity
coumarin ligation and YN155 (comprising residues 1-154 of EYFP) for BiFC, is fused to the C-terminus of FRB.
We first assayed YFP BiFC against proximity coumarin ligation at low expression levels of our
constructs; we empirically determined that this condition is obtained 36 hours after
transfection. We attempted to label both coumarin proximity ligation and YFP BiFC cells using
similar experimental conditions, and fixed the cells in order to directly compare expression
levels of these constructs by immunofluorescence. In order to achieve significant coumarin
proximity labeling at these low protein concentrations, we extended our coumarin incubation
time to 40 minutes; the good signal-to-noise obtained here demonstrate that for low-
abundance proteins, longer labeling times can provide increased sensitivity, while the low
concentrations mean the background remains low. YFP BiFC cells were grown either at 370C
after transfection, or 370C followed by incubation at 300C for 12 hours. This 30*C incubation has
been reported to increase signal, possibly by enhancing fluorophore maturation.[25] Rapamycin
was added to the BiFC cells during the final 12 hours before labeling to induce complex
formation. All cells were then fixed and stained for the c-myc epitope tag on the FKBP
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construct, and labeling intensity quantified as a function of FKBP expression level (Figure 4-
24A). First, we note that at low expression levels, both coumarin proximity labeling and BiFC
produce signal that linearly correlates with expression level of the constructs. Second, it is clear
that the response of coumarin proximity labeling (with extended labeling times) and BiFC under
normal growth conditions (that is, growth at 37"C) produces a nearly equivalent response in
terms of signal-to-noise. Finally, incubation at 30"C clearly increases the signal-to-noise
response of BiFC by approximately two-fold, as previously reported; under these conditions,
BiFC is superior to coumarin proximity labeling. However we note that growth at lower
temperatures may alter expression levels, aggregation, and the likelihood of an interaction
occurring.
However, an important problem of BiFC becomes clear at high expression levels, which we
empirically determined can be accessed 24 hours after transfection (Figure 4-24B). Under these
conditions, coumarin proximity labeling can be performed for only 10 minutes, generating a
bright response that increases linearly with expression level of the FRB construct. However, the
YFP BiFC cells surprisingly show an inverse correlation of YFP signal with expression level. (We
attempted to perform this experiment under the 300C growth condition for the BiFC cells, but
were unable to identify any immunostaining in cells in the absence of rapamycin despite several
replicates; since we could not detect expression of the constructs, we were unable to assess the
background under that condition and eliminated it from our analysis.)
Visual inspection of the primary imaging data makes clear the reason for this signal decay
(Figure 4-25). Both in the presence of rapamycin and in its absence, FRB-YN155 displays
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extensive aggregation. YFP fluorescence, which arises when the reporter folds properly, is
diffuse and localized evenly across the cytoplasm; the aggregates and plaques visualized by
immunofluorescence do not co-localize with the reconstituted YFP signal and therefore
probably do not contribute to the signal. In contrast, FRB-LpIA(W37V) does not display
aggregation under any condition. Therefore we conclude that the BiFC reporter fragments are
not folded and tend to aggregate; at high expression levels, the aggregation competes with
folding and signal generation. Therefore there is an expression level "ceiling" above which BiFC
signal decreases. Furthermore, we hypothesize that the low background observed with BiFC in
the absence of an interaction occurs because the fusion proteins are entirely misfolded and
aggregated. The tendency of YFP BiFC reporters to aggregate has been previously reported,
supporting our proposed mechanism.[23]
We conclude from these studies that, at low expression levels, the signal-to-noise ratios
attainable by coumarin proximity labeling and BiFC are similar, though BiFC signal may be
increased approximately two-fold through growth at decreased temperatures, and at high
expression levels, our labeling method is superior because BiFC signal is limited at the upper
range of protein concentrations by aggregation. We note that this is the case for the FRB and
FKBP fusion constructs utilized in this study; the aggregation phenotype may be specific to
these constructs, and may not occur for other proteins.
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Figure 4-24. Comparison of proximity coumarin
ligation to BiFC: single-cell analysis. HEK cells were
transfected with fusions of the split-YFP BiFC
reporter or coumarin proximity ligation reporter to
FRB and FKBP and the signal to background ratio for
each system was compared. Under low expression
conditions (A), single-cell plots of signal against FKBP
expression (anti-c-myc immunostaining) reveal that
BiFC produces a similar response to coumarin
proximity labeling for cells grown at 37C, but can be
forced to produce higher signal via growth at 30IC.
Under high expression conditions (B), single-cell plots
of signal against FRB expression (anti-HA
immunostaining) reveal that coumarin proximity
labeling produces superior signal-to-noise, and BiFC
response decays with increasing expression level.
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Figure 4-25. Comparison of proximity coumarin
ligation to BiFC: representative images. The BiFC
and coumarin proximity ligation reporters were
compared under high expression conditions. These
representative images are from the dataset used to
generate the plots shown in Figure 4-20B. Top, YFP
BiFC images. The YFP signal is shown in yellow on
the left superimposed on the DIC image. FRB-YN155
immunofluorescence is shown on the right in red.
White arrows indicate aggregates of protein. Botton,
coumarin proximity ligation images. Coumarin signal
is shown in cyan, superimposed on the DIC image on
the left. FRB-LpIA(W37V) immunofluorescence is
shown in red on the right. All immunofluorescence
images are normalized on the same intensity scale.
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In addition to the aggregation problem we have identified here, we note that BiFC has
additional limitations relative to proximity coumarin ligation. First, maximal maturation of the
EYFP fluorophore requires several hours after the protein folds, so detection of inducible PPIs is
limited with BiFC.[24] Second, the folding of EYFP after the PPI occurs is demonstrably not
reversible, so the complex is trapped by this method.[22] Because coumarin proximity labeling
requires a relatively short labeling time for maximal signal, and does not trap the interaction
partners, it should be the method of choice for investigating any system that would be
perturbed by any of those factors, independent of aggregation concerns. Furthermore, we
established that longer labeling times can increase the sensitivity of our detection of low-
abundance proteins, as long as background is independently verified to remain low; we
speculate that this result may apply to the detection of transient PPIs as well.
In conclusion, we utilized the rapamycin-dependent interaction of FRB and FKBP to validate our
proximity coumarin ligation method, to optimize our reporter, and to demonstrate that the
method is at best superior to and at worst comparable to the well-established YFP BiFC
method. We then sought to apply our method to a biologically relevant PPI.
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Part II: Application of proximity coumarin ligation to study the interaction of PSD-95 and
neuroligin-1 in neurons
Introduction
While the rapamycin-dependent interaction of FRB and FKBP is an excellent system for
developing and validating a method, it is also a simple system of easy-to-manipulate small
proteins that are amenable to fusions. Furthermore our fusion construct design was guided by a
crystal structure of the proteins in complex with one another, which is certainly not available
for most PPIs. We therefore sought to apply our method to "real" proteins, intact proteins that
have stringent requirements for the permissible insertion points for fusion constructs (that is,
which have been demonstrated to be perturbed by fusions unless the inserted sequence is
placed in a specific location in the protein of interest), and for which no crystal structure of the
interaction complex exists. Furthermore, we wanted to push the envelope to see if we could
accomplish labeling in delicate primary cells such as neurons. We found exactly the system we
sought in the interaction of PSD-95 with neuroligin-1 in the postsynaptic density of excitatory
neuronal synapses.
An interesting feature of PPIs involved in intracellular signaling is their modularity; that is, many
PPIs are mediated by canonical interaction domains. Examples are SH2 domains, which bind
phosphotyrosine residues,[26] and SH3 domains, which bind proline-containing consensus
sequences.[27] For application of proximity coumarin ligation in a real system, we chose a PDZ
domain-mediated PPI. PDZ domains bind a consensus motif at the C-terminus of their target
proteins. Several classes of PDZ domains have been characterized based on their sequence
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specificity. In particular, class I PDZ domains recognize the consensus sequence S/T-X-(p, where
S/T is serine or threonine, X is any amino acid, and p is a hydrophobic residue.[28] Interactions
of cell-surface protein substitutents of the post-synaptic terminus, including cell adhesion
molecules, receptors ,and ion channels, with PDZ domain-containing scaffolding proteins are
responsible for anchoring and organizing these cell-surface molecules at the appropriate
locations.[29]
Neuroligin-1 is a transmembrane cell adhesion protein present at the post-synaptic terminus of
excitatory synapses.[30] It forms a stable trans-synaptic complex with neurexin, a pre-synaptic
cell adhesion molecule.[31] Neuroligin family members are necessary and sufficient for synaptic
differentiation,[32] and mutations in neuroligin-1 have been shown to be linked to autism
spectrum disorders.[33] The interaction of neuroligin-1 with neurexin is thought to be
important for synapse maturation and development. [34]
Another important interaction of neuroligin-1, with PSD-95, occurs inside the cell, and is
mediated by a PDZ domain. Neuroligin-1 contains a C-terminal domain that extends into the
cytosol and bears a canonical recognition sequence for class I PDZ domains, the tripeptide TRV,
at its C-terminus.[35] PSD-95 is a cytosolic scaffolding protein present in the post-synaptic
density of excitatory synapses that bears three PDZ domains. The first two PDZ domains of PSD-
95 have been shown (via multiple techniques including yeast two-hybrid screens,
bioluminescence resonant energy transfer, co-localization imaging and co-
immunoprecipitation) to associate with the C-termini of potassium channels,[35] NMDA
receptors,[36] and stargazin,[37] a scaffolding protein involved in recruitment of AMPA
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receptors. The third PDZ domain of PSD-95 has been demonstrated by yeast two-hybrid
screening, co-affinity purification, and co-localization imaging to specifically interact with the C-
terminus of neuroligin-1.[35] The interaction of PSD-95 with neuroligin-1 has been
demonstrated to be involved in excitatory synapse maturation through over-expression
studies.[38, 39] A diagrammatic representation of the interaction of neuroligin-1 with PSD-95 is
presented in Figure 4-26.
+- N-terminus
Synapse
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Figure 4-26. Diagrammatic representation of the interaction of neuroligin-1 and PSD-95 in the post-synaptic
density. Neuroligin-1 is a transmembrane synaptic adhesion protein presented at the post-synaptic terminus.
Its N-terminal domain participates in extracellular protein-protein interactions. The intracellular C-terminus of
neuroligin-1 interacts with the third PDZ domain of PSD-95, a scaffolding protein of the post-synaptic density
containing 3 PDZ domains, an SH3 domain, and a guanylate kinase domain. Figure adapted from Irie, M., et al.,
Binding of neuroligins to PSD-95. Science, 1997. 277(5331): p. 1511-1515.
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Many questions remain about the spatial and temporal characteristics of the PSD-95-neuroligin-
1 interaction in neurons. It has been demonstrated that PSD-95 is responsible for localizing
neuroligin-1 to excitatory synapses.[40] Two mechanisms are possible for this regulation. Either
PSD-95 can traffic neuroligin-1 to the appropriate synapses, which would imply that PSD-95 and
neuroligin-1 interactions occur at both synaptic and extra-synaptic sites; alternatively,
neuroligin-1 can be present at excitatory synapses, and subsequent association of PSD-95 can
stabilize its localization, which would imply that these proteins only interact at synapses. We
suspect that our method can address this question, and others, in the future due to its excellent
spatial and temporal resolution.
Results and discussion
Specific labeling of the interaction of PSD-95 and neuroligin-1 in HEK cells
Our first task was to design fusions of LpIA(W37V) and LAP1 to our proteins of interest. Since
PDZ domains bind the C-terminus of their interaction partners, C-terminal fusions (such as GFP)
to proteins bearing PDZ-binding motifs act as dominant negative mutations that block the
interaction.[41] Internal GFP fusions to neuroligin-1 after threonine residue 776 that do not
impair its interactions, trafficking, and localization had been previously reported.[42] We
reasoned that the sensitivity of neuroligin-1 to fusions made LAP1, rather than LpIA, the better
choice to fuse to it. Therefore, Dr. Justin Cohen inserted LAP1 after T776 of neuroligin-1 using
overlap extension PCR. The LAP1 is, again, internal in the neuroligin-1 sequence, with the final
28 amino acids of neuroligin-1 following the LAP1 in the recombinant protein. This construct
does afford proximity coumarin labeling (vide infra), but it was not obvious a priori that this
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internal LAPI peptide would be sterically accessible or kinetically competent for labeling. The
construct was additionally constructed with an N-terminal AP tag to allow cell-surface
biotinylation and streptavidin labeling, so the entire construct is called AP-neuroligin-1-LAP1
(Figure 4-27).
GSGSTS.GSGKPGSGE FLAG
Last 28
T776 amino acids
Figure 4-27. Domain structures of neuroligin-1 and PSD-95 constructs. PSD-95 was fused to a C-terminal 15-
amino acid linker, followed by the FLAG epitope, then LpIA(W37V). Neuroligin-1 was N-terminally tagged with
the biotin ligase acceptor peptide, AP, to facilitate streptavidin labeling. LAPI peptide was inserted after
threnonine 776 of neuroligin-1, and the final 28 amino acids of neuroligin-1 follow the peptide and comprise
the C-terminus of the construct.
We had access to a fusion of PSD-95 to mCherry wherein mCherry is placed at the C-terminus of
PSD-95. This construct has previously been demonstrated to localize properly to excitatory
synapses and to be correctly recruited to developing excitatory synapses (a functional assay),
[43] as well as to interact normally with its binding partners in recruitment assays,[44] so we
construed that this fusion geometry does not affect the localization and function of PSD-95. We
therefore reasoned that placing LpIA(W37V) at the C-terminus of PSD-95 would probably afford
a construct with similar behavior to PSD-95-mCherry.
However, the design of the PSD-95-LpIA(W37V) fusion presented an unanticipated
experimental difficulty: LpIA enzymatic activity can be affected in the context of fusion to
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another protein. Our first design utilized the 10-amino acid FLAG epitope tag as a linker
between PSD-95 and LpIA(W37V), and though this construct can be expressed in HEK cells, it
did not label either the neuroligin-1-LAP1 construct or a positive control construct, LAP2-YFP,
which is a kinetically competent substrate that expresses at a high level and is robustly labeled
by enzymatically active LpIA(W37V) constructs (data not shown). We subsequently re-designed
our fusion construct with an additional flexible 15-amino acid linker between PSD-95 and FLAG-
LpIA(W37V) (Figure 4-23), theorizing that the longer linker could allow LplA to fold properly
and/or access its substrate. The linker we chose has been successfully employed in the Ting lab
in the past for construction of flexible multi-domain fluorescence resonant energy transfer
(FRET) reporters.[45, 46] We confirmed enzymatic activity of this construct in an imaging assay
by coumarin labeling of co-expressed LAP2-YFP in HEK cells (data not shown). Therefore,
multiple validation steps are necessary when utilizing proximity coumarin ligation for detection
of new PPIs; first, it must be determined that the proteins of interest are not perturbed by
fusion to LpIA and LAP; and second, it must be established that the LpIA is enzymatically active
and that the LAP tag is accessible using positive control experiments.
We then sought non-interacting mutants of our constructs to utilize as negative controls to
determine if our labeling is real and interaction-dependent. We constructed a negative control
construct wherein the three C-terminal amino acids of our AP-neuroligin-1-LAP1 construct are
deleted. Recalling that the LAPl is internal, it should be clear that these three amino acids, TRV,
constitute the C-terminus of AP-neuroligin-1. This deletion is expected to eliminate the
interaction, as these amino acids constitute the most strongly conserved part of the PDZ
domain recognition sequence; furthermore the crystal structure of PSD-95 in complex with a
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peptide derived from the protein CRIPT-1 shows that the final three amino acids of the bound
peptide are deep in the binding pocket and are responsible for a majority of the interactions
with the PDZ-domain.[47] In fact, previous reports bear this prediction out; this three-amino
acid deletion has previously been reported to eliminate the interaction of neuroligin family
members with PDZ domains in yeast two-hybrid assays.[35, 48] We designate this deletion
mutant as AP-neuroligin-1-LAP1-APDZ to indicate that the PDZ binding motif has been deleted.
No point mutant of PSD-95 that abrogates its interaction with neuroligin-1 has, to our
knowledge, been reported. Close inspection of the PSD-95 crystal structure reveals why this
might be the case; the target peptide interacts with many residues in the PDZ domain via both
amino acid side chains and also amide bond interactions in the PSD-95 peptide backbone, so no
single mutation (or obvious small number of mutations) would obviously abrogate the binding
interaction.[47] Rather than deleting entire domains of PSD-95, as previously reported,[35] we
simply chose to utilize LpIA(W37V) as a non-interacting negative control.
We tested coumarin proximity labeling of these constructs in HEK cells. We began in
heterologous cells to simplify the optimization process, since we already knew that coumarin
labeling works well in these cells in general. Furthermore, this interaction was first
characterized in heterologous cells, so we knew that PSD-95 and neuroligin-1 can interact in
this context.[35]
When PSD-95-LpIA(W37V) is co-expressed with AP-neuroligin-1-LAP1 in living cells, ten minutes
of coumarin labeling affords bright coumarin labeling proximal to the plasma membrane, as
expected for labeling of a membrane protein. When AP-neuroligin-1-LAP1 is replaced with the
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non-interacting mutant AP-neuroligin-1-LAP1-APDZ, and also when PSD-95-LpIA(W37V) is
replaced with LpIA(W37V), the interaction does not occur and labeling is abolished (Figure 4-
28).
With longer labeling times (i.e., a coumarin incubation of 40 minutes) and high expression
levels, we do observe non-specific labeling in both negative controls equivalent to the level of
labeling in the presence of the interaction; we have never observed this level of background in
the case of FRB and FKBP labeling, even after one hour of labeling (data not shown). This is
probably a consequence of extremely high over-expression of these particular constructs in the
heterologous context, and demonstrates that, while our method exhibits extremely good
dynamic range, the need remains to carefully control expression levels when investigating PPIs,
as well as to optimize labeling conditions for each new pair of proteins under investigation,
confirming that, for the protein pair utilized and the labeling conditions employed, background
is low.
We conclude that we can specifically label the interaction of neuroligin-1 and PSD-95 in HEK
cells. Our next task was to establish whether we could carry this labeling into neurons.
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AP-neuroligin-1-LAP1
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Figure 4-28. Imaging the interaction of PSD-95 and neuroligin-1 in living HEK cells. HEK cells were
transfected with PSD-95-LpIA(W37V), AP-neuroligin-LAP1, and GFP as a co-transfection marker. Cells
were labeled with (AM), coumarin for 10 minutes, followed by wash-out of excess coumarin for 60
minutes. Coumarin signal is shown to the left in cyan. GFP signal, which denotes transfected cells, is
superimposed on the DIC image on the right. Replacing AP-neuroligin-LAPI with the non-interacting
mutant AP-neuroligin-LAP1-APDZ, or replacing PSD-95-LpIA(W37V) with LpIA(W37V) eliminates labeling,
indicating that coumarin signal is interaction-dependent.
Coumarin proximity labeling of the interaction of PSD-95 and neuroligin-1 in neurons
Working together with Dr. Amar Thyagarajan, we determined that PSD-95-LpIA(W37V) and AP-
neuroligin-1-LAP can be expressed in cultured dissociated rat hippocampal neurons, with
optimal expression of both constructs obtained 24 hours after co-transfection. We note that
under our experimental conditions, we are purposely over-expressing our fusion constructs in
order to attain good coumarin signal. PSD-95-LpIA(W37V) was observed to localize to puncta in
neuronal processes, as expected for a synaptic protein, providing good evidence that the fusion
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of PSD-95 to LpIA(W37V) did not significantly perturb its trafficking and localization. Dr.
Thyagarajan extended these experiments to include coumarin labeling (Figure 4-29). Neurons
were transfected on DIV4 (5 days in vitro) with PSD-95-LpIA(W37V), AP-neuroligin-1-LAP1, and
BirA-ER, a previously reported construct[49] that localizes BirA to the endoplasmic reticulum
and allows biotinylation of cell-surface proteins as they traverse the secretory pathway. Cells
were incubated overnight with 10 pM biotin to give biotinylation of AP-neuroligin-1-LAP1. On
DIV5, the neurons were labeled with coumarin, then labeled with streptavidin-Alexa Fluor 568
conjugate to visualize AP-neuroligin-1-LAP1. After fixation with formaldehyde and methanol
permeabilization, immunostaining against the FLAG epitope on PSD-95-LpIA(W37V) was
performed. The results (Figure 4-29A) show bright coumarin labeling both in cell bodies and
neuronal processes, which co-localizes to a large extent with the PSD-95-LpIA(W37V)
immunofluorescence signal. If AP-neuroligin-1-LAP1 is replaced with the non-interacting
mutant AP-neuroligin-1-LAP1-APDZ (Figure 4-29B), the coumarin signal in the processes is
eliminated. Low coumarin background remains in the cell body; this is probably because the
local concentration of both proteins is very high in the cell body. Reassuringly, immunostaining
and streptavidin staining demonstrate that both the wild-type and non-interacting mutant
neuroligin constructs express at similar levels and have grossly similar localizations. This
provides support for the idea that the non-interacting neuroligin-1 mutant does not abrogate
labeling simply because it is not functional or mistrafficked, but rather that the elimination of
coumarin signal is simply due to the lack of interaction with our PSD-95 fusion construct.
We therefore conclude that proximity coumarin labeling accurately reports on the interactions
of real proteins, and furthermore that it is amenable to labeling delicate primary cells such as
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neurons. We are currently characterizing the interaction of neuroligin-1 and PSD-95 in neurons
further. We plan to determine if the locations of coumarin labeling coincide with genuine
synaptic markers in order to confirm that our constructs localize, as expected, to excitatory
synapses; furthermore we are investigating whether there is an interaction-dependent increase
in the interaction of neuroligin-1 and PSD-95.
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Figure 4-29. Imaging the interaction of PSD-95 and neuroligin-1 in rat hippocampal neurons. Neurons were
transfected on DIV4 with PSD-95-LpIA(W37V), AP-NLG1-LAP1, and BirA-ER. Neurons were incubated with 10 PM
biotin overnight to afford biotinylation of AP-neuroligin-LAP1. On DIV5, neurons were labeled with 20 pM
(AM) 2-coumarin for 15 minutes, washed for 45 minutes, then fixed with paraformaldehyde and permeabilized
with methanol. Anti-FLAG epitope immunostaining against PSD-95-LplA(W37V) was performed to visualize
enzyme localization and expression level. (A) Coumarin labeling is seen in neuronal processes and cell bodies.
(B) Replacing AP-neuroligin-1-LAP1 with the non-interacting mutant neuroligin-1-LAP1-APDZ eliminates
coumarin labeling, except for low background in the cell body, probably due to high local concentrations.
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Part IlIl: Conclusion
In conclusion, we have developed new methods for detecting PPIs in mammalian cells. While
proximity lipoylation does produce a good response in the presence of a PPI and low
background labeling in the absence of an interaction, its utility for imaging assays is limited by
the presence of endogenous lipoylated proteins in cells that cannot be removed. It may yet
prove useful in gel-based assays and for proteomic analysis.
Proximity coumarin ligation, in contrast, has proved to be an effective method for imaging PPIs
in living mammalian cells. In contrast to previously reported methods, it offers several distinct
advantages. Unlike PCAs,[22] proximity coumarin ligation does not trap the interaction
complex, leaving the interaction partners free to dissociate after labeling. Background is
extremely low due to the poor affinity of LplA for LAP1, reducing false positive results. Unlike
the traditional yeast two hybrid assay,[50] it is applicable in mammalian cells and works for
membrane proteins (such as neuroligin-1). Furthermore, it compares favorably to BiFC in terms
of signal-to-background ratio without being subject to aggregation.
Several fundamental limitations to this technology remain. First, the coumarin fluorophore is
not yet fully optimal for biological imaging. The pKa of 7-hydroxycoumarin is 7.5, so at
physiological pH only about half of the fluorophore is deprotonated.[51] Unfortunately, only
the deprotonated form of 7-hydroxycoumarin is fluorescent, so the maximal signal we can
attain is limited not only by labeling yield but also by coumarin ionization. Second, the 7-
hydroxycoumarin photobleaches quickly. Third, significant cellular autofluorescence exists in
blue wavelengths, and the short excitation light used for coumarin imaging cannot penetrate
tissues. These factors limit the utility of coumarin labeling for biological imaging. In the future,
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the photophysical properties of proximity ligation can be improved by engineering LpIA to
accept brighter coumarins, such as Pacific Blue, a fluorinated coumarin with a pKa of 3.7,[51]
and red fluorophores, such as resorufin. These efforts are already underway in the Ting
research group.
A second limitation to our sensitivity is the slow catalytic rate of LpIA(W37V) of 0.010 s1. This
rate is 10 to 30 times slower than the catalytic rates determined for lipoic acid and other
engineered unnatural substrates for LpIA.[7] This limits the sensitivity of the method and
prevents us from using labeling times of less than about ten minutes. While in vitro selections
could produce a faster LplA mutant, this will require significant engineering effort.
A third limitation is our total labeling time of approximately one hour. Most of this time is
required for excess coumarin wash-out prior to imaging. A shorter labeling time, on the order
of the lifetime of the PPI of interest, would be ideal, but it is difficult to envision a solution to
this problem using enzyme-catalyzed labeling, unless a fluorogenic probe that fluoresces upon
ligation could be developed.
A fourth problem is that, while our peptide is very small and therefore likely to minimally
perturb its fusion partner, LpIA is a large enzyme, at 42 kilodaltons, and could potentially cause
misfolding or mistrafficking of proteins to which it is fused. There is no simple solution to this
problem, so every new protein under investigation must be rigorously characterized to ensure
that it folds, traffics, localizes, and functions properly upon fusion to LpIA.
Another limitation is the low activity of LpIA in the secretory pathway that we and
othermembers of our laboratory have observed, which renders it useless for labeling in these
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compartments and at the cell surface. This may be due to the oxidizing nature of these
compartments; disulfide formation between surface cysteine residues of LpIA has been
previously reported to inactivate the enzyme.[52] While proximity coumarin ligation has been
demonstrated to work in the cytosol and nucleus, a truly general method requires engineering
LpIA to be active in all subcellular and extracellular environments.
A final problem is that once the coumarin has been ligated to the LAP, it remains covalently
bound, even if the PPI is no longer occurring. Therefore our coumarin signal does not directly
correspond to a complex of interacting proteins, but rather reports on protein that underwent
interaction during the labeling time. While this does provide useful information about the PPI,
an ideal method would turn on during the interaction, and turn off upon dissociation, as is the
case with fluorescence resonant energy transfer, or FRET. Unfortunately such a system is not
easily achievable using a ligase enzyme-based reporter.
Despite these limitations, we expect that coumarin proximity ligation should prove generally
useful for PPI detection due to its robust response to both model and real PPIs in both cell lines
and primary cells. In the future, we will apply coumarin proximity ligation to analysis of the
dynamics of the PSD-95-neuroligin-1 interaction during synapse development as well as the
localization of this interaction complex in neurons. We additionally plan to extend live-cell
proximity labeling to fluorophores with improved photophysical properties.
In the future, we hope to extend proximity-dependent coumarin labeling to trans-synaptic PPI
labeling. Dr. Amar Thyagarajan has recently reported a new methodology called BLINC, or biotin
labeling of intercellular contacts (A. Thyagarajan and A. Y. Ting, Cell 2010, in press). BLINC is an
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extension of proximity biotinylation to the imaging of cell-surface PPIs in living cells. In this
case, each cell-surface interaction partner is fused to either biotin ligase (BirA) or the BirA
acceptor peptide, AP; when the proteins interact, in particular across cell-cell junctions,
biotinylation occurs and streptavidin staining reports on the interaction. BLINC has been utilized
to investigate the trans-synaptic interaction of neuroligin-1 and neurexin, which, as previously
mentioned, is a synaptic adhesion complex important for synapse formation and maturation.
However, this method is only applicable to dissociated cultures of neurons, because
streptavidin is too large to diffusively penetrate tissue sections or tissues of living animals.
Because our coumarin probe is small, we anticipate that proximity coumarin labeling with LpIA
could address this permeability issue, as well as decreasing labeling times due to the single-step
labeling protocol. Once LpIA variants that are active on the cell surface have been developed
through current Ting lab engineering efforts, this extension of coumarin proximity labeling to
"L-LINC," or LpIA labeling of intercellular contacts, will be an exciting future direction.
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Methods
Cloning and mutagenesis
Nucleotide sequences of all constructs utilized in this study are available at
http://stellar.mit.edu/S/project/tinglabreagents/r02/materials.html. Constructs were prepared
either by standard restriction cloning methods or QuikChange mutagenesis (Stratagene) as
described by the manufacturer.
Mammalian cell culture
HEK, HeLa, and COS-7 cells were cultured in growth media, consisting of Dulbecco's
modification of Eagle's medium (DMEM, Cellgro) supplemented with 10% fetal bovine serum
(FBS, PAA Laboratories), 50 units/mL penicillin, and 50 pg/mL streptomycin (Cellgro). Cells were
maintained at 370C under an atmosphere of 5% CO2 unless otherwise noted. For cellular
imaging, cells were grown on glass coverslips. HeLa and COS-7 cells were grown directly on the
glass substrate. HEK cells were grown on glass pre-treated with 50 pg/ml fibronectin (Millipore).
Fluorescence imaging
Cells were imaged in Dulbecco's phosphate buffered saline (DPBS) on glass coverslips. A Zeiss
Axiovert 200M inverted microscope with a 40x oil-immersion objective was used for
epifluorescence imaging. Coumarin (400/20 excitation, 425 dichroic, 435/30 emission),
YFP/Alexa Fluor 488 (493/16 excitation, 506 dichroic, 525/30 emission), mCherry/Alexa Fluor 568
(57020 excitation, 585 dichroic, 605/30 emission), Alexa Fluor 647 (630/0 excitation, 660
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dichroic, 680/30 emission) and differential interference contrast (DIC) images were collected.
For confocal imaging, we utilized a Zeiss AxioObserver inverted microscope with a 60x oil-
immersion objective, outfitted with a Yokogawa spinning disk confocal head, a Quad-band
notch dichroic mirror (405/488/M6"47), and 405 (diode), 491 (DPSS), 561 (DPSS), and 640 nm
(diode) lasers (all 50 mW). Coumarin (405 laser excitation, 445/40 emission), GFP/Alexa Fluor
488 (491 laser excitation, 52838 emission), Alexa Fluor 568 (561 laser excitation, 617/73
emission), Alexa Fluor 647 (640 laser excitation, 700/75 emission), and DIC images were
collected. All image analysis was with Slide Book software (Intelligent Imaging Innovations).
Fluorophore intensities in each experiment were normalized to the same intensity ranges.
Acquisition times ranged from 20 milliseconds to 5 seconds.
Protein expression and purification
E. coli BL21 cells transformed with pET expression plasmids for either FRB-LpIA or FKBP-LAP1
were grown in Luria broth supplemented with 100 ptg/mL ampicillin at 37"C until reaching OD
0.6. Protein expression was induced with 420 ptM IPTG at 30"C for 5 hours. Cell were harvested
by centrifugation (6,000 x g, 10 minutes, 4"C) then lysed with B-PER (Thermo Scientific)
containing 2.5 mM PMSF, protease inhibitor cocktail (Calbiochem), and DNase I (New England
Biolabs). The lysate was cleared by centrifugation (17,700 x g, 15 minutes, 4"C). The
hexahistidine-tagged proteins were purified by affinity chromatography on Ni-NTA agarose
(Qiagen). Clarified lysate was loaded onto 1 mL nickel-nitrilotriacetic acid agarose resin (Qiagen)
by gravity flow, then washed with binding buffer (50 mM Tris-HCI pH 7.8, 300 mM NaCl)
followed by washing buffer (binding buffer + 30 mM imidazole). Fractions were analyzed by
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SDS-PAGE, and fractions containing pure protein were dialyzed three times against 4 liters of
phosphate buffered saline (PBS), pH 7.4. Protein concentration was determined by BCA assay
(Thermo Scientific) with bovine serum albumin (BSA) as a standard. Purified proteins were
aliquoted, flash frozen, and stored at -80"C.
In vitro proximity lipoylation
FRB-LpIA, FKBP-LAP1, and rapamycin were combined at 10 ptM in PBS, pH 7.4, with 5 mM
MgCl 2, and incubated at room temperature for 30 minutes to pre-induce the interaction. 1 mM
lipoic acid was added, then reactions were initiated with 5 mM ATP. Identical reactions with
rapamycin omitted served as negative controls. The reactions were allowed to proceed for
either 1 minute or 4 minutes, then quenched with a final concentration of 45 mM EDTA pH 8.0.
in vitro reaction mixtures were combined with SDS-PAGE loading buffer, then boiled for 5
minutes to denature all proteins. 30 tL of each reaction mixture were loaded per lane on a 16%
acrylamide SDS-PAGE gel, electrophoresed, then analyzed by Western blotting, as described
below.
Immunoblotting detection of proximity lipoylation in cells
COS-7 cells were grown to 50% confluency in a 24-well plate, then transfected with 600 ng FRB-
LpIA -pcDNA3 and 600 ng FKBP-LAP1per well using Lipofectamine 2000 (Invitrogen) according
to the manufacturer's instructions. For comparison of signal-to-noise, FKBP-LAP1-pcDNA3 was
replaced with FKBP-LAP2-pcDNA3 or FKBP-E2p-pcDNA3. 24 hours after transfection, growth
media was removed and fresh growth media containing 100 nM rapamycin was applied to the
cells for one hour at 370C. Rapamycin was omitted from parallel wells as a negative control. The
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media was then removed, and pre-warmed DPBS containing 500 pM lipoic acid was applied to
the cells for one minute. The labeling solution was removed and the cells were immediately
lysed (and the reaction therefore quenched) with direct application of SDS-PAGE loading buffer
(40 ptL per well). All proteins were denatured by boiling for 5 minutes. 30 ptL of this material was
loaded per well on a 14% acrylamide SDS-PAGE gel, electrophoresed, then analyzed by
Western blotting, as described below.
Western blotting
Samples were run on SDS-PAGE gels, then transferred to nitrocellulose for 120 minutes at 500
mA. (Parallel reactions or wells were run on an identical SDS-PAGE gel, then stained with
Coommassie brilliant blue, as loading controls.) After transfer, membranes were blocked with
3% BSA in tris-buffered saline with 0.05% Tween-20 (TBS-T) for 1 hour at room temperature.
For lipoic acid detection, the membrane was treated with rabbit polyclonal anti-lipoic acid
antibody (Calbiochem) at a 1:300 dilution in 3% BSA in TBS-T at room temperature for one
hour, then washed three times for 5 minutes with TBS-T. The membrane was then incubated
with goat anti-rabbit horseradish peroxidase conjugate (Bio-Rad) in 3% BSA in TBS-T at a 1:3000
dilution for one hour at room temperature, then again washed three times for 5 minutes with
TBS-T. Chemiluminescence detection was performed with SuperSignal West Pico reagent
(Pierce) for in vitro reactions, or SuperSignal West Femto reagent (Pierce) for cell lysates, and
imaged on an Alpha Innotech Chemilmager 5500. Spot densitometry was performed using
AlphaEase FC version 3.2.2 software (Alpha Innotech).
Immunofluorescence detection of proximity lipoylation in cells
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COS-7 cells were grown to 50% confluency on glass coverslips, then transfected with 200 ng
FRB-LplA -pcDNA3 and 400 ng FKBP-LAP1-NLS-pcDNA3 per 0.95 cm2 surface area using
Lipofectamine 2000 according to the manufacturer's instructions. 24 hours after transfection,
growth media was removed and fresh growth media containing 100 nM rapamycin was applied
to the cells for one hour at 370C. Rapamycin was omitted from parallel wells as a negative
control. The media was then removed, and pre-warmed DPBS containing 500 pM lipoic acid
was applied to the cells for one minute. The cells were washed once with ice-cold DPBS, then
fixed with 3.7% paraformaldehyde in DPBS at 4"C for 10 minutes, then permeabilized with
methanol at -20*C for 10 minutes. Fixed cells were washed with DPBS, then blocked overnight
with blocking buffer (3% BSA in DPBS with 0.1% Tween-20). Lipoic acid and the c-myc epitope of
the FKBP-LAP-NLS construct were detected with immunostaining. Rabbit anti-lipoic acid
antibody and mouse anti-c-myc antibody (Calbiochem) were added together, both at a 1:300
dilution, in blocking buffer for one hour at room temperature. Cells were washed three times
for five minutes each with DPBS. Cells were then treated with 1:1000 dilutions of goat anti-
rabbit antibody conjugated to Alexa Fluor 568 (Invitrogen) and goat anti-mouse antibody
conjugated to Alexa Fluor 657 (Invitrogen) in blocking buffer for one hour at room temperature.
Cells were again washed three times for five minutes each with DPBS prior to imaging. Confocal
images were acquired at 60x magnification.
Proximity coumarin ligation in the cytoplasm of live HEK cells
HEK cells were grown to 70% confluency on fibronectin-coated glass coverslips, then
transfected with 400 ng FRB-LpIA(W37V)-pcDNA3, 400 ng FKBP-LAP1-pcDNA3, and 20 ng GFP as
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a co-transfection marker per 0.95 cm2 using Neofectin (Mid-Atlantic Biolabs) according to the
manufacturer's instructions. The GFP expression plasmid was a kind gift from Dr. Joshua Sanes
(Harvard). For the LAP2 peptide comparison, FKBP-LAP1-pcDNA3 was replaced with FKBP-LAP2-
pcDNA3. For negative control experiments, FKBP-LAP1-pcDNA3 was replaced with FKBP-
LAP1(K-*A)-pcDNA3, or FRB-LpIA(W37V)-pcDNA3 was replaced with FRB-LpIA-pcDNA3. 24
hours after transfection, 100 nM rapamycin was added in growth media for 1 hour at 37"C, or
omitted as a negative control. Growth media was then removed and the cells were labeled by
applying 20 pM (AM) 2-coumarin in serum-free DMEM at 370C for 10 minutes. Excess coumarin
was washed out with three changes of fresh DMEM over 60 minutes at 370C. Cells were imaged
in DPBS. Confocal images were acquired at 60x magnification.
Proximity coumarin ligation in the nucleus of live cells
This experiment was conducted exactly as for the cytoplasmic labeling, except that FKBP-LAP1-
pcDNA3 was replaced with FKBP-LAP1-NLS-pcDNA3, FKBP-LAP2-NLS-pcDNA3, or FKBP-
LAP1(K-*A)-NLS-pcDNA3, as appropriate. Confocal images were acquired at 60x magnification.
Proximity coumarin ligation in the cytoplasm offixed cells
Cells were grown and transfected exactly as for live cytoplasmic labeling, except that after
transfection, cells were grown at 300C under an atmosphere of 5% CO2 in order to control cell
division and expression level. 24 hours after transfection, 100 nM rapamycin was added in
growth media for 1 hour at 37"C, or was omitted as a negative control. Growth media was then
removed and the cells were labeled by applying 20 pM (AM) 2-coumarin in serum-free DMEM at
370C for 10 minutes. Excess coumarin was washed out with one application of fresh DMEM for
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30 minutes, then cells were fixed with 3.7% paraformaldehyde in DPBS at 4"C for 10 minutes,
then permeabilized with methanol at -20*C for 10 minutes. Fixed cells were washed with DPBS,
then blocked for one hour at room temperature with blocking buffer. Cells were stained with a
1:1000 dilution of rabbit anti-HA antibody (Rockland Immunochemicals) in blocking buffer at
40C overnight. Cells were then washed three times with DPBS for five minutes each. Cells were
then treated serially for 1 hour at room temperature with the following antibodies, each diluted
1:1000 in blocking buffer, in the following order: goat anti-rabbit Alexa Fluor 647 conjugate,
followed by mouse anti-c-myc, followed by goat anti-mouse Alexa Fluor 568 conjugate
(Invitrogen). Three five-minute DPBS washes were applied between each antibody incubation
step. After staining, cells were imaged in DPBS. Confocal images were acquired at 60x
magnification.
Comparison of LAP1 17-mer and 22-mer, LpIA(W37V) and LpIA(W371)
HEK cells were grown to 70% confluency on fibronectin-coated glass coverslips, then
transfected with 600 ng FRB-LpIA-pcDNA3 (either the W371 or W37V mutant) and FKBP-LAP1-
NLS-pcDNA3 (either the 17-mer or 22-mer LAP) per 0.95 cm2 using Lipofectamine 2000
according to the manufacturer's instructions. 36 hours after transfection, 100 nM rapamycin
was added in growth media for 1 hour at 37*C, or was omitted as a negative control. Growth
media was then removed and the cells were labeled by applying 20 pM (AM) 2-coumarin in
serum-free DMEM at 37"C for 20 minutes. Excess coumarin was washed out with one
application of fresh DMEM for 30 minutes, then cells were fixed with 3.7% paraformaldehyde in
DPBS at 4*C for 10 minutes, then permeabilized with methanol at -200C for 10 minutes. Fixed
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cells were washed with DPBS, then blocked for one hour at room temperature with blocking
buffer. Cells were then stained with a 1:1000 dilution of chicken anti-c-myc antibody (Aves) in
blocking buffer at room temperature for one hour. Cells were then washed three times with
DPBS for five minutes each, then stained with a 1:1000 dilution of goat anti-chicken Alexa Fluor
568 conjugate (Invitrogen) for one hour at room temperature. Cells were washed three times
with DPBS for five minutes each prior to imaging in DPBS. Epifluorescence images were
acquired at 40x magnification.
For quantitation, regions of interest (ROls) were manually drawn on transfected nuclei by
visually inspecting the anti-c-myc immunofluorescence images. Average intensities of coumarin
and anti-c-myc immunofluorescence were copmuted. Background correction was applied by
drawing a ROI on an untransfected cell in each field of view and subtracting these background
intensities from all values generated from that particular field of view. Coumarin intensity was
then plotted against anti-c-myc intensity for each cell.
Proximity coumarin ligation in other cell lines
COS-7 and HeLa cells were grown to 50% confluency on glass coverslips, then transfected with
400 ng FRB-LpIA(W37V)-pcDNA3, 400 ng FKBP-LAP1-pcDNA3, and 20 ng GFP (a co-transfection
marker) per 0.95 cm2 using Lipofectamine 2000 according to the manufacturer's instructions.
Cells were then labeled and imaged exactly as described for cytoplasmic labeling of HEK cells.
Confocal images were acquired at 60x magnification.
Kinetics
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The Michaelis-Menten curve for determining the values of kcat and Km for coumarin ligation by
LpIA W37V onto FKBP-LAP was generated from HPLC experiments used to determine the initial
reaction rate (Vo). The conditions used were as follows: 2 pM enzyme, 1 mM 7-OH coumarin, 2
mM magnesium acetate, and 25 mM sodium phosphate buffer, pH 7.2. The amount of FKBP-
LAP was varied from 1.5 mM to 200 pM. Each initial rate was measured in triplicate and the
error bars shown represent ± 1 s.d.
Rapamycin dose-response
HEK cells were grown to 70% confluency on fibronectin-coated glass coverslips, then
transfected with 400 ng FRB-LpIA(W37V)-pcDNA3 and 400 ng FKBP-LAP1-pcDNA3 per 0.95 cm2
using Lipofectamine 2000 according to the manufacturer's instructions. 24 hours after
transfection, concentrations of rapamycin ranging from 0.3 nM to 300 nM were added in
growth media for 1 hour at 370C. Growth media was then removed and the cells were labeled
by applying 20 pM (AM) 2-coumarin in serum-free DMEM at 37"C for 10 minutes. Excess
coumarin was washed out with one application of fresh DMEM for 30 minutes, then cells were
fixed with 3.7% paraformaldehyde in DPBS at 40C for 10 minutes, then permeabilized with
methanol at -20"C for 10 minutes. Fixed cells were washed with DPBS, then blocked overnight
in blocking buffer at 40C. Cells were then immunostained serially with 1:1000 dilutions in
blocking buffer of the following antibodies in the following order, for one hour each at room
temperature: mouse anti-c-myc, goat anti-mouse Alexa Fluor 647 conjugate, rabbit anti-HA,
goat anti-rabbit Alexa Fluor 568 conjugate. Three five-minute DPBS washes were applied
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between each antibody incubation step. After staining, cells were imaged in DPBS.
Epifluorescence images were acquired at 40x magnification.
For quantiation, ROls were manually drawn on transfected cells by visually inspecting the anti-
c-myc immunofluorescence images. Average intensities of coumarin, anti-c-myc
immunofluorescence, and anti-HA immunofluorescence were computed. Background
correction was applied by drawing a ROI on an untransfected cell in each field of view and
subtracting these background intensities from all values generated from that particular field of
view. ROls with anti-HA intensities greater than 3000 were kept for analysis, leaving at least 8
data points for each rapamycin concentration and as many as 25. The coumarin intensity was
ratioed to the anti-c-myc intensity for each ROI, then multiplied by 100 for ease of data display;
these values were averaged for each rapamycin concentration. Error is reported as standard
error of the mean.
Wedge methodfor labeling yield estimation
Cellular labeling and imaging: HEK cells were grown to 70% confluency on fibronectin-coated
glass coverslips, then transfected with either 800 ng each or 100 ng each of FRB-LpIA(W37V)-
pcDNA3 and mCherry-FKBP-LAP1-pcDNA3 per 0.95 cm2 using Lipofectamine 2000 according to
the manufacturer's instructions. 36 hours after transfection, 100 nM rapamycin was added in
growth media for 1 hour at 37"C, or omitted to assess background. Growth media was then
removed and the cells were labeled by applying 20 ptM (AM) 2-coumarin in serum-free DMEM at
370C for 10 or 20 minutes. Excess coumarin was washed out with three changes of fresh DMEM
over 60 minutes at 37"C. Cells were imaged in DPBS. For image analysis, ROls were manually
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drawn on tranfected cells by manualy inspecting the mCherry channel, and average coumarin
and mCherry intensities were acquired for each ROI. Epifluorescence images were acquired at
40x magnification.
Preparation of mCherry standard: mCherry in pRSETB was a gift from Roger Tsien. This protein
was expressed and purified from E. coli exactly as described above for FRB-LplA and FKBP-LAP1
except that concentration was measured by UV-visible absorbance using the reported
extinction coefficient of mCherry of 72,000 M1 cm1 at 587 nm.[53]
Preparation of FKBP-LAP1-coumarin conjugate standard: Coumarin was enzymatically
conjugated to FKBP-LAP1 in an in vitro reaction containing 25 pM purified LpIA(W37V), 1 mM
FKBP-LAP1, 1 mM coumarin probe, 5 mM ATP, 1 mM Mg(OAc)i in PBS. The reaction was
incubated overnight at 30*C, then subjected to HPLC purification. The product peak was
manually collected. HPLC eluate was dried down on a rotavap followed by lyophilization to
dryness, and the resulting material was dissolved in 1 mL PBS. The final concentration was
determined by BCA assay.
The identity of the product was confirmed by mass spectrometry. The collected HPLC eluate
was injected onto an Applied Biosystems 200 QTRAP mass spectrometer. The flow rate was 10
p/min and detection was in positive ionization mode. The calculated mass of 17546 ± 5 Da
agrees within the error of the instrument with the expected mass of 17540 Da.
For quantitation we use the wedge method. We constructed a wedge-shaped chamber from
three glass coverslips. The wedge for our mCherry standard was 5 mm long and the wedge for
our FKBP-LAP1-coumarin standard was 5.5 mm long. Each increased monotonically from 0 to
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150 pm in the z dimension. The wedge was filled with approximately 10 PL standard solutions
(40 pM mCherry, 1 ptM FKBP-LAP1-coumarin), then imaged under conditions identical to those
used for cellular imaging. We assumed that our cells are, on average, 5 pam thick, so calculated
the region of the wedge that represented 5 ptm in height and measured the intensity of
mCherry and FKBP-LAP1-coumarin at those locations as a standard for the concentration of
these molecules inside single cells. Because free coumarin is completely washed out of cells by
our protocol, the ratio of coumarin intensity to mCherry intensity represents the labeling yield
inside cells.
Comparison of YFP BiFC with proximity coumarin ligation
Low expression level comparison: For YFP BiFC analysis, HEK cells were grown to 70%
confluency, then transfected with 1 tg each of FRB-YN155-pcDNA3 and FKBP-YC155-pcDNA3
per 0.95 cm2 using Lipofectamine 2000 according to the manufacturer's instructions. One set of
BiFC cells was grown at 370C after transfection for 36 hours. Another set of BiFC cells was grown
for 24 hours after transfection at 370C, then moved to 300C for 12 hours. 24 hours after
transfection, 100 nM rapamycin was applied to all BiFC cells. 36 hours after transfection, cells
were fixed with paraformaldehyde and methanol as previously described.
For coumarin proximity ligation, cells were transfected with 1 pg each of FRB-LpIA(W37V)-
pcDNA3 and FKBP-LAP1-pcDNA3 per 0.95 cm2 using Lipofectamine 2000 according to the
manufacturer's instructions. 36 hours after transfection, cells were treated with rapamycin,
labeled, and fixed as described for proximity coumarin ligation in the cytoplasm of fixed cells.
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All cells were blocked for one hour at room temperature in blocking buffer, then stained with a
1:1000 dilution of chicken anti-c-myc antibody in blocking buffer at room temperature for one
hour. Cells were then washed three times with DPBS for five minutes each, then stained with a
1:1000 dilution of goat anti-chicken Alexa Fluor 568 conjugate for one hour at room
temperature. Cells were washed three times with DPBS for five minutes each prior to imaging in
DPBS. Epifluorescence images were acquired at 40x magnification.
For image analysis, ROls were manually drawn on the anti-c-myc immunofluorescence channel,
and average coumarin and anti-c-myc intensities were acquired.
High expression level experiment: For YFP BiFC analysis, HEK cells were grown to 70%
confluency, then transfected with 100 ng each of FRB-YN155-pcDNA3 and FKBP-YC155-pcDNA3
per 0.95 cm2 using Lipofectamine 2000 according to the manufacturer's instructions. Cells were
grown at 37"C for 24 hours after transfection in the presence of 100 nM rapamycin. Cells were
then fixed with paraformaldehyde and methanol as described.
For coumarin proximity labeling, 70% confluent HEK cells were transfected with 100 ng each
FRB-LpIA(W37V)-pcDNA3 and FKBP-LAP1-pcDNA3 per 0.95 cm2 using Lipofectamine 2000
according to the manufacturer's instructions. 24 hours after transfection, cells were treated
with rapamycin, coumarin labeled, and fixed as described for proximity coumarin ligation in the
cytoplasm of fixed cells.
All cells were blocked with blocking buffer at room temperature for one hour. Cells were
stained with rabbit anti-HA antibody at a 1:1000 dilution in blocking buffer at room
temperature for one hour, washed three times with DPBS, then stained with goat anti-rabbit
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Alexa Fluor 568 conjugate in blocking buffer at room temperature for one hour prior to washing
and imaging. Epifluorescence images were acquired at 40x magnification.
For image analysis, transfected cells were identified in the anti-HA immunofluorescence
channel and ROls were drawn by hand; in some cases of intracellular aggregation, the ROI had
to be drawn on the DIC image in order to define the shape of the entire cell. Average YFP and
anti-HA intensities were acquired for each ROI.
Proximity coumarin labeling of the interaction of PSD-95 and neuroligin-1 in HEK cells
HEK cells were grown to 70% confluency on fibronectin-coated glass coverslips, then
transfected with 100 ng PSD-95-LpIA(W37V)-pNICE, 500 ng neuroligin-1-LAP1-pNICE, and 20 ng
2GFP per cm using Neofectin according to the manufacturer's instructions. For negative
controls, neuroligin-1-LAP1-pNICE was replaced with an equal amount of neuroligin-1-LAP1-
pNICE APDZ-pNICE, or PSD-95-LpIA(W37V) -pNICE was replaced with 20 ng FLAG-LpIA(W37V)-
pcDNA3. 24 hours after transfection, the cells were labeled by applying 20 ptM (AM) 2-coumarin
in serum-free DMEM at 37"C for 10 minutes. Excess coumarin was washed out with three
changes of fresh DMEM over 60 minutes at 372C. Cells were imaged in DPBS. Confocal images
were acquired at 60x magnification.
Proximity coumarin ligation in neurons
Hippocampal neurons were dissociated from E18 Sprague Dawley rat embryos and cultured as
previously described[54, 55] and suspended in MEM supplemented with 10% FBS and 2% B-27
supplement. Neurons were plated onto poly-L-lysine coated glass coverslips (12 mm diameter)
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at a density of 120,000 per well. 12 hours later media was replaced with NeuroBasal media
supplemented with B-27 and 0.5 mM GlutaMaxTM (Invitrogen). Neurons were co-transfected
with 1pg of AP-neuroligin-1-LAP1, 350 ng of PSD95-LpLA(W37V)and 450 ng of BirA-ER plasmids
at days in vitro (DIV) 5 using Lipofectamine 2000 (Invitrogen) in 500 Pl of MEM. After
transfection for 4 hours, the MEM was replaced with the pre-conditioned media in which the
cells were cultured initially with 10 tM biotin added to afford overnight labeling of AP-tagged
protein. 1 pg of AP-neuroligin-1-LAP1-APDZ was used as a negative control in place of AP-NLG1-
LAP1. Coumarin labeling was performed 24 hours after transfection by incubating cells with 20
pM (AM) 2-coumarin in serum-free Modifed Eagle's Medium (MEM) (Sigma) at 370C for 15
minutes, followed by a 45-minute wash in MEM at 37*C. Biotinylated AP-neuroligin-1-LAP1 and
AP-neuroligin-1-LAP1-APDZ were visualized by staining with streptavidin-Alexa Fluor 568
conjugate in Tyrode's buffer containing 1% dialyzed bovine serum albumin for 5 minutes at
room temperature. Cells were rinsed, then fixed with formaldehyde and methanol as described
above. The FLAG epitope on the PSD-95-LpIA(W37V) construct was visualized by
immunostaining with monoclonal anti-FLAG M2 antibody (Sigma) followed by goat anti-mouse
Alexa Fluor 488 (Invitrogen).
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